EPA Jacket 11556-155

ISB'S Front-end PRIA Completeness Screen Draft 3; 10/25/07

EPA	Receipt Date: $9/24$	PA Reg. Number:	//55	6-1	PLL
	Check List Item		Yes	No	N/A
Ì	Has the PRIA Fee been Paid; is a copy of Pay.gov receipt included in the Submission				
2	Is an Application Form (EPA Form 857) Submission Package, is it completely fille including package type?		X		
3	Is a Confidential Statement of Formula (EPA Form 8570-29) Included in the Submission Package, is it completely filled out and signed (boxes 1-21)?				
4	Is a Formulator's Exemption Statement (EPA Form 8570-27) Included in the Submission Package?			X	######################################
5	Is a Certification with Respect to Citati Form 8570-34) Included in the Submission		X		
6	Is a Data Matrix (EPA Form 8570-35) In Submission Package?	ncluded in the	X	1	
7	Is a Label Included in the Submission Package?		X		
8	Arc Data Included in the Submission Pac	kage?	X		
0	Is the Submission an Amendment?				

Plasse read instructions on reverse before completing form.	Form Appr	oved, OMB No. 2076	Print Form			
SEPA Environmental Protection A Washington, DC 20450		Registrati Amendme X Other	OR OPP Identifier Number			
Application fo	r Pesticide - Sec	tion I				
1. Company/Product Number I 1SS6-155	2. EPA Product Men Richard Gebken	ager	3. Proposed Classification			
4, Compony/Product (Namo) PNR1427 Insecticide	PM# 13 None Restrict					
5. Nome and Address of Applicant (Include ZIP Code) Bayer HealthCare LLC, Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390 Check if this is a new address 6. Expedited Review. In accordance with FiFRA Section 3(c) (b)(i), my product is similar or identical in composition and labelities: EPA Reg. No. Product Name						
S	ection - II					
Amendment - Explain below. Resubmission in response to Agency letter dated Notification - Explain below. Explanation: Use additional page(s) if necessary. [For section 1 and	Agency lott "Me Too" / Other - Exp	Application,				
S	ction - III					
1. Meterial This Product Will Be Packaged In:						
Yes X No X No No Per It "Yoe" No. per It "	ter Soluble Packeging Yes No Yes" No. per kage wgt containo		nteiner Motel Meetic Slass Seper Other (Specify)			
3. Location of Net Contents Information 4. Size(s) Retail Co Label Container 1 Collar	stainor	5. Location of Label On Label X On Labeling	Directions secompanying product			
6. Manner in Which Label is Affixed to Product Lithograph Paper glued Stonciled	Othe					
Section - IV						
1. Contect Point Complete items directly below for identification of Individuel to be contacted, if necessary, to process this application.						
Nome Title EPA I	leg. Affairs Manager		llephone No. (Include Aree Code) ুঁ ী 3-268-275			
Certification I certify that the statements I have made on this form and all attachments therato are true, accurate and complete. I ecknowledge that any knowingly false or misleading statement may be punishable by line or imprisonment or both undor applicable law.						
10th of the	leg. Affairs Manager					
4. Typed Name V 5. Date Douglas A. Spilker, Ph D.	30 March	2012				

Seresto ™ Small Dog

For 8 - month prevention and treatment of ticks and fleas on small dogs and puppies 7 weeks of age and older and up to 18 lbs. (8 kg)

ACTIVE INGREDIENT: Flumethrin; [Cyano(4-fluoro -3-phenoxyphenyl)methyl 3-[2-chloro -2-(4 - chlorophenyl)ethenyl] -2,2 - dimethylcyclopropanecarboxylate]*......4.5% Imidacloprid.......10.0% OTHER INGREDIENTS85.5%

*Trans Z=1/trans Z=2 ratio: max 66% trans Z=1 and min 34% trans Z=2

Net Contents: 1 Collar 0.44 oz. (12.5 cm) per collar

EPA Reg. No. 11556 - 155

EPA Est. No. 11556 - KS - 1

See insert inside for additional Product Information and Directions for Use.

READ THE ENTIRE LABEL BEFORE EACH USE

DO NOT OPEN UNTIL READY TO USE DO NOT LET CHILDREN PLAY WITH THIS COLLAR

Manufactured For: Bayer HealthCare LLC, Animal Health Division P.O. Box 390, Shawnee Mission, Kansas 66201 USA Made in Germany

Batch No.: KP05KTJ SSID: 2180

Mat. No.: 81544906

Seresto[™] Small Dog

10.0% imidacloprid 4.5% flumethrin

Do not let children play with this collar FOR USE ON DOGS

See insert for complete label information.

Do not open until ready to use.

BAYER

EPA Reg. No. 11556 - 155 EPA Est. No. 11556 - K\$ - 1

Seresto ™ Large Dog

For 8 — month prevention and treatment of ticks and fleas on large dogs and pupples 7 weeks of age and older and above 18 lbs. (8 kg)

ACTIVE INGREDIENT:

Flumethrin; [Cyano(4-fluoro-3-phenoxyphenyl)methyl 3-[2-chloro	- 2-
(4 - chlorophenyl) ethenyl] -2,2 - dimethylcyclopropanecarboxylate]*	4.5%
lmidacloprid	10.0%
OTHER INGREDIENTS	
Total	

*Trans Z - 1/trans Z - 2 ratio: max 66% trans Z - 1 and min 34% trans Z - 2

Net Contents: 1 Collar 1.6 oz. (45.0 gm) per collar

EPA Reg. No. 11556 - 155

EPA Est. No. 11556 - KS - 1

See insert inside for additional Product Information and Directions for Use.

READ THE ENTIRE LABEL BEFORE EACH USE

DO NOT OPEN UNTIL READY TO USE DO NOT LET CHILDREN PLAY WITH THIS COLLAR

Manufactured For: Bayer HealthCare LLC, Animal Health Division P.O. Box 390, Shawnee Mission, Kansas 66201 USA Made in Germany

Mat. No.: 81544930 Batch No.: KP05KF6

SSID: 2181

Seresto[™] Large Dog

10.0% imidacloprid 4.5% flumethrin

Do not let children play with this collar FOR USE ON DOGS

See insert for complete label information.

Do not open until ready to use.

BAYER

EPA Reg. No. 11556 — 155 EPA Est. No. 11556 — KS — 1

Seresto™ Small Dog

For 8-month prevention and treatment of ticks and fleas on small dogs and pupples 7 weeks of age and older and up to 18 lhs. (8 kg)

Seresto™ Large Dog

For 8-month prevention and treatment of ticks and fleas on large dogs and puppies 7 weeks of age and older and above 18 lbs. (8 kg)

- Repets and kills ticks for 8 months, including Deer ticks, (Ixodes scapularis) vector
 of Lyme disease and anaplasmosis), American dog ticks, (Dermacentor variabilis)
 vector of Rocky Mountain spotted fever and ehrlichiosis, Brown dog ticks,
 (Rhipicephalus sanguineus) vector of ehrlichiosis, anaplasmosis, bartonelfosis,
 babesiosis, canine hemoplasmosis, and Rocky Mountain spotted tever), and Lone
 Star ticks (Amblyomma americanum) vector of erhichiosis
- · Prevents tick infestations within 48 hours after application
- . Re-intesting ticks are repelled and/or killed as quickly as 6 hours
- Quickly kills fleas on dogs within 24 hours and continues to prevent infestations for 8 months
- Reinfesting fleas are killed vrithin 2 hours with protection against turther flea infestation lasting 8 months
- · Kills fleas before they lay eggs
- · Aids in control of thea larvae in the dog's surrounding
- Treatment with Seresto kitls fleas and may reduce the risk of tapeworm infections (Dipytidium caninum), Bartonellosis (Bartonella vinsonii, Bartonella spp.), and Rickettsiosis (Rickettsia fetis), which are types of canine vector bome diseases
- · Aids in the treatment and control of Sarcoptic mange
- · Make sure to replace the collar after 8 months for year-round control prevention
- No need to remove collar when your pet goes swimming or gets bathed
- · Water resistant
- Patented Bayer polymer matrix ensures that both active ingredients are slowly and continuously released in low concentrations

ACTIVE INGREDIENT:

Flumethrin; [Cyano(4-fluoro-3-phenoxyphenyl)methyl 3-[2-chloro-2-	
(4-chlorophenyl)ethenyl) -2,2-dimethylcyclopropanecarboxylate(*	4.5%
Imidacloprid,	10.9%
OTHER INGREDIENTS	85.5%
Total	t00.0%

*Trans Z-1/trans Z-2 ratio: max 66% trans Z-1 and min 34% trans Z-2

EPA Reg. No. t1556-155

EPA Est. No. 11556-KS-1

READ THE ENTIRE LABEL BEFORE EACH USE DD NOT OPEN UNTIL READY TO USE DO NOT LET CHILDREN PLAY WITH THIS COLLAR KEEP OUT OF REACH OF CHILDREN

HOT LINE NUMBER

Have the product container or label with you when calling a poison control center or doctor, or going for treatment.

- For CONSUMER QUESTIONS, call 1-800-255-6826.
- For medical emergencies involving HUMANS, call 1-890-422-9874.
- For medical emergencies involving ANIMALS, call 1-800-422-9874.

DIRECTIONS FOR USE


It is a violation of Federal Law to use this product in a manner inconsistent with its labeling. Do not contaminate feed or food.


HOW TO APPLY

One collar per animal to be fastened around the neck.

Remove cotlar from protective bag directly before use. Unrolt collar and make sure that there are no remnants from the plastic connectors inside the collar. Insert end of the collar through the buckle, Adjust the collar around the animal's neck without tightening it too tight (as a quide, it should be possible to insert 2 fingers between the collar and the neck). Pull excess collar through the loop(s) and cut off any excess length extending beyond 1 inch (2 cm) beyond the toop(s).







The coltar should be worn continuously for the 8 month protection period. Check periodically and adjust fit if necessary, especially when puppies are rapidly growing.

This collar is designed with a satety-closure mechanism. In the unlikely event of a dog being trapped, the dog's own strength is sufficient to widen the collar to allow for quick release.

Reptace the collar atter 8 months for optimal tlea and tick protection.

PRODUCT INFORMATION

Kills (teas which may cause tlea allergy dermatitis (FAD) or (tea bite hypersensitivity (FBH).

Seresto kills existing tleas on dogs within 24 hours. Reintesting fleas are killed within 2 hours with protection against further flea intestation lasting elght (8) months. Pre-existing pupae in the environment may continue to emerge for six (6) weeks or longer depending upon the climatic conditions: Seresto aids in the control of flea tarvae in the dog's surroundings following contact with a Seresto-treated dog.

Ticks atready on the dog prior to treatment may not be killed immediately after collar application and may remain attached and visible. At the time of application remove ticks already on the dog. The prevention of infestations with new ticks starts within 48 hours after application of the collar. Re-infesting ticks are repelled and/or killed as quickly as 6 hours.

Aids in the treatment and control of Sarcoptic mange.

Seresto is water resistent and remains effective following a shampoo treatment, swimming or after exposure to rain or sunlight. Under normal conditions, ettectiveness lasts for 8 months. In order to maintain an eight-month duration, dogs must not be bathed more than once per month. For dogs that swim once a month or more, the control duration is reduced to 5 months. In case of loss of collar, a new coltar may be applied immediately.

Occasionally slight itching may be observed in animats that are not used to wearing collars in the first few days after fitting. Ensure that the collar is not fitted too tightly. Slight hair loss and mild skin reactions due to the mechanical irritation of the collar may occur at the application site which usually recover within 1 or 2 weeks without the need for collar removal. If you notice any serious effects or other effects not mentioned in this leaflet, ptease inform your veterinarian.

Do not attach a leash to the collar as this may cause breakage.

Keep the collar in the bag and in the outer packaging until use. As with any pesticide product, do not allow small children to play with the collar or to put them into their mouths. Avoid contact with eyes, skin or clothing. Wash thoroughly with soap and cold water after fitting the collar. People with sensitivity reactions to the ingredients of the collar should avoid contact with the collar. Do not place collar in mouth. Not intended for use on humans.

For external use on dogs only. Do not use on other animals. Oo not use on puppies under seven weeks of age. Do not get this product in dog's eyes or mouth. As with any product, consult your veterinarian before using this product on debilitated, aged, breeding, pregnant, or nursing animals. Individuat sensitivities, while rare, may occur after using ANY pesticide product for pets. If signs of sensitivity occur remove collar and bathe your pet with mild soap and rinse with large amounts of water. It signs persist, or become more severe, consult a veterinarian immediately. It your animal is on medication, consult your veterinarian before using this or any other product. If your dog is experiencing an adverse event, contact your veterinarian and, call t-800-422-9874.

The patented Bayer polymer matrix system ensures that both active ingredients are slovily and continuously released in low concentrations from the collar towards the animal. This avoids peak concentrations and ensures that concentrations of both active ingredients are present in the dog's haircoat during the entire efficacy period. The active ingredients spread from the site of direct contact over the entire skin surface.



STORAGE AND DISPOSAL

Do not contaminate water, food or feed by storage or disposal.

Pesticide Storage: Store in original unopened container in a cool, dry place that is inaccessible to children.

Container Disposal: Dispose of container, pouch and expired collabilit trash.

LIMITED WARRANTY AND LIMITATION OF DAMAGES

Bayer HealthCare LLC, Animal Health Division, warrants that this material conforms to the chemical description on the tabel. TO THE EXTENT CONSISTENT WITH APPLICABLE LAW, BAYER MAKES ND DTHER EXPRESS OR IMPLIED WARRANTY, INCLUDING ANY OTHER EXPRESS OR IMPLIED WARRANTY OF FITNESS OR MERCHANTABILITY, and no agent of Bayer is authorized to do so except in writing with a specific reference to this warranty. To the extent consistent with upplicable law any damages arising from a breach of this warranty shall be limited to direct damages and shall not include consequential commercial damages such as loss of profits or values, etc.

Bayer (reg'd), the Bayer Cross (reg'd), and Seresto are trademarks of Bayer



Manufactured For Bayer HealthCare LLC Animal Health Division P.O. Box 390 Shawnee Mission, Kansas 66201 USA Made in Germany

81544906 81544930 16720



U.S. ENVIRONMENTAL PROTECTION AGENCY Office of Pesticide Programs Registration Division (H7505C) 1200 Pennsylvania Avenue, N.W.

Washington, D.C. 20460

_	EPA Reg. Number:	Date of Issuance:			e:	******
	11556-155	MAR	1	6	2012	
	Term of Issuance: Unconditional	_				
	Name of Pesticide Produc	t:				
	PNR 1427 Insecti	cide		`	!	

NOTICE OF PESTICIDE:

X Registration Reregistration

(Under FIFRA as amended)

Name and Address of Registrant (include ZIP Code):

Bayer HealthCare LLC Animal Health Division

P.O. Box 390

Shawnee Mission, KS 66201-0390

Note: Changes in labeling differing in substance from that accepted in connection with this registration must be submitted to and accepted by the Registration Division prior to use of the label in commerce. In any correspondence on this product always refer to the above EPA registration number.

On the basis of information furnished by the registrant, the above named pesticide is hereby registered/reregistered under the Federal Insecticide, Fungicide and Rodenticide Act.

Registration is in no way to be construed as an endorsement or recommendation of this product by the Agency. In order to protect health and the environment, the Administrator, on his motion, may at any time suspend or cancel the registration of a pesticide in accordance with the Act. The acceptance of any name in connection with the registration of a product under this Act is not to be construed as giving the registrant a right to exclusive use of the name or to its use if it has been covered by others.

This product is unconditionally registered in accordance with FIFRA sec. 3(c)(5) for a period of one year from the date of registration. This registration will expire on March 17, 2013.

Once a pesticide is registered, however, it is not regarded as permanently acceptable. Registration does not eliminate the need for continual reassessment of pesticides. If the Agency determines that, at any time, additional data are required to maintain in effect an existing registration, the Agency will require submission of such data under FIFRA section (3).

- 1. You will make the following label changes before you release the product for shipment:
 - a) Revise the EPA Registration Number to read "EPA Reg. No. 11556-155."
 - b) Replace the following claim: "For 8-month prevention and treatment of ticks, fleas, and lice on ... etc" with "For 8-month prevention and treatment of ticks and fleas on ... etc". Also replace "Replace the collar after 8 months for (optimal) (continuous) flea, (lice) and tick protection" with "Replace the collar after 8 months for (optimal) (continuous) flea, and tick protection". All claims related to "8 months" must be limited to fleas and ticks only. Other pests are not controlled for that duration.
 - Claims against lice must be limited to one month.

d)	Tick claims for killing within 6 hours of re-infestation on cats must be removed from t	h
	abel. Based on the submitted or cited data the claim only is supported for dogs.	

Signature of Approving Official: Richard Gebken Product Manager Insecticide Branch/Registration Division (7505P)

March 16,2012

- e) All waterproof claims must be clarified as follows:
 - In order to maintain an eight month control duration, dogs must not be bathed more than once per month.
 - If dogs swim once per month, the control duration must be revised to 5 months.
 - Water exposure (i.e. immersion, bathing, or prolonged exposure to rain) can only be once per month.
- f) On page 2 delete the directions for killing roaches and ants (in the environment").
- g) All claims related to control of flea larvae in the pet's environment must be removed or revised to "aids on control" for fleas in the pet's environment.
- h) All disease claims must be deleted, unless the claim is stated "kills/controls xxx pest that may vector yyy".
- i) All claims of "breaking the flea life cycle" must be deleted.
- 2. Please submit three (3) copies of your final printed labeling before releasing the product for shipment. If these conditions are not complied with, the registration will be subject to cancellation in accordance with FIFRA section 6(e). Your release for shipment of the product bearing amended labeling constitutes acceptance of these conditions. A stamped copy of the label is enclosed for your records.

If you have any questions regarding this action, please contact BeWanda Alexander at www.alexander.bewanda@epa.gov or (703) 305-7460.

ACCEPTED with COMMEN. In EPA Letter Dated

MAR 16 2012
Under the Federal Insecticide.
Fungleide, and Rodenticide Act.
as amended, for the pesticide
registered under SPA Reg. No.

1155/0-155

Page 1 of 12

Page 1 of 13

Note to Reviewer: Brackets [] and parentheses () denote optional language

Reason To Issue: Propose new registration

PNR1427 Insecticide

Alternate Brand Names: Seresto Small Dog; Seresto Large Dog; Seresto Cat

Optional Language for Small Collar

[For 8-month prevention and treatment of ticks, fleas, and lice on (small) dogs and puppies 7 weeks of age and older and up to [(18 lbs.)(8 kg)] [body weight]]

-or-

[For 8-month prevention and treatment of ticks and fleas on cats and kittens 10 weeks of age and older

-or-

[For 8-month prevention and treatment of ticks, fleas, and lice on (small) dogs and puppies 7 weeks of age and older and up to [(18 lbs.)(8 kg)] [body weight]] [and/or] prevention and treatment of ticks and fleas on cats and kittens 10 weeks of age and older

Optional Language for Large Collar:

[For 8-month prevention and treatment of ticks, fleas and lice for 8 months on (large) dogs and puppies 7 weeks of age and older and above [(18 lbs.)(8 kg)] [body weight]]

[Selected optional label claims bulleted here from pages 9 to 15]

ACTIVE INGREDIENT:	
Flumethrin; [Cyano(4-fluoro-3-phenoxyphenyl)methyl 3-[2-chloro-2-(4-	
chlorophenyl)ethenyl] -2,2-dimethylcyclopropanecarboxylate]*	4.5%
Imidacloprid	10.0%
OTHER INGREDIENTS	85.5%
Total	100%

^{*}Trans Z-1/trans Z-2 ratio: max 66% trans Z-1 and min 34% trans Z-2

Net Contents: (X) Collar (s) –	XX oz. (XX grams) per collar
EPA Reg. No. 11556-XXX	EPA Est. No. 11556-TBD

Supersedes: 09/20/10

Page 2 of 13

Manufactured For

Bayer HealthCare LLC
Animal Health Division
P.O. Box 390
Shawnee Mission, Kansas 66201 USA

Made in Germany

READ THE ENTIRE LABEL BEFORE EACH USE

[For small collar: USE ON [(DOGS)(CATS)]]

-or-

[For small collar: USE ON SMALL DOGS and CATS]

-or-

[For large collar: USE ONLY ON DOGS]

DO NOT OPEN UNTIL READY TO USE DO NOT LET CHILDREN PLAY WITH THIS COLLAR [OR REFLECTORS]

KEEP OUT OF REACH OF CHILDREN [CHOKING HAZARD - CONTAINS SMALL PARTS]

See [(back panel)(insert)] for additional Product Information and Directions for Use.

HOT LINE NUMBER

Have the product container or label with you when calling a poison control center or doctor, or going for treatment.

- For CONSUMER QUESTIONS, call 1-800-255-6826.
- For medical emergencies involving HUMANS, call 1-800-422-9874.
- For medical emergencies involving ANIMALS, call I-800-422-9874.

Date: 03/12/12 Supersedes: 09/20/10

Page 3 of 13

DIRECTIONS FOR USE

It is a violation of Federal Law to use this product in a manner inconsistent with its labeling. Do not contaminate feed or food.

HOW TO APPLY

One collar per animal to be fastened around the neck.


Remove collar from protective bag directly before use. Unroll collar and make sure that there are no remnants from the plastic connectors inside the collar. Insert end of the collar through the buckle. Adjust the collar around the animal's neck without tightening it too tight (as a guide, it should be possible to insert 2 fingers between the collar and the neck). Pull excess collar through the loop(s) and cut off any excess length extending beyond (l/one/an) inch (2 cm) beyond the loop(s).


[After application of the collar, three reflector clips may be fixed permanently to the collar to increase the animal's visibility in the dark. Take the clips out of the bag. The clips should be evenly distributed on the non-overlapping part of the collar. The clips are correctly applied when a clicking sound is heard. For safety reasons once the reflectors are fixed to the collar the clasp closes permanently and cannot be re-opened.]


[Optional Visuals:

Dog











Date: 03/I2/12 Supersedes: 09/20/10

Page 4 of 13

Cat









The collar should be worn continuously for the 8 month protection period. Check periodically and adjust fit if necessary, especially when [(pupples)(kittens)] are rapidly growing.

This collar is designed with a safety-closure mechanism. In the unlikely event of a [(dog)(cat)(pet)] being trapped, the [(dog's)(cat's)(pet's)] own strength is sufficient to widen the collar to allow for quick release.

Replace the collar after 8 months for (optimal) (continuous) flea, (lice) and tick protection.

PRODUCT INFORMATION

Kills fleas which may cause flea allergy dermatitis (FAD) or flea bite hypersensitivity (FBH).

[(PNR 1427 Insecticide)(Brandname)(This product)(The collar)] kills existing fleas on [(dogs)(cats)] within 24 hours. Reinfesting fleas are killed within 2 hours with protection against further flea infestation lasting eight (8) months. Pre-existing pupae in the environment may continue to emerge for six (6) weeks or longer depending upon the climatic conditions.

Larval flea stages in the [(dog's)(cat's)] surroundings are killed following contact with a [(PNR 1427 Insecticide)(brand name)]-treated [(dog)(cat)].

Ticks already on the [(dog)(cat)] prior to treatment may not be killed immediately after collar application and may remain attached and visible. At the time of application remove ticks already on the [(dog)(cat)]. The prevention of infestations with new ticks starts within 48 hours after application of the collar.

Supersedes: 09/20/10

Page 5 of 13

Re-infesting ticks are [(repelled)(killed)(repelled and/or killed)] as quickly as 6 hours.

(Kills lice on dogs.)

Aids in the treatment (and control) of Sarcoptic mange.

[(PNR 1427 Insecticide)(Brand name)(This product)(The collar)] is waterproof and remains effective following a shampoo treatment, swimming or after exposure to rain or sunlight. Under normal conditions, effectiveness lasts for 8 months. In case of loss of collar, a new collar may be applied immediately.

Occasionally slight itching may be observed in animals that are not used to wearing collars in the first few days after fitting. Ensure that the collar is not fitted too tightly. Slight hair loss and mild skin reactions due to the mechanical irritation of the collar may occur at the application site which usually recover within 1 or 2 weeks without the need for collar removal. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinarian.

Do not attach a leash to the collar as this may cause breakage.

Keep the collar in the bag and in the outer packaging until use. As with any pesticide product, do not allow small children to play with the collar (or reflectors,) or to put them into their mouths. Avoid contact with eyes, skin or clothing. Wash thoroughly with soap and cold water after fitting the collar. People with sensitivity reactions to the ingredients of the collar should avoid contact with the collar. [Choking hazard. Contains small parts]. Do not place collar [or reflectors] in mouth. Not intended for use on humans.

For external use on [(dogs)(and)(cats)] only. Do not use on other animals. [(Do not use on puppies under seven weeks of age.)(Do not use on kittens under ten (10) weeks of age.)] Do not get this product in [(dog's)(cat's)] eyes or mouth. As with any product, consult your veterinarian before using this product on debilitated, aged, breeding, pregnant, or nursing animals. Individual sensitivities, while rare, may occur after using ANY pesticide product for pets. If signs of sensitivity occur remove collar and bathe your pet with mild soap and rinse with large amounts of water. If signs persist, or become more severe, consult a veterinarian immediately. If your animal is on medication, consult your veterinarian before using this or any other product. If your [(dog)(or)(cat)] is experiencing an adverse event, contact your veterinarian and, call I-800-422-9874.

The patented Bayer polymer matrix system ensures that both active [(substances) (ingredients)] are slowly and continuously released in low concentrations from the collar towards the animal. This avoids peak concentrations and ensures that concentrations of both

Supersedes: 09/20/10

Page 6 of 13

active [(substances)(ingredients)] are present in the [(cat's)(and/or)(dog's)] haircoat during the entire [(protection)(efficacy)] period. The active [(substances)(ingredients)] spread from the site of direct contact over the entire skin surface.

[INSERT DIAGRAM THAT DEPICTS RELEASE FROM MATRIX.]

STORAGE AND DISPOSAL

Do not contaminate water, food or feed by storage or disposal.

Pesticide Storage: Store in original unopened container in a cool, dry place that is

inaccessible to children.

Container Disposal: Dispose of container, pouch and expired collar in trash.

LIMITED WARRANTY AND LIMITATION OF DAMAGES

Bayer HealthCare LLC, Animal Health Division, warrants that this material conforms to the chemical description on the label. TO THE EXTENT CONSISTENT WITH APPLICABLE LAW, BAYER MAKES NO OTHER EXPRESS OR IMPLIED WARRANTY, INCLUDING ANY OTHER EXPRESS OR IMPLIED WARRANTY OF FITNESS OR MERCHANTABILITY, and no agent of Bayer is authorized to do so except in writing with a specific reference to this warranty. To the extent consistent with applicable law any damages arising from a breach of this warranty shall be limited to direct damages and shall not include consequential commercial damages such as loss of profits or values, etc. [The reflector clips contained herein are only meant to be used in combination with the specific collar and have been tested only for such use and purpose. To the extent consistent with applicable law, Bayer excludes liability for any misuse and use other than in combination with the specific collar as described in the packaging leaflet.]

Supersedes: 09/20/10

Page 7 of 13

Pouch Label

[(PNR 1427 Insecticide)(Brand name)]

10.0% imidacloprid 4.5% flumethrin

Do not let children play with this collar (or reflectors).
FOR USE ON (CATS)(DOGS)(CATS & DOGS)
See (outer container/leaflet) for complete label information.
Do not open until ready to use.

BAYER

EPA Reg. No. 11556-XXXX EPA Est. No. 11556-TBD

Lot No. 0000000

Reason To Issue: Propose new registration Date: 03/12/12
Supersedes: 09/20/10

Page 8 of 13

Note to Reviewer: Brackets [] and parentheses () denote optional language

Optional/Alternative Marketing Claims - Dogs

General Claims - Dogs

- Two active [(substances)(ingredients)] provide dual action against ticks, fleas, and lice (on dogs)
- For use on dogs and puppies 7 weeks of age and older
- Tick, (and) flea (and lice) (prevention)(control)(and) treatment for dogs 7 weeks of age or older
- [(PNR 1427)(Brand name)(This product)] is indicated for the prevention and treatment of ticks, fleas and lice on dogs and puppies (7 weeks of age and older)
- [Effective][Long-lasting] [protection] for 8 months
- Kills (and repels) ticks, (and) kills fleas (and lice)(for 8 months)
- Reliable 8-month protection against ticks, fleas, and lice on dogs (and puppies)
- [3-way] protection against fleas, ticks and lice
- 8-month protection against ticks, fleas and lice
- For (small) dogs up to [(18 lbs.)(8 kg)] [body weight]
- For (large) dogs above [(18 lbs.)(8 kg)] [body weight]
- For external use on dogs
- For [(small dogs and puppies)(large dogs)]
- Fully effective within 48 hours after initial application of collar

Tick Claims - Dogs

- e Repels and kills ticks, including [(Deer)(Black-legged)] ticks, (Ixodes scapularis) (vector of Lyme disease and anaplasmosis), American dog ticks, (Dermacentor variabilis) (vector of Rocky Mountain spotted fever and ehrlichiosis), Brown dog ticks, (Rhipicephalus sanguineus) (vector of ehrlichiosis, anaplasmosis, bartonellosis, babesiosis, canine hemoplasmosis, and Rocky Mountain spotted fever), and Lone Star ticks (Amblyomma americanum) (vector of ehrlichiosis) for 8 months
- Treatment with [(PNR 1427)(brand name)(this product)(the collar)] kills ticks that may transmit Anaplasmosis (Anaplasma phagocytophilium), Bartonellosis (Bartonella vinsonii, Bartonella spp.), Babesiosis (Babesia canis, B. gibsoni), Borreliosis (Borrelia burgdorferi), canine hemoplasmosis (Mycoplasma haemocanis), Ehrlichiosis (Ehrlichia canis, E. chaffeensis, E. ewingii), Hepatozoonosis (Hepatozoon canis and H. americanum), and Rickettsiosis (Rickettsia rickettsii) [,which are types of (canine) vector borne diseases]
- Efficacy against ticks (by repelling and killing) that may transmit Anaplasmosis (Anaplasma phagocytophilium), Bartonellosis (Bartonella vinsonii, Bartonella spp.),

Supersedes: 09/20/10

Page 9 of 13

Babesiosis (Babesia canis, B. gibsoni), Borreliosis (Borrelia burgdorferi), canine hemoplasmosis (Mycoplasma haemocanis), Ehrlichiosis (Ehrlichia canis, E. chaffeensis, and E. ewingii), Hepatozoonosis (Hepatozoon canis and H. americanum), and Rickettsiosis (Rickettsia rickettsii) [,which are types of (canine) vector borne diseases]

- Kills [(Deer)(Black-legged)] ticks (, which may carry Lyme disease and Anaplasmosis)
- Kills American dog ticks (, which may carry Rocky Mountain spotted fever and Ehrlichiosis)
- Kills all [(life)(blood feeding)] stages of ticks
- Kills tick adults, larvae, and nymphs
- Kills ticks within 48 hours of (intitial) application
- Prevents tick infestations within 48 hours after (inititial) application
- [(Kills)(Repels)] ticks in 6 hours after (intial) efficacy has been obtained
- Re-infesting ticks are [(repelled)(killed)(repelled and/or killed)] as quickly as 6 hours
- Protects against all types of ticks (attacking dogs)
- Protects your (dog)(and/or)(puppy) from all types of ticks (for 8 months)
- Easy, effective [(treatment and prevention)(control)] of ticks, (and) fleas (,and lice)

Flea Claims - Dogs

- (Rapidly/Quickly]) Kills fleas on dogs within [24] hours and continues to prevent infestations for 8 months
- Kills fleas before they lay eggs
- Reinfesting fleas are killed within 2 hours with protection against further flea infestation lasting 8 months
- Larval flea stages in the dog's surroundings are killed following contact with a [(PNR 1427)(brand name)] -treated dog, (which will aid in environmental control)
- Prevents, treats, and controls flea larvae in the dog's immediate surroundings
- Prevents, treats, and controls adult and larval stages of the flea
- Protects your (dog)(and/or)(puppy) from fleas (for 8 months)
- For the treatment and prevention of flea infestations [on your dog (and in your dog's immediate surroundings)]
- One treatment prevents further flea infestations (on dogs) for 8 months
- Controls existing flea infestations by killing adult fleas
- Prevents reinfestations by killing adult fleas before they lay eggs
- Prevents fleas on treated dogs from infesting (reinfesting) your home
- Treatment with [(PNR 1427)(brand name)(this product)(the collar)] kills fleas and may reduce the incidence of [flea allergy dermatitis (FAD)][flea bite hypersensitivity (FBH)][flea bite dermatitis (FBD)]
- For prevention and treatment of flea infestation(s) for 8 months

Supersedes: 09/20/10 Page 10 of 13

• [8-month] prevention and treatment of cat fleas (Ctenocephalides felis), dog fleas (Ctenocephalides canis) and human fleas (Pulex irritans) on dogs

- Kills cat fleas (Ctenocephalides felis,) dog fleas (Ctenocephalides canis) and human fleas (Pulex irritans) on dogs
- Treatment with [(PNR 1427)(brand name)(this product)(the collar)] kills fleas and may reduce the (risk/incidence) of tapeworm infections (*Dipylidium caninum*), Bartonellosis (*Bartonella vinsonii, Bartonella spp.*), and Rickettsiosis (*Rickettsia felis*) [, which are types of (canine) vector borne diseases]
- Efficacy against fleas that may transmit tapeworm infections (*Dipylidium caninum*), Bartonellosis (*Bartonella vinsonii, Bartonella spp.*), and Rickettsiosis (*Rickettsia felis*) [,which are types of (canine) vector borne diseases]
- Breaks the flea life cycle
- Stops fleas from feeding by (their) paralysis and death
- Kills fleas that may cause anemia in dogs

Lice & Other Efficacy Claims - Dogs

- Kills [(biting) (chewing)] lice
- For treatment and prevention of [(biting) (chewing)] lice (infestations)
- Controls existing [(biting) (chewing)] lice infestations
- Treats, prevents and controls [(biting) (chewing)] lice (infestations)
- Provides effective control of [(biting) (chewing)] lice (infestations)
- Kills [(biting) (chewing)] lice and prevents further infestations
- For treatment and prevention of infestations of [(biting) (chewing)] lice
- Aids in the treatment (and control) of Sarcoptic mange

Optional/Alternative Marketing Claims – Cats

General Claims - Cats

- Two active [(substances)(ingredients)] provide dual action against ticks and fleas (on cats)
- For use on cats and kittens 10 weeks of age and older
- [Effective][Long-lasting] [protection] for 8 months
- Tick, (and) flea (prevention)(control)(and) treatment for kittens 10 weeks of age or older
- Tick and flea treatment for cats and kittens 10 weeks of age and older
- [(PNR 1427)(Brand name) (The collar)(This product)] is indicated for the prevention and treatment of ticks and fleas on cats and kittens (10 weeks of age and older)
- Kills (and repels) ticks and kills fleas (for 8 months)
- (Reliable) (8-month) protection against ticks and fleas [on cats (and kittens)]
- [Dual] [2-way] protection against ticks and fleas

Supersedes: 09/20/10

Page 11 of 13

• For external use on cats

- For cats and kittens
- Fully effective within 48 hours after initial application of collar

Tick Claims - Cats

- Repels and kills ticks, including [(Deer)(Black-legged)] ticks, (Ixodes scapularis) (vector of Lyme disease and anaplasmosis), American dog ticks (Dermacentor variabilis) (vector of Rocky Mountain spotted fever, cytauxzoonosis, and ehrlichiosis), Brown dog ticks, (Rhipicephalus sanguineus) (vector of ehrlichiosis, anaplasmosis, babesiosis, and Rocky Mountain spotted fever), and Lone Star ticks (Amblyomma americanum) (vector of cytauxzoonosis and ehrlichiosis) (for 8 months)
- Treatment with [(PNR 1427)(brand name)(this product)(the collar)] kills ticks that may transmit Anaplasmosis (Anaplasma phagocytophilium), Babesiosis (Babesia canis, B.spp.), Borreliosis (Borrelia burgdorferi), Ehrlichiosis (Ehrlichia canis, E. spp.), Cytauxzoonosis (Cytauxzoon felis), and Rickettsiosis (Rickettsia rickettsii) [,which are types of (cat) vector borne diseases]
- Efficacy against ticks (by repelling and killing) that may transmit Anaplasmosis (Anaplasma phagocytophilium), Babesiosis (Babesia canis, B. spp.), Borreliosis (Borrelia burgdorferi), Ehrlichiosis (Ehrlichia canis, E. spp.), Cytauxzoonosis (Cytauxzoon felis), and Rickettsiosis (Rickettsia rickettsii) [,which are types of (cat) vector borne diseases]
- Kills [(Deer)(Black-legged)] ticks (, which may carry Lyme disease)
- Kills American dog ticks (, which may carry Rocky Mountain spotted fever)
- Kills all (life) (blood feeding) stages of ticks
- Kills tick adults, larvae, and nymphs
- Kills ticks within 48 hours of (intitial) application
- Prevents tick infestations within 48 hours after (initial) application
- [(Kills)(Repels)] ticks in 6 hours after (intitial) efficacy has been obtained
- Re-infesting ticks are [(repelled)(killed)(repelled and/or killed)] as quickly as 6 hours
- Protects against all types of ticks (attacking cats)
- Protects your (cat)(and/or)(kitten) from all types of ticks (for 8 months)
- Easy, effective [(treatment and prevention)(control)] of ticks and fleas

Flea Claims - Cats

- (Rapidly/Quickly) Kills fleas on cats within [24] hours and continues to prevent infestations (for 8 months)
- Kills and repels fleas before they lay eggs

Supersedes: 09/20/10 Page 12 of 13

Reinfesting fleas are killed within 2 hours with protection against further flea infestation (lasting 8 months)

- Larval flea stages in the cat's surroundings are killed following contact with a [(PNR 1427)(brand name)(collar)] -treated cat (which will aid in environmental control)
- Prevents, treats, and controls flea larvae in the cat's immediate surroundings
- Prevents, treats, and controls adult and larval stage of the flea
- Protects your (cat)(and/or)(kitten) from fleas (for 8 months)
- For the treatment and prevention of flea infestations on your cat (and in your cat's immediate surroundings)
- One treatment prevents further flea infestations (for 8 months)
- Controls existing flea infestations by killing adult fleas
- Prevents reinfestations by killing adult fleas before they lay eggs
- Treatment with [(PNR 1427)(brand name)(the collar)(this product)] kills fleas and may reduce the incidence of [flea allergy dermatitis (FAD)][flea bite hypersensitivity (FBH)][flea bite dermatitis (FBD)]
- For prevention and treatment of flea infestation(s) for 8 months
- [8-month] prevention and treatment of cat fleas (Ctenocephalides felis), dog fleas (Ctenocephalides canis) and human fleas (Pulex irritans) on cats
- Treatment with [(PNR 1427)(brand name) (the collar)(this product)] kills fleas that may transmit Bartonellosis (*Bartonella henselae*), tapeworm infections (*Dipylidium caninum*), Feline infectious anemia (*Mycoplasma spp.*), and Rickettsiosis (*Rickettsia felis*)
- Efficacy against fleas that may transmit Bartonellosis (*Bartonella henselae*), tapeworm infections (*Dipylidium caninum*), Feline infectious anemia (*Mycoplasma spp.*), and Rickettsiosis (*Rickettsia felis*)
- Breaks the flea life cycle
- Stops fleas from feeding by (their) paralysis and death
- Kills fleas that may cause anemia in cats

Other Efficacy Claims - Cats

Aids in the treatment (and control) of Sarcoptic mange

Optional/Alternative Marketing Claims - General

- Protects for 8 months
- (8-month) [(protector band)(pet collar)(collar)]
- [(Kills)(Protects)] for 8 months
- (Make sure to) replace (the) collar after 8 months [for year-round (control)(prevention)]
- Remains effective after bathing or swimming

Supersedes: 09/20/10 Page 13 of 13

• Remains effective following shampooing, swimming or after rain

- [(Wetness)(Moisture)] does not reduce the collar's effectiveness
- No need to remove (the) collar while bathing pet
- No need to remove collar when (your) pet goes swimming or [(gets bathed)(bathing)]
- Waterproof
- Water resistant
- Fragrance-free
- Odorless
- No (noticeable) odor
- Non-greasy
- Easy to use
- (Easy)(convenient)(to use)(to apply)
- [(Graphite)(Gray)][Red][Yellow][(collar)(color)]
- (Adjustable)(convenient)(easy-to-apply) collar
- (Light) reflectors for added visibility (in the evening and at night)
- (Three) (3) (visibility) reflectors (included)
- (Snap-on) reflectors (included) for added (night-time)(pet)(visibility)
- One collar per animal (to be fastened around the neck)
- Contains one collar
- [(Patented)(Bayer)(technology) (polymer)(matrix)(system)] ensures that both active [(substances)(ingredients)] are (slowly) (and continuously) released (in low concentrations).
- (Patented) (Bayer) (Polymer) Matrix: [(effective)(dependable)(long-lasting)] (flea and tick) control (for 8 months)
- (Depot effect:) [Active (substances)(ingredients)] stored inside the polymer matrix and gradually released over time]
- [(Continuous)(Even distribution)(Steady)] release) of active [(substances)(ingredients)] (over 8 months)
- (Continuous) protection (over 8 months)
- Contains [(Patented)(Bayer) (polymer)(matrix)(system)]

Optional/Alternative Marketing Claims – Combined label for small collar for use on small dogs and cats

For external use on small dogs and cats only



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

MEMORANDUM:

To: BeWanda Alexander

From: Clayton Myers, Entomologist

Date: March 14, 2012

Subject: PRODUCT PERFORMANCE DATA EVALUATION RECORD

DP barcode:

385561, 385623, 393362

Decision no.:

440307

Submission no:

882827, 902307

Action code:

R110.0

Product Name:

PNR 1427 Insecticide

EPA Reg. No or File Symbol:

11556-RLL

Formulation Type:

RTU Pet Collar

Ingredients statement from the label with PC codes included: Flumethrin, 4.50% PC: 36007; Imidacloprid,

10.00%, PC: 129099

Application rate(s) of product and each active ingredient (Ibs. or gallons/1000 square feet or per acre as appropriate; and g/m² or mg/cm² as appropriate): One collar per animal, cut to fit with some slack around neck (varies somewhat upon animal size). Claims through 8 months for some pests, including waterproof/washing/water immersion.

- I. Aetion Requested: Data was submitted to support pest claims for a ready to use, indoor, non-food product; a companion animal collar impregnated with 2 active ingredients.
- II. Background: The registrant seeks to register a flumethrin/imidacloprid combo pet collar product for control of fleas and ticks and lice on dogs, and fleas and ticks on cats. The registrant has submitted 20 studies to support efficacy claims.
- III. MRID Summaries: (Primary Review attached)

a. MRID 4857650I

- (I) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against Deer ticks, *Ixodes scapularis* adults and nymphs against hair taken from treated animals via an *in vitro* exposure study. Three dogs were acclimated and used for this study, with 2 animals provisioned with the treated collars (one as a backup), and one left as an untreated control. Pre-treatment hair samples were taken and tick exposures conducted to confirm no insecticidal activity of untreated hair. Periodically after treatment, through 240 days (8 months), hair samples were taken from the test dog and control dog from various body surfaces. One gram of hair was placed into each of 6 Petri dishes to which were added 10 nymph and 10 adult ticks. Counts of live and dead ticks were made after 48 hours of exposure. Mortality was calculated using Abbott's formula.
- (3) Efficacy for all exposures and all tick stages exceeded 97% through 240 days after initial placement of the collar, with most of the exposures resulting in 100% control. Authors conclude

that efficacy is supported for Deer ticks. The primary reviewer concurred that the data was adequate to support 8 month efficacy claims Deer ticks, but noted that the collars were not exposed to any weathering and thus the claims were only supportive of dogs kept indoors.

(4) The study is acceptable to 8 month control claims against Deer ticks, *Ixodes scapularis*, on dogs, with control starting within 48 hours of collar placement.

b. MRID 48576502

- (1) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against Deer ticks, *Ixodes scapularis* adults on dogs treated with the collar. Dogs were acclimated and prequalified for tick retention. 16 dogs were used in the study with 8 each (4 males and 4 females) allocated to either a treatment or control group. 50 ticks were placed on each dog one day prior to placement of collars. Dogs under 18 lbs received a small collar and larger dogs received the large collar. Ticks were counted 2 days after placement of collars via removal. Periodic re-infestations were made onto the dogs, with counts and removal at 48 hours. The study was carried through 247 days (8 months). Mortality was calculated using Abbott's formula.
- (3) Efficacy for all exposures and all tick stages exceeded 96% through 247 days after initial placement of the collar, with most of the exposures resulting in 100% control. Authors conclude that efficacy is supported for Deer ticks. The primary reviewer concurred that the data was adequate to support 8 month efficacy claims Deer ticks, but noted that the collars were not exposed to any weathering and thus the claims were only supportive of dogs kept indoors.
- (4) The study is acceptable to 8 month control claims against Deer ticks, *Ixodes scapularis*, with control starting within 48 hours of collar placement.

c. MRID 48240116

- (1) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against Dermacentor variabilis and Rhipicephalus sanguineus ticks and Ctenocephalides felis fleas on dogs treated with the collar. Dogs were acclimated and pre-qualified for flea retention. 16 dogs were used in the study with 8 each (4 males and 4 females) allocated to either a treatment or control group. 50 ticks of each species and 100 fleas were placed on each dog one day prior to placement of collars. All dogs were over 18 lbs. and thus, all dogs received the large collar. Ticks and fleas were counted 2 days after placement of collars via removal. Periodic re-infestations were made onto the dogs, with counts and removal at 48 hours. The study was carried through 254 days (8 months). Mortality was calculated using Abbott's formula.
- (3) Flea efficacy for all exposures exceeded 96% through 246 days after initial placement of the collar. Flea efficacy upon the day 7 re-infestation was also greater than 90% within 2 hours of re-infestation. Tick efficacy for both species exceeded 90% through 240 days after initial placement, except for the 2 day assessment, which was inadequate (likely due to the time taken for the material to spread through the dogs hair initially). Authors conclude that efficacy is supported for fleas and ticks. The primary reviewer concurred that the data was adequate to support 8 month efficacy claims for American Dog Ticks, Brown Dog Ticks, and Fleas, but noted that the collars were not exposed to any weathering and thus the claims were only supportive of dogs kept indoors.
- (4) The study is acceptable to 8 month control claims against Ticks (ABT and BDT) and fleas, with control starting within 48 hours of collar placement for fleas.

d. MRID 48240117

- (1) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against *Amblyomma americanum* adult ticks and *Ctenocephalides felis* fleas on cats treated with the collar. Cats were acclimated and pre-qualified for flea retention. 16 domestic short-hair cats were used in the study with 8 each (mixed sex) allocated to either a treatment or control group. 50 ticks and 100 fleas were placed on each cat one day prior to placement of collars. Ticks and fleas were

counted 2 days after placement of collars via removal. Periodic re-infestations were made onto the cats, (alternating between fleas and ticks over the course of the study) with counts and removal at 48 hours. The study was carried through 246 days (8 months). Mortality was calculated using Abbott's formula.

- (3) Flea efficacy for all exposures exceeded 90% through 246 days after initial placement of the collar (8 months). Flea efficacy upon the day 7 re-infestation was also greater than 90% within 2 hours of re-infestation. Tick efficacy exceeded 90% through 240 days after initial placement, except for the 2 day assessment, which was inadequate (likely due to the time taken for the material to spread through the cats' hair initially). Authors conclude that efficacy is supported for fleas and ticks. The primary reviewer concurred that the data was adequate to support 8 month efficacy claims for Lone Star Ticks, and Fleas, but noted that the collars were not exposed to any weathering and thus the claims were only supportive of cats kept indoors.
- (4) The study is acceptable to 8 month control claims against *Amblyomma americanum* and fleas on cats, with control starting within 48 hours of collar placement for fleas.

e, MRID 48240118

- (1) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against *R. sanguineus* and *D. variabilis* adult ticks and *Ctenocephalides felis* fleas on dogs treated with the collar after water immersion and shampooing. Dogs were acclimated and pre-qualified for flea retention. 32 dogs were used in the study with 8 each allocated to 4 groups: Treated immersed, Treated shampooed, Untreated immersed, Untreated shampooed. Shampooing was conducted monthly and the immersion group was immersed in water monthly. 50 ticks of each species and 100 fleas were placed on each dog at times prior to placement of collars. Ticks and fleas were counted 2 days after placement of collars via removal. Periodic re-infestations were made onto the dogs, with counts and removal at 48 hours. The study was carried through 232 days (7 months). Mortality was calculated using Abbott's formula,
- (3) Flea efficacy for the shampoo group exceeded 90% through day 225. For water immersion, efficacy only exceeded 90% though day 141. R. sanguineus efficacy exceeded 90% though day 232 for both groups. D. variabilis efficacy exceeded 90% though day 225 for shampooing but only day 197 for water immersion. The primary reviewer concurred with the author's conclusion that data was adequate to support 8 month claims for prevention of fleas and ticks when shampooed once per month. Because D. variabilis efficacy was only adequate for 7 months and flea efficacy was only adequate through day 141, only a 5 month claim would be acceptably supported. The reviewer also states that the label must specify that bathing/swimming should be no more than once per month for the claims to be supported by this data set.
- (4) The study is acceptable to support 8 month claims against fleas and ticks for dogs that are shampooed no more than once per month. For dogs that swim once per month, flea claims are limited to 5 months and tick claims to 7 months.

f. MRID 48240119

- (1) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against *Ixodes ricinus* adult ticks and *Ctenocephalides felis* fleas on cats treated with the collar. Cats were acclimated and pre-qualified for flea retention. 20 domestic short-hair cats were used in the study with 10 each (mixed sex) allocated to either a treatment or control group. 40 ticks were placed on each cat two days prior to placement of collars. 100 fleas were placed on the day before treatment. Ticks and fleas were counted 2 days after placement of collars via removal. Periodic reinfestations were made onto the cats, (alternating between fleas and ticks over the course of the study) with counts and removal at 48 hours. The study was carried through 237 days (8 months). Mortality was calculated using Abbott's formula.
- (3) Tick efficacy for all exposures exceeded 90% through 239 days after initial placement of the collar (8 months), except for the 2 day assessment, which was inadequate (likely due to the time taken for the material to spread through the cats' hair initially). Flea efficacy exceeded 90%

through 239 days after initial placement. Authors conclude that efficacy is supported for fleas and ticks. The primary reviewer concurred that the data was adequate to support 8 month efficacy claims for Ticks, and Fleas.

(4) Because *Ixodes ricinus* is a species known to have similar susceptibility to *Ixodes scapularis* the data are adequate to support 8 month efficacy claims for *Ixodes* ticks. For fleas, the study is acceptable to 8 month control claims on cats.

g. MRID 48240120

- (1) GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against Ixodes ricinus and Rhipicephalus sanguineus ticks and Ctenocephalides felis fleas on dogs treated with the collar. Dogs were acclimated and pre-qualified for flea retention. 20 dogs were used in the study with 10 each allocated to either a treatment or control group. 40-50 ticks of each species and 100 fleas were placed on each dog two days prior to placement of collars. All dogs were over 18 lbs. and thus, all dogs received the large collar. Ticks and fleas were counted 2 days after placement of collars via removal. Periodic re-infestations were made onto the dogs, with counts and removal at 48 hours. The study was carried through 237 days (8 months). For female ticks, engorgement was determined for female ticks. Mortality was calculated using Abbott's formula. To evaluate repellency, ticks attached to the dogs on day -8 (pre-qualifying) were counted at 3 and 6 hours after placement to verify the appropriateness of time points for evaluation. Tick counts for repellency determination was done the same way after every re-infestation without removal of ticks. A flea larvicidal assessment was conducted on days -7 to -5, and then in 2 to 5 week intervals from day 12 forward to when dogs were not infested with parasites. Fleece-lined board were placed on the floors of dog kennels for 3 hours on 3 consecutive days. Samples were cut from the blankets, placed in petri dishes, and frozen. Remaining parts of the blanket were also frozen and stored. The wooden board was cleaned and a new blanket fixed. After removal from the freezer, petri dishes were allowed to reach room temperature and ~50 fiea eggs from the same colony were placed in the middle of the blanket sample. Flea rearing medium was spread over the surface and samples were incubated for 28 days.
- (3) Tick efficacy for both species exceeded 90% through 238 days after initial placement, except for the 2 day assessment, which was inadequate (likely due to the time taken for the material to spread through the dogs hair initially). Tick repellency, within hours of placement, for both species exceeded 90% from 27 to 236 days after initial treatment. Adult flea efficacy exceeded 99% from day 2 to day 238 after treatment. Larvicidal effects against fleas exceeded 99% for days 12-245 after treatment. The primary reviewer concurred that the study was adequate to support 8 month flea and tick claims.
- (4) Because *Ixodes ricinus* is a species known to have similar susceptibility to *Ixodes scapularis* the data are adequate to support 8 month efficacy claims for *Ixodes* ticks. For *R. sanguineus* and fleas, the study is acceptable to 8 month control claims against ticks and fleas.

h. MRID 48240121

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate killing efficacy of the test product against *Ixodes ricinus* adult ticks and *Ctenocephalides felis* fleas on cats treated with the collar. Cats were acclimated and pre-qualified for flea retention. 20 domestic short-hair cats were used in the study with 10 each (mixed sex) allocated to either a treatment or control group. 40 ticks were placed on each cat two days prior to placement of collars. 100 fleas were placed on the day before treatment. Ticks and fleas were counted 2 days after placement of collars via removal. Periodic reinfestations were made onto the cats, (alternating between fleas and ticks over the course of the study) with counts and removal at 48 hours. The study was carried through 237 days (8 months). Mortality was calculated using Abbott's formula. To evaluate repellency, ticks attached to the cats on day -8 (pre-qualifying) were counted at 3 and 6 hours after placement to verify the appropriateness of time points for evaluation. Tick counts for repellency determination was done the same way after every re-infestation without removal of ticks. A flea larvicidal assessment was

conducted on days -7 to -5, and then in 2 to 5 week intervals from day 12 forward to when cats were not infested with parasites. Fleece-lined board were placed on the floors of cat transport boxes for 3 hours on 3 consecutive days. Samples were cut from the blankets, placed in petri dishes, and frozen. Remaining parts of the blanket were also frozen and stored. The wooden board was cleaned and a new blanket fixed. After removal from the freezer, petri dishes were allowed to reach room temperature and ~50 flea eggs from the same colony were placed in the middle of the blanket sample. Flea rearing medium was spread over the surface and samples were incubated for 28 days. Efficacy against flea eggs was evaluated by rearing flea eggs with debris that fell out of the cats' hair (100 mg of debris: 100 mg of flea medium). Eggs were incubated for 4 days and hatch was evaluated.

- (3) Tick efficacy for all exposures exceeded 90% through 239 days after initial placement of the collar (8 months), for both killing and repellence (237 days). Flea efficacy exceeded 90% through 169 days after initial placement. Larvicidal efficacy exceeded 90% through 37 days. Ovicidal efficacy never reached 90% for flea eggs. Authors conclude that efficacy is supported for fleas and ticks. The primary reviewer concurred that the data was adequate to support 8 month efficacy claims for Ticks. For fleas, the supported efficacy duration was shorter. The author concurred that use of the collar could aid in the control of flea larvae, and thus other fleas in the pets environment
- (4) Because *Ixodes ricinus* is a species known to have similar susceptibility to *Ixodes scapularis* the data are adequate to support 8 month efficacy claims for *Ixodes* ticks. For fleas, the study is acceptable to support a 5 month claim on flea adults, and an aids in control claim for flea larvae. No larvicidal claims are supported.

i. MRID 48240122

(1) non-GLP study

}

- (2) A clinical field study was conducted using parasite infested animals. The study enrolled 346 animals from France, Germany, Hungary, and Portugal.
- (3) The study is rated supplemental regarding claims on the label for pests found in the United States.

j. MRID 48240123

- (1) non-GLP study ·
- (2) A clinical field study was conducted using parasite infested animals. The study enrolled 346 animals from France, Germany, Hungary, and Portugal.
- (3) The study is rated supplemental regarding claims on the label for pests found in the United States.

k. MRID 48240124

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the onset of efficacy against cat fleas, Ctenocephalides felis on cats. Cats were acclimated and pre-qualified for flea retention. 16 domestic short-hair cats were used in the study with 8 each (mixed sex) allocated to either a treatment or control group. After qualification, 100 fleas were placed on each cat on the day of placement of collars. Fleas were counted 1 day after placement of collars via removal. Mortality was calculated using Abbott's formula.
- (3) Flea efficacy at one day after placement (and treatment) was 99.8%. The study authors indicate the study is acceptable to support a claim that the product controls fleas within 24 hours. The primary reviewer concurs with this conclusion.
- (4) The study is acceptable to support claims against fleas on cats for killing within 24 hours.

l. MRID 48240125

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the onset of efficacy against cat fleas, Ctenocephalides felis on dogs. Dogs were acclimated and pre-qualified for flea retention. 16 dogs

were used in the study with 8 each (mixed sex) allocated to either a treatment or control group. After qualification, 100 fleas were placed on each cat on the day of placement of collars. Fleas were counted 1 day after placement of collars via removal. Mortality was calculated using Abbott's formula.

- (3) Flea efficacy at one day after placement (and treatment) was 100.0%. The study authors indicate the study is acceptable to support a claim that the product controls fleas within 24 hours. The primary reviewer concurs with this conclusion.
- (4) The study is acceptable to support claims against fleas on dogs for killing within 24 hours.

m. MRID 48240126

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the killing efficacy of flumethrin against 2 *Ixodes* species in an in vitro exposure assay. Flumethrin was dissolved in acetone and transferred into snap cap vials and centrifuged for 2 hours at room temperature. Vials were uncapped and acetone was evaported to leave a uniform coating on the inside of the vial (44.7 sq cm). Five unfed ticks were transferred to each vial, capped, and kept at room temperature. Efficacy was evaluated by placing vials to a heating table to observe ticks for heat avoidance behavior, after 24 and 48 h exposure. There were 7 dosages tested along with untreated and solvent control groups. There were 6 reps per concentration per tick species, with 5 ticks per vial. Inferential statistical analysis was performed using repeated measures ANOVA with concentration, tick species, and time as fixed effects in the model. The 2 and 3 way interactions were also included as mixed effects into the model.
- (3) 24 hour tick efficacy for all species exceeded 90% at doses of 0.288 ppm and higher. For 48 hours, >90% efficacy was observed at doests of 0.0576 ppm and higher. Study authors say these data suggest similar susceptibility responses of the 2 *Ixodes* spp. toward flumethrin.
- (4) The study is rated as supplemental, as the data are based upon technical grade active ingredient, and other product specific collar data have already been submitted to support tick efficacy claims. However, the data are acceptable to demonstrate that efficacy data between the two *Ixodes* species are similar and could be used to support bridging arguments for *Ixodes* efficacy data between the two species.

n, MRID 48240127

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the onset of activity of the submitted collar against *Ixodes ricinus* on cats. 16 cats were assigned to either a treated or control group (8 cats per group). Cats were prequalified for tick retention. Cats were infested with 20 adult female and 15 adult male ticks on SD -6, 0, and 2 (cats were sedated). On SD 2, female ticks were counted and removed at 48 hours after treatment. After re-infestation, tick counts for repellency were made at 6 h after re-infestation. After tick removal, engorgement status was determined. For determination of repellency, the female ticks were specified during counting as dead or alive. Efficacy (mortality or repellency) was calculated using Abbott's formula, and compared statistically between the 2 groups using a 2 tailed Wilcoxon-Mann-Whitney-U-test (p = 0.05). (3) Killing efficacy for ticks at 48 hours after treatment was 95.5%. Repelling efficacy at 6 hours after the SD 2 re-infestation was 100%.
- (4) The study is acceptable to support killing claims against *Ixodes* ticks on cats within 48 hours and supports the claims of preventing tick infestations within 48 hours after initial application on cats.

o. MRID 48240128

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate efficacy against *Ixodes ricinus* ticks on dogs. 14 dogs (7 per treatment) were used in the study, and were housed in individual pens with petroleum jelly barriers to prevent escape of ticks. On SD -2, 40 ticks were placed on each dog. On SD 0, the dogs assigned to the collar group were fitted. Reinfestations were made on days 7, 28, 56, 84,

- 112, 133, 168, 196, 223, and 238 with 35 ticks placed on each dog. Ticks were counted at 48 h after each infestation. On SD 0, live attached ticks were counted without removal. Efficacy was calculated using Abbott's Formula.
- (3) Killing control efficacy for day 2 wasy 89.9, and was 100% for all other reinfestations through day 240.
- (4) The study is acceptable to support claims against Ixodes ricinus for 8 months.

p. MRID 48240129

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the onset of activity of the submitted collar against *Ixodes ricinus* and *Rhipicephalus sanguineus* on dogs. 16 dogs were assigned to either a treated or control group (8 dogs per group). Dogs were prequalified for tick retention. Dogs were infested with 20 adult female and 15 adult male *Ixodes* ticks and 50 mixed sex *Rhipicephalus* ticks on SD -5, 0, and 2 (cats were sedated). On SD 2, female *Ixodes* ticks and all *Rhipicephalus* were counted and removed at 48 hours after treatment. After re-infestation, tick counts for repellency were made at 6 h after re-infestation. After tick removal, engorgement status was determined. For determination of repellency, the female ticks were specified during counting as dead or alive. Efficacy (mortality or repellency) was calculated using Abbott's formula, and compared statistically between the 2 groups using a 2 tailed Wilcoxon-Mann-Whitney-U-test (p = 0.05).
- (3) Killing efficacy for ticks at 48 hours after treatment was 96.8% for R. sanguineus and 96.2% for Ixodes. Repelling efficacy at 6 hours after the SD 2 re-infestation was 99.2% for R. sanguineus and 100% for Ixodes.
- (4) The study is acceptable to support killing claims against *Ixodes* and *R. sangutneus* ticks on dogs within 48 hours and supports the claims of preventing tick infestations within 48 hours after initial application on dogs.

g. MRID 48240130

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the killing efficacy of flumethrin/imidacloprid against 3 tick species (Ixodes ricinus, Rhipicephalus sanguineus, and Dermacentor reticulatus) in an in vitro exposure assay. An appropriate amount of the test compound mixture (1:1.85 flumethrin: imidacloprid) was dissolved in acetone and transferred into snap cap vials and centrifuged for 2 hours at room temperature. Vials were uncapped and acetone was evaported to leave a uniform coating on the inside of the vial (44.7 sq cm). Five unfed adult ticks, 10 unfed nymphs, or approximately 25 unfed larvae were transferred to each vial, capped, and kept at room temperature. Efficacy was evaluated by placing vials to a heating table to observe ticks for heat avoidance behavior, after 24 and 48 h exposure. There were 8 dosages tested along with untreated and solvent control groups. There was one repolicate per treatment per tick species. Inferential statistical analysis was performed using repeated measures ANOVA with concentration, tick species, and time as fixed effects in the model. The 2 and 3 way interactions were also included as mixed effects into the model.
- (3) 24 and 48 hour efficacy for all stages of *Ixodes ricinus* ticks was >90% for concentrations of 7.2 ppm and higher of test material. 24 and 48 hour efficacy for all stages of *Rhipicephales* sanguineus was >90% for concentrations of 1.44 ppm and higher. 24 and 48 hour efficacy for all stages of *Dermacentor reticulatus* ticks was >90% for concentrations of 0.288 ppm and higher.
- (4) The study is rated as supplemental, as the data are based upon technical grade active ingredients, and other product specific collar data have already been submitted to support tick efficacy claims.

r. MRID 48240131

- (1) non-GLP study
- (2) A laboratory study was conducted to evaluate the killing efficacy of a pet collar against existing natural infestations of dog lice, *Trichodectes canis*. 18 dogs were evaluated in the study, with 9 dogs placed in either a control or treated group. Natural lice infestations were evaluated by

counts at 8 specified sites on each dog and lice were not removed. On SD's -5, -2, -1, 2, 7, 14, 21, 28, and 35, lice counts were made for each dog for a minimum of 5 minutes per dog. Counts at a number of sites were determined based upon finding lice at sites specified in the study. Effectiveness was calculated using Abbott's formula, based upon pre and post-treatment counts for each dog at each interval. Infestation was defined as a dog having at least one louse and viable eggs present or >/= 10 live lice. The effectiveness threshold was set at 95%. Lice counts were also compared statistically using ANOVA.

- (3) 48 hour efficacy was 95.1% and efficacy was 100% for the remainder of the study.
- (4) The study is acceptable to support claims against dog lice (*Trichodectes canis*) for one month on dogs. Claims longer than one month are not supported by this data set.

s. MRID 48240132

- (1) GLP study
- (2) A laboratory study was conducted to evaluate the killing efficacy of a pet collar against existing natural infestations of sarcoptic mange mites, Sarcoptes scabiei. 10 dogs were evaluated in the study, and were determined to be infested with S. scabiei but not Demodex spp. There was no control group. Dogs were subject to mite counts via skin scrapings on days -2, 29, 60, and 90 from 5 different body areas suspected of being infested. Scrapes were made with a blade to that capillary oozing occurred. The scraping was transferred to a marked microscope slide containing mineral oil for examination for the presence of live mites. Clinical signs and extent of scabietic lesions on each dog were assessed on the days when scrapings were made, and classified via a qualitative scale for scales, and hair loss. Photographs were taken to assist in these qualitative assessments. An overall success rate was calculated by dividing the number of dogs with no live mites by the total number of dogs in the group and multiplying by 100. The study authors defined effectiveness as a success rate that was >/= 90%.
- (3) Mite presence was reduced to 10% on days 29 and 60, with 0% mite occurrence by day 90. The percent of dogs showing papules on skin decreased from 75% to 20% by day 90, and skin crusting was reduced similarly. Study authors conclude that since mite numbers were reduced by 100% over the course of the study (along with the other clinical measurements), that the study should support claims against sarcoptic mange mites.
- (4) The primary reviewer points out that the lack of a control group is a deficiency, but that overall evidence of mite reduction is acceptable given the design of the study. The study is partially acceptable, and can be used to support an "aids in control" or "aids in treatment" claim for Sarcoptic mange.

t. MRID 48240133

- (1) non-GLP study
- (2) An *in vitro* laboratory study was conducted to evaluate the killing efficacy (speed of kill) for hair clipped from animals treated with a a pet collar--against brown dog tick, *Rhipicephalus sanguineus*. 2 predecessor studies were conducted where hair was clipped from treated animals from various parts of the animal's bodies. For this study, a chest hair sample was taken with a flumethrin content that was most equivalent to the mean group was chosen for a contact test to evaluate the onset of efficacy. Approximately 0.1g of each sample of the left and right chest were taken, weighed, and mixed; for both cats and dogs. 6 unfed adult ticks were counted into glass vials on SD -3 and kept in an incubator. On SD 0, the ticks were placed onto treated hair samples in petri dishes and kept in an incubator. Tick status was evaluated at 2, 6, 8, 12, 24, and 48 h after initial contact. The study was repeated at 7, 14, 21, 30, 59, 90, 120, 149, 181, 210, and 240 days after initial animal treatment with the collar. Status was assessed by visual examination of the ticks reaction to a heating plate. Mortality was assessed and %Efficacy was calculated using Abbott's formula.
- (3) For dogs, all ticks were alive at the 2 h examination for every treatment duration. Efficacy reached 100% by the 6 hour examination for all treatment intervals through 210 days. At 240 days, the efficacy did not exceed 90% until 12 hours of exposure had elapsed, but 83% efficacy was observed from 6-8h. For cats, all ticks were alive at the 2 h examination for every treatment

duration. Efficacy reached 100% by the 6 hour examination for all treatment intervals through 210 days. At 240 days, the efficacy did not exceed 90% until 8 hours of exposure had elapsed, but 50% efficacy was observed at 6h. The study author argues that taking atactic ticks would not be able to attach to skin, overall efficacy in dog and cat hair exceeds 98% after 6 h exposure.

(4) The primary reviewer points out that the lack of a control group is a deficiency, as efficacy was based upon comparisons with SD -1 data. The data supports the addition of *R. sanguineus* claims for dogs within 6 hours after initial efficacy has been obtained, and re-infesting ticks are controlled as quickly as 6 hours. Claims against ticks are supported for cats, but not for the 6 hour onset of activity.

u. MRID 48240134

This study contains data in support of an imidacloprid spot-on product that is not applicable to this submission. It is rated as supplemental.

v. MRID 48240137

This study contains data in support of an imidacloprid spot-on product that is not applicable to this submission. It is rated as supplemental.

IV. RECOMMENDATIONS:

- (1) Labeling:
 - (a) What pests and site/pest combinations may be added as follows to the label based on the submitted or cited data?

For 8 month prevention and treatment of ticks, fleas, on dogs and cats.

For 1 month prevention and treatment of lice on dogs

Kills ticks within 48 hours of treatment or re-infestation

Kills fleas within 24 hours of treatment or re-infestation

Aids in control of flea larvae in pet's environment

Kills lice on dogs

Kills ticks within 6 hours of reinfestation on dogs

Kills re-infesting fleas (after initial 7 days) within 2 hours

(b) What pests and site/pest combinations must be removed from the label?

Claims against lice must not exceed 1 month

Waterproof claims must be clarified as followed:

- -In order to maintain an 8 month control duration, dogs must not be bathed more than once per month
- -If dogs swim once per month, the control duration must be revised to 5 months
- -Water exposure (i.e. immersion, bathing, or prolonged exposure to rain) can only be once per month Tick claims for killing within 6 hours of reinfestation on cats must be removed—the claim only is supported for dogs.
- (c) List changes to the directions for use:

Remove the directions for killing roaches and ants ('in the environment') on page 2.

(d) List changes to the optional marketing claims:

Claims against lice must be limited to one month

All claims related to '8 months' must be limited to fleas and ticks only. Other pests are not controlled for that Page 9 of 10

duration.

All claims related to control of flea larvae in the pet's environment must be removed or revised to 'aids on control' for fleas in the pet's environment. This product does not provide efficacy as an area-wide/premise treatment against flea larvae.

All disease claims must be deleted, unless the claim is stated "kills/controls xxx pest that may vector yyy."

All claims of "breaking the flea life cycle" must be deleted. This claim implies efficacy against flea eggs and larvae similar to IGR products that are specifically designed to break the flea life cycle for months. This product does not have that level of efficacy against eggs and larvae.



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND POLILITION PREVENTION

OFFICE OF PESTICIDE PROGRAMS REGISTRATION DIVISION (7505P)

February 1, 2012

MEMORANDUM: Acute Toxicity Study and Waiver Request DERs for 11556-RLL

Subject:

Name of Pesticide Product: PNR1427 INSECTICIDE COLLAR

EPA Reg. No. /File Symbol: 11556-RLL

DP Barcode:

DP 385538

Decision No.:

440307

Action Code:

R110.0

PC Codes:

129099 (Imidacloprid

036007 (Flumethrin: 96.2%)

From:

Byron T. Backus, Ph.D., Toxicologist

Bynt. B-0 E.M. Chelw F-6.1, 2012 Fall 2012

To:

BeWanda Alexander/Richard Gebken RM 10

Insecticide Branch

Registration Division (7505P)

Technical Review Branch Registration Division (7505P)

Registrant:

BAYER HEALTHCARE LLC

FORMULATION FROM LABEL:

Active Ingredient(s): by wt. 036007 Flumethrin* 4.5% 129099 Imidacloprid 10.0% Other Ingredient(s): 85.5% TOTAL 100.0%

ACTION REQUESTED: The Risk Manager requests:

"Please review attached acute toxicity studies submitted in support of a new end use product containing two active ingredients: one currently registered (imidacloprid) and a new active ingredient (flumethrin)."

^{*}Trans Z-1/trans Z-2 ratio: max 66% trans Z-1 and min 34% trans Z-2

BACKGROUND:

The material received for review includes waiver requests for acute oral toxicity, acute dermal toxicity, acute inhalation toxicity, and primary eye irritation (MRIDs 48240102 through 48240105), as well as a primary dermal irritation study (in MRID 48240106) and a dermal sensitization study (MRID 48240107). This product is a collar (PNR1427 Insecticide, with an ingredient statement indicating that it contains 4.5% flumethrin and 10.0% imidacloprid); both ingredients are embedded in a plastic matrix.

COMMENTS AND RECOMMENDATIONS:

- 1. It is noted by TRB that although lmidacloprid-containing formulations have been registered as cat and dog spot-ons, no lmidacloprid-containing collars have been registered, so this collar represents both a new use for lmidacloprid and a new active ingredient in Flumethrin.
- A contractor (Summittee Corporation) did the primary reviews on the waiver requests and acute toxicity studies, producing a DER for each; TRB did secondary reviews on the DERs, making revisions where appropriate.
- 3. TRB concludes that, based on the nature of this product (a plastic collar for use on dogs and/or cats) and the relatively low release rates of the two active ingredients from the collar matrix, waivers are appropriate for the oral toxicity, dermal toxicity, inhalation toxicity and eye irritation studies. The remaining two reports (primary dermal irritation study in MRID 48240106 and dermal sensitization study in 48240107) have been classified as acceptable.
- 4. The following is the acute toxicity profile for EPA File Symbol 11556-RLL (PNR1427 INSECTICIDE COLLAR), based on the considerations indicated above:

Acute oral toxicity	IV	Waived	MRID 48240102
Acute dermal toxicity	IV	Waived	MRID 48240103
Acute inhalation toxicity	IV	Waived	MRID 48240104
Primary eye irritation	1 V	Waived	MRID 48240105
Primary dermal irritation	IV	Acceptable	MRID 48240106
Dermal sensitization Not	a sensitizer	Acceptable	MRID 48240107

5. Based on the acute toxicity profile above, and taking into consideration the proposed uses specified on the label, information in the CSF, and declaration of ingredients on the proposed label, the following would be the precautionary and first aid labeling for EPA File Symbol 11556-RLL as obtained from the Label Review System:

PRODUCT ID #:

011556-00155

PRODUCT NAME:

PNR1427 INSECTICIDE

PRECAUTIONARY STATEMENTS

SIGNAL WORD: 0

CAUTION

Hazards to Humans:

[The registrant has proposed the following: "Do not open package until ready to use. Do not allow children to play with the collar [or reflectors]. Avoid contact with eyes, skin or clothing. Wash thoroughly with soap and cold water after fitting the collar. People with sensitivity reactions to the ingredients of the collar should avoid contact with the collar. [Choking hazard. Contains small parts]. Do not place collar [or reflectors] in mouth. Not intended for use on humans." These statements are acceptable.]

Hazards to Domestic Animals:

[The statements proposed by the registrant are acceptable (refer to http://www.epa.gov/PR Notices/pr96-6.html). It is noted that the minimum ages (not to be used on pupples under seven weeks of age or kittens under ten weeks of age) are supported by the puppy and kitten studies in MRIDs 48240110 and 48240111, respectively (refer to the TRB review for 11556-155 dated January 27, 2012).

First Aid:

[No statements required; registrant has the option of using Toxicity Category III statements].

The CSF (dated 8/25/2010) for EPA File Symbol 11556-RLL should also be reviewed and accepted by the TRB Chemistry Team.

DATA EVALUATION RECORD

CYCLOPROPANECARBOXYLIC ACID [PNR 1427]

STUDY TYPE: ACUTE ORAL TOXICITY - RAT [OPPTS 870.1100; OECD 425] ACUTE DERMAL TOXICITY - RAT [OPPTS 870.1200; OECD 402] ACUTE INHALATION TOXICITY - RAT [OPPTS 870.1300; OECD 403] ACUTE EYE IRRITATION - RABBIT [OPPTS 870.2400; OECD 405] ACUTE DERMAL IRRITATION - RABBIT [OPPTS 870.2500; OECD 404] DERMAL SENSITIZATION - GUINEA PIG [OPPTS 870.2600; OECD 406] MRID: 48240102, 48240103, 48240104, 48240105, 48240106, and 48240107

Prepared for
Registration Division
Office of Pesticide Programs
U.S. Environmental Protection Agency
One Potomac Yard
2777 South Crystal Drive
Arlington, VA 22202

Prepared by Summitec Corporation 9724 Kingston Pike, Suite 602 Knoxville, Tennessee 37922

Task Order No. 3-B-37

Primary Reviewer:) 2-1/
Donna L. Fefee, D.V.M.	Signature: Donne T. Fifte
	Date: 301 15 201
Secondary Reviewers:	-11 - ·
Thomas C. Marshall, Ph.D., D.A.B.T.	Signature: hown CMarshall
	Date: JUL 15 2011 22
	Robert to Ren
Robert H. Ross, M.S., Program Manager	Signature:
	Date: JUL 3 2011
Quality Assurance:	Armilo All II a.
Jennifer Goldberg, B.S.	Signature:
	Date: JUL 15 2011

Disclaimer

This review may have been altered subsequent to the contractor's signatures above.

EPA Reviewer: Byron T. Backus, Ph.D. Date: January 31, 2012

Risk Manager (EPA); 10

STUDY TYPE: Acute Oral Toxicity - Rat; OPPTS 870.1100; OECD 425

TEST MATERIAL: PNR1427 Insecticide (Imidacloprid [10% w/w] + Flumethrin [4.5% w/w]); solid collar.

<u>CITATION</u>: Chopade, H. (2010) Request for waiver from the requirement of acute oral toxicity study · PNR1427 Insecticide. Study Number 33854. Unpublished study prepared by Bayer Healthcare LLC, Animal Health Division, Shawnee Mission, Kansas. August 31, 2010. MRID 48240102.

SPONSOR: Bayer Healthcare LLC, Animal Health Division, 12707 W. 63rd Street, Shawnee Mission, Kansas

EXECUTIVE SUMMARY: Bayer Healthcare LLC, Animal Health Division requests a waiver from the requirement for an acute oral toxicity study (OPPTS 870.1100; OECD 425). The request is based on the following:

The formulation is a solid that contains highly hydrophobic inert ingredients along with active ingredients that have low water solubilities. The study author states that it is therefore impractical to obtain a solution or suspension of the formulation in water, corn oil, or other vehicles commonly used for dosing solids in an acute toxicity study.

According to the study author, U.S. EPA representatives (B. Backus and B. Alexander) considered this waiver request to be reasonable but requested that Bayer Healthcare LLC, Animal Health Division include information on the release rate of the active ingredients from the collar in the justification for the waiver.

Release rates of active ingredients are given in the following representative Companion Animal Safety Studies:

MRIDs 4824018 + 48674702 (61-day study with adult cats; refer to DP 385560 + DP 396978): One collar group: 347.82 mg Imidacloprid and 98.72 mg Flumethrin (equals dosage rates of 89.93 mg Imidacloprid/kg and 25.15 mg Flumethrin/kg or 1.474 mg Imidacloprid/kg/day and 0.412 mg Flumethrin/kg/day).

MRIDs 48240109 + 48674701 (61-day study with adult cats; refer to DP 385560 + DP 396978): One collar group: 971.79 mg Imidacloprid and 224.93 mg Flumethrin (equals dosage rates of 83.42 Imidacloprid/kg and 19.09 mg Flumethrin/kg or 1.368 mg Imidacloprid/kg/day and 0.313 mg Flumethrin/kg/day).

MRID 48240110 (180-day study with puppies; collars were replaced on days 29, 90, 125, and 148; refer to DP 385560 + DP 396978): One collar group: 219.14 mg lmidacloprid and 51.74 mg Flumethrin in the period from Days 0 to 29 (equals dosage rates of 76.98 mg lmidacloprid and 18.69 mg Flumethrin/kg or 2.654 mg lmidacloprid/kg/day and 0.644 mg Flumethrin/kg/day).

MRID 48240111 (180-day study with kittens; collars were replaced on days 29, 90, 125 and 149; refer to DP 385560 + DP 396978): One collar group: 182.81 mg Imidacloprid and 12.69 mg Flumethrin in the period from Days 0 to 29 (equals dosage rates of 123.42 mg Imidacloprid/kg and 8.51 mg Flumethrin/kg or 4.256 mg Imidacloprid/kg/day and 0.293 mg Flumethrin/kg/day).

The label for PNR1427 Insecticide indicates the Flumethrin Trans Z-1/trans Z-2 ratio: max 66% trans Z-1 and min 34% trans Z-2. From MEID 48240203 the rat oral LD50 value for Flumethrin technical (59.9% trans-Z1-isomer and 40.1% trans-Z2- isomer) is 175 mg/kg (1/3 rats dosed at this level died) with a 95% P.L. confidence limit of 42.89 to 104 mg/kg. The dosage rates given above range from 0.293 to 0.644 mg Flumethrin/kg/day; the 0.644 mg corresponds to a cumulative dosage of 18.69 mg/kg given over a 29-day period, or 10.7% of the 175 mg/kg for a single dose LD50.

The LD50 for technical (75%) Imidacloprid is 424 mg/kg for male rats and 450-475 mg/kg for females (refer to MRID 42055331, TXR 0011070). The maximum cumulative dosage in the 61-day studies was 89.93 mg Imidacloprid/kg, or 21.2% of the 424 mg/kg for a single dose LD50.

The following is from a TRB review dated December 29, 2011 for 11556-RLL (DP 392118; TXR 5013553):

The dosage rates from a \sim 10 g cat collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (28-91 day) Cat & Kitten Studies: Imidacloprid: Mean dosage rate = 1.88 mg/kg/day (range: 0.71-3.72 mg/kg/day). Flumethrin: Mean dosage rate = 0.19 mg/kg/day (range: 0.05-0.44 mg/kg/day).

Long-term (238-245 day) Cat Studies: Imidacloprid: Mean dosage rate = 0.46 mg/kg/day (range: 0.33-0.60 mg/kg/day). Flumethrin: Mean dosage rate = 0.088 mg/kg/day (range: 0.06-0.12 mg/kg/day).

The dosage rates from a ~35 g dog collar containing ~10% Imidacloprid and ~4.5% Flumethrin were the following:

Short-term (23-91 day) Dog & Puppy Studies: Imidacloprid: Mean dosage rate = 1.49 mg/kg/day (range: 0.70-2.44 mg/kg/day). Flumethrin: Mean dosage rate = 0.24 mg/kg/day (range: 0.07-0.42 mg/kg/day).

Long-term (238-245 day) Dog Studies: Imidacloprid: Mean dosage rate = 0.42 mg/kg/day (range: 0.33-0.52 mg/kg/day). Flumethrin: Mean dosage rate = 0.12 mg/kg/day (range: 0.09-0.18 mg/kg/day).

Based on the relatively low rates of release of these actives (and particularly the very slow release of flumethrin), TRB concludes that the acute oral LD50 toxicity study for this collar can be waived, and that it can be assigned to EPA Toxicity Category IV by this exposure route.

EPA Reviewer: Byron T. Backus, Ph.D. Date: January 31, 2012

Risk Manager (EPA): 10

STUDY TYPE: Acute Dermal Toxicity - Rat; OPPTS 870.1200; OECD 402

TEST MATERIAL: PNR1427 Insecticide (Imidacloprid [10% w/w] + Flumethrin [4.5% w/w]); solid collar.

<u>CITATION</u>: Chopade, H. (2010) Request for waiver from the requirement of acute dermal toxicity. Study Number 33855. Unpublished study prepared by Bayer HealthCare LLC, Animal Health Division, Shawnee Mission, Kansas. August 31, 2010. MRID 48240103.

SPONSOR: Bayer Healthcare LLC, Animal Health Division, 12707 W. 63rd Street, Shawnee Mission, Kansas

EXECUTIVE SUMMARY: Bayer Healthcare LLC, Animal Health Division requests a waiver from the requirement for an acute dermal toxicity study (OPPTS 870.1200; OECD 402). The request is based on the following:

The formulation is a solid that contains highly hydrophobic inert ingredients along with active ingredients that have low water solubilities. This, along with the fact that it is difficult to pulverize the collar into a fine powder, would make it difficult to properly moisten the ground material with a suitable vehicle in order to maintain the contact with the test animals' skin.

The same rate of release arguments for the active ingredients considered in the oral LD50 waiver can also be applied to this situation.

Based on the relatively low rates of release of these actives (and particularly the very slow release of flumethrin), TRB concludes that the acute dermal LD50 toxicity study for this collar can be waived, and that it can be assigned to EPA Toxicity Category IV by this exposure route.

EPA Reviewer: ___Byron T. Backus, Ph.D. Date: January 31, 2012

Risk Manager (EPA): 10

STUDY TYPE: Acute Inhalation Toxicity - Rat; OPPTS 870.1300; OECD 403

TEST MATERIAL: PNR1427 Insecticide (Imidacloprid [10% w/w] + Flumethrin [4.5% w/w]); solid collar.

<u>CITATION</u>: Chopade, H. (2010) Request for waiver from the requirement of acute inhalation toxicity study - PNR1427 Insecticide. Study Number 33856. Unpublished study prepared by Bayer HealthCare LLC, Animal Health Division, Shawnee Mission, Kansas. August 31, 2010. MRID 48240104.

SPONSOR: Bayer Healthcare LLC, Animal Health Division, 12707 W. 63rd Street, Shawnee Mission, Kansas

EXECUTIVE SUMMARY: Bayer Healthcare LLC, Animal Health Division requests a waiver from the requirement for an acute inhalation toxicity study (OPPTS 870.1300; OECD 403). The request is based on the following:

The end use formulation is a solid plastic that is difficult to pulverize into a fine powder, and it also is not volatile. It was not possible to grind the material finely enough or suspend the material in the air.

The reviewer agrees that non-volatile products that cannot be readily aerosolized (e.g. plastic, viscous liquids, waxes, and resins) and that are not heated or diluted to an inhalable state during use or application are appropriate candidates for an inhalation waiver.

The reviewer recommends that this waiver be granted.

EPA Reviewer: Byron T. Backus, Ph.D. Date: February 1, 2012

Risk Manager (EPA): 10

STUDY TYPE: Primary Eye Irritation - Rabbit; OPPTS 870.2400; OECD 405

TEST MATERIAL: PNR1427 Insecticide (Imidacloprid [10% w/w] + Flumethrin [4.5% w/w]); solid collar.

<u>CITATION</u>: Chopade, H. (2010) Request for waiver from the requirement of acute eye irritation toxicity study - PNR1427 Insecticide. Unpublished study prepared by Bayer HealthCare LLC, Animal Health Division, Shawnee Mission, Kansas. August 31, 2010. MRID 48240105.

SPONSOR: Bayer Healthcare LLC, Animal Health Division, 12707 W. 63rd Street, Shawnee Mission, Kansas

EXECUTIVE SUMMARY: Bayer Healthcare LLC, Animal Health Division requests a waiver from the requirement for a primary eye irritation study (OPPTS 870.2400; OECD 405). The request is based on the following:

The formulation is a solid that is difficult to pulverize into a fine powder. It also contains highly hydrophobic inert ingredients along with active ingredients that have low water solubilities. These properties would make it difficult to dissolve or suspend the coarsely pulverized material in a suitable vehicle and accurately measure 100 mg or 0.1 mL.

The Agency recommended use of a cryogenic grinding method for one of the TGAI (Flumethrin). The results of this study (from MRID 48240211 the technical Flumethrin remained a powder at low temperature, but reverted to a glassy substance when brought to room temperature; see TRB review TXR 5013525 dated December 6, 2011) indicated that it was impractical to use this methodology to conduct an eye irritation study.

A primary eye irritation study (in MRID 42055334) conducted on technical (75%) Imidacloprid (refer to TXR 0011070) demonstrated it is in EPA Toxicity Category IV by this exposure route.

In addition, this formulation is a plastic collar, and the actives are embedded in and released only slowly from the matrix.

Based on the above considerations, TRB concludes that a waiver for the eye irritation study is appropriate. The formulation (a dog or cat collar) can be assigned to EPA Toxicity Category IV by this exposure route.

EPA Reviewer: Byron T. Backus, Ph.D. Date: January 30, 2012

Risk Manager (EPA): 10

STUDY TYPE: Primary Dermal Irritation - Rabbit; OPPTS 870.2500; OECD 404

TEST MATERIAL: PNR 1427; 9.96% Imidacloprid, 4.35% Flumethrin; Lot No.: KP05KF6; EPSL Reference No.: 090626-2R; Gray solid collar; pH: not available; expiration date: December 1, 2009; stored at room temperature; found to be stable for the duration of testing.

<u>CITATION</u>: Durando, J. (2009) PNR 1427: primary skin irritation study in rabbits. Study Number 27805. Unpublished study prepared by Eurofins | Product Safety Laboratories, Dayton, New Jersey. September 30, 2009. MRID 48240106.

SPONSOR: Bayer Healthcare LLC, Animal Health Division, 12707 W. 63rd Street, Shawnee, Kansas

EXECUTIVE SUMMARY: In a primary dermal irritation study (MRID 48240106), two male and one female, young adult, New Zealand albino rabbits were dermally exposed for 4 hours to 1"x1" pieces of PNR 1427 (9.96% Imidacloprid, 4.35% Flumethrin; Lot #KP05KF6) moistened with 0.1 mL of distilled water. The doses were applied to intact, clipped, 6-cm² application sites on the trunk and covered by a 4-ply gauze pad secured with semi-occlusive 3-inch Micropore tape wrapped around the trunk. The animals were observed at 30-60 minutes and 24, 48, and 72 hours after patch removal, and any irritation at the dose sites was scored according to Draize. The animals were supplied by Robinson Services Inc., Clemmons, North Carolina; the body weights and exact ages of the animals were not provided.

There were no observations of edema. At 30-60 minutes after patch removal, all treated sites exhibited very slight erythema (score=1). At 24 hours, very slight erythema remained present on one site but had resolved on the other two sites. At 48 and 72 hours, all sites were clear of erythema, edema, and/or other changes to the skin. No abnormal systemic clinical signs were reported.

In this study, the primary Irritation Index (PII) is 0.33, and the formulation is a slight irritant. PNR 1427 is classified as EPA Toxicity Category IV for primary dermal irritation.

This study is classified as Acceptable. It does satisfy the guideline requirement for a primary skin irritation study (OPPTS 870.2500; OECD 404) in the rabbit.

COMPLIANCE: Signed and dated GLP, Quality Assurance, and Data Confidentiality statements were provided.

RESULTS and DISCUSSION:

INDIVIDUAL SKIN IRRITATION SCORES (ERYTHEMA/EDEMA)

		Hours after patch removal				
Animal No.	Sex	1	24	48	72	
3501	М	1/0	0/0	0/0	0/0	
3502	M	1/0	0/0	0/0	0/0	
3503	F	1/0	1/0	0/0	0/0	
Severity of Irritation - Mo		1.00/0.00	0.33/0.00	0.00/0.00	0.00/0.00	

A. <u>Observations</u>: There were no observations of edema. At 30-60 minutes after patch removal, all treated sites exhibited very slight erythema (score=1). At 24 hours, very slight erythema remained present on one site but had resolved on the other two sites. At 48 and 72 hours, all sites were clear of erythema, edema, and/or other changes to the skin. No abnormal systemic clinical signs were reported.

B. Results: The PDII is 0.33.

C. <u>Reviewer's Conclusions</u>: In agreement with the study author, the test material is a slight irritant. The test material is classified as EPA Toxicity Category IV.

D. <u>Deficiencies</u>: As a minor deficiency, the ages of the animals were not provided.

EPA Reviewer: Byron T. Backus, Ph.D. Date: January 30, 2012

Risk Manager (EPA): 10

STUDY TYPE: Dermal Sensitization - Guinea Pig; OPPTS 870.2600; OECD 406

TEST MATERIAL: PNR 1427; 9.96% Imidacloprid, 4.35% Flumethrin; Lot No.: KP05KF6; EPSL Reference No.: 090626-2R; Gray solid collar; pH: not available; expiration date: December 1, 2009; stored at room temperature; found to be stable for the duration of testing.

<u>CITATION</u>: Durando, J. (2009) PNR 1427: dermal sensitization study in guinea pigs (Buehler method). Study Number 27806. Unpublished study prepared by Eurofins | Product Safety Laboratories, Dayton, New Jersey. October 12, 2009. MRID 48240107.

SPONSOR: Bayer Healthcare LLC, Animal Health Division, 12707 W. 63rd Street, Shawnee, Kansas

EXECUTIVE SUMMARY: In a dermal sensitization study (MRID 48240107), twenty young adult, male, Hartley albino guinea pigs were tested with PNR 1427 (9.96% Imidacloprid, 4.35% Flumethrin; Lot #KP05KF6) using the Buehler method. For induction and challenge the test material was applied as a 20-22 mm circle (cut from the solid material), moistened with 0.1 mL of distilled water and held in place with non-allergenic Durapore adhesive tape. A separate naïve control group of ten males was treated during challenge only. The animals were supplied by Elm Hill Breeding Labs, Chelmsford, Massachusetts and weighed 302-400 g; exact ages of the animals were not reported.

No positive dermal reactions were seen following challenge. No abnormal systemic clinical signs were reported, and all of the animals gained weight over the course of the study.

Based on this study, PNR 1427 is not a dermal sensitizer.

This study is classified as acceptable. It does satisfy the guideline requirement for a primary dermal sensitization study (OPPTS 870.2600; OECD 406) in the Guinea pig.

COMPLIANCE: Signed and dated GLP, Quality Assurance, and Data Confidentiality statements were provided.

I. PROCEDURE

- A. <u>Induction</u>: The dorsal area and flanks of the animals were clipped one day prior to each treatment. For each of three successive weekly inductions, a 20-22 mm circle (cut from the solid test material) moistened with 0.1 mL of distilled water was applied to the left side of each animal and secured in place with adhesive tape wrappings for six hours. Reactions were scored 24 and 48 hours post application.
- B. <u>Challenge</u>: Twenty-seven days after the first induction, the test animals were challenged with a 20-22 mm circle (cut from the solid test material) moistened with 0.1 mL of distilled water, applied to naive sites on the right side of each animal for 6 hours using the same procedure as described for induction. Reactions were scored 24 and 48 hours post application.

C. <u>Naive Controls</u>: At challenge, a separate "naive" group of ten previously untreated animals was also treated with a 20-22 mm circle (cut from the solid test material) moistened with 0.1 mL of distilled water. Reactions were scored 24 and 48 hours post application.

II. RESULTS and DISCUSSION:

- A. <u>Reactions and duration</u>: No erythema was seen at any dose site, following induction or challenge.
- B. <u>Positive control</u>: The study report included the results from a positive control study with alpha-Hexylcinnamaldehyde (EPSL Study #27592, completed on June 26, 2009). The positive control study was conducted within six months of the submitted study, and the study author stated that the induction and challenge procedures used in both studies were similar. The reviewer considers the results to be appropriate.
- C. <u>Reviewer's Conclusions</u>: In agreement with the study author, the test material is *not* a dermal sensitizer.
- D. <u>Deficiencies</u>: According to minutes taken during a teleconference between representatives of Bayer Healthcare LLC, Animal Health Division and representatives of the U.S. EPA (provided in MRIDs 48240102, 48240103, 48240104, 48240105), a U.S. EPA respresentative requested that a dermal sensitization be conducted using ground collar material. The current study instead used cut pieces of the collar with no explanation provided. As a minor deficiency, the ages of the animals were not provided.

ACUTE TOX ONE-LINERS:

1. DP BARCODE: 385538				···.
2. PC CODES: 129099, 036007				
3. CURRENT DATE: February 1, 2	2012			
4. TEST MATERIAL: PNR 1427 (9.96% Imidack	oprid, 4.35% Flumethrin; Lot #KP05	KF6)	
Study/Species/Lab Study#/Date	MRID	Results	Tox. Cat.	Core Grade
Acute oral toxicity / rat Bayer HealthCare LLC, Animal Health Division	48240102	Waiver Recommended	IV	W
Study #33854 / August 31, 2010 Acute dermal toxicity / rat Bayer HealthCare LLC, Animal Health Division	48240103	Waiver Recommended	1V	W
Study #33855 / August 31, 2010 Acute inhalation toxicity / rat Bayer HealthCare LLC, Animal Health Division Study #23856 / August 21, 2010	48240104	Waiver Recommended ·	1V	w
Study #33856 / August 31, 2010 Primary eye irritation / rabbit Bayer HealthCare LLC, Animal Health Division Study #33857 / August 31, 2010	48240105	Waiver Recommended.	lV	W
Primary dermal irritation /rabbit Eurofins Product Safety Laboratories Study #27805 / September 30, 2009	48240106	Slight irritant; PI1=0.33	IV	A
Dermal Sensitization /guinea pig Eurofins Product Safety Laboratories Study #27806 / October 12, 2009	48240107	Not a sensitizer		A

Core Grade Key: A =Acceptable, S = Supplementary, U = Unacceptable, W = Waived



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

OFFICE OF PESTICIDE PROGRAMS REGISTRATION DIVISION (7505P)

Byron T. Bodons 12/29/2011 Myadus Ph.D.

December 29, 2011

MEMORANDUM: IMIDACLOPRID 10%/FLUMETHRIN 4.5% DOG & CAT COLLARS:

DOSAGE AND RELEASE RATES OF ACTIVES

Subject:

Name of Pesticide Product: PNRI427 INSECTICIDE

EPA Reg. No. /File Symbol: 11556-RLL

DP Barcode:

DP 392118

Decision No.:

440307

Action Code: PC Code:

RI10.0 036007 (Flumethrin: 4.5%)

129099 (Imidacloprid: 10.0%)

From:

Byron T. Backus, Ph.D., Toxicologist

Technical Review Branch

Registration Division (7505P)

To:

BeWanda Alexander/Richard Gebken RM 10

Insecticide Branch

Registration Division (7505P)

Registrant:

BAYER HEALTHCARE LLC

FORMULATION FROM LABEL:

Active Ingredient(s): 036007 Flumethrin 129099 Imidacloprid Other Ingredient(s):

by wt. 4.5%

I0.0% 85.5%

TOTAL

100.0%

Action Requested: The Risk Manager requests a review of MRID 482401-40, a 117-page document summarizing dosages and release rates of imidacloprid and flumethrin from a number of cat and dog collar studies.

COMMENTS AND RECOMMENDATIONS:

The following is the executive summary for the review compilation in MRID 48240140:

The material in MRID 48240140 represents the compilation of release rates in a series of studies of the two active ingredients from cat and dog collars containing ~10% Imidacloprid and ~4.5% Flumethrin. Collars were weighed, then worn by cats or dogs for varying periods of time, after which they were weighed and analyzed for content of the two active ingredients.

The dosage rates from a \sim 10 g cat collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (28-91 day) Cat & Kitten Studies: Imidacloprid: Mean dosage rate = 1.88 mg/kg/day (range: 0.71-3.72 mg/kg/day). Flumethrin: Mean dosage rate = 0.19 mg/kg/day (range: 0.05-0.44 mg/kg/day).

Long-term (238-245 day) Cat Studies: Imidacloprid: Mean dosage rate = 0.46 mg/kg/day (range: 0.33-0.60 mg/kg/day). Flumethrin: Mean dosage rate = 0.088 mg/kg/day (range: 0.06-0.12 mg/kg/day).

The dosage rates from a \sim 35 g dog collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (23-91 day) Dog & Puppy Studies: Imidacloprid: Mean dosage rate = 1.49 mg/kg/day (range: 0.70-2.44 mg/kg/day). Flumethrin: Mean dosage rate = 0.24 mg/kg/day (range: 0.07-0.42 mg/kg/day).

Long-term (238-245 day) Dog Studies: lmidacloprid: Mean dosage rate = 0.42 mg/kg/day (range: 0.33-0.52 mg/kg/day). Flumethrin: Mean dosage rate = 0.12 mg/kg/day (range: 0.09-0.18 mg/kg/day).

This report is classified as acceptable (Non-Guideline). It provides useful information regarding the rates of release of the two active ingredients from a collar containing ~10% Imidacloprid and ~4.5% Flumethrin and the exposure to cats and dogs wearing this collar.

Reviewer: Byron T. Backus, Ph.D. Date: December 29, 2011

Risk Manager (EPA): 10

STUDY TYPE: Active Release Rates from Cat & Dog Collars (Non-Guideline)

TEST MATERIAL: Collars containing ~10% Imidacloprid and ~4.5% Flumethrin

<u>CITATION</u>: Stanneck, D. (2010) Dosage of the Imidacloprid 10% Flumethrin 4.5% Collar and Release of the Active Ingredients over Time in Cats and Dogs: Review Compilation. Project Number: 35992, PNR1427. Unpublished study prepared by Bayer HealthCare, LLC. 120 p. June 28, 2010. MRID 48240140.

SPONSOR: Bayer HealthCare, LLC

Animal Health Division

P.O. Box 390

Shawnee Mission, KS 66201-0390

EXECUTIVE SUMMARY:

The material in MRID 48240140 represents the compilation of release rates in a series of studies of the two active ingredients from cat and dog collars containing ~10% Imidacloprid and ~4.5% Flumethrin. Collars were weighed, then worn by cats or dogs for varying periods of time, after which they were weighed and analyzed for content of the two active ingredients.

The dosage rates from a \sim 10 g cat collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (28-91 day) Cat & Kitten Studies: Imidacloprid: Mean dosage rate = 1.88 mg/kg/day (range: 0.71-3.72 mg/kg/day). Flumethrin: Mean dosage rate = 0.19 mg/kg/day (range: 0.05-0.44 mg/kg/day).

Long-term (238-245 day) Cat Studies: Imidacloprid: Mean dosage rate = 0.46 mg/kg/day (range: 0.33-0.60 mg/kg/day). Flumethrin: Mean dosage rate = 0.088 mg/kg/day (range: 0.06-0.12 mg/kg/day).

The dosage rates from a \sim 35 g dog collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (23-91 day) Dog & Puppy Studies: Imidacloprid: Mean dosage rate = 1.49 mg/kg/day (range: 0.70-2.44 mg/kg/day). Flumethrin: Mean dosage rate = 0.24 mg/kg/day (range: 0.07-0.42 mg/kg/day).

Long-term (238-245 day) Dog Studies: Imidacloprid: Mean dosage rate = 0.42 mg/kg/day (range: 0.33-0.52 mg/kg/day). Flumethrin: Mean dosage rate = 0.12 mg/kg/day (range: 0.09-0.18 mg/kg/day).

This report is classified as acceptable (Non-Guideline). It provides useful information regarding the rates of release of the two active ingredients from a collar containing ~10% Imidacloprid and ~4.5% Flumethrin and the exposure to cats and dogs wearing this collar.

<u>COMPLIANCE</u>: Signed and dated GLP (noting that this study was not conducted in full compliance with GLP standards), and Data Confidentiality statements were provided. There is no Quality Assurance Statement (presumably because this report represents a review compilation).

RESULTS:

Collars were weighed, then worn by cats or dogs for varying periods of time, after which they were weighed and analyzed for content of the two active ingredients.

Cat studies:

Dosage rates in cat studies (from Table 5 on p. 8 of MRID 48240140):

3

Study Number	Breed & (body weight	Study Duration	lmidacloprid	Flumethrin exposure
	range in kg)	(Days)	exposure (mg/kg/day)	(mg/kg/day)
146.266	DSH (3.3-5.1)	2	7.36	0.18
		7	4.73	0.18
		14	3.03	0.23
		28	2.08	0.12
		56	1.44	0.10
		84	1.13	0.18
146.164	DSH (2.3-5.1)	30	3,04	0.44
		238	0.56	0.12
146.303	DSH (3.7-4.7)	238	0.39	0.06
146.159	Mix (2.1-4.7)	60	1.27	0.20
152.152	DSH (2.8-5.3)	61	1.62	0.32
152,150	DSH kittens (0.97-	30	3.72	0.20
	1.26 study day 0)	60	1.91	0,14
146.747	DSH (3.6-5.7)	28	0.71	0,05
146.156	DSH (2.8-5.3)	238	0.42	0.07
146.045	DSH (3.8-7.0)	241	0.33	0.10
146.155	DSH (2.7-	240	0.60	0.09

There are two mechanisms by which an active can be released from a collar: 1) Simple wear, and 2) Diffusion from the matrix. An approximation of the amount of an active released from wear can be calculated by: weight loss – (amount of imidacloprid lost + amount of flumethrin loss) = amount of plastic lost. Then: (amount of plastic lost)/[1 – (original percentage of imadocloprid + original percentage of flumethrin)] = total amount lost by wear. Then: (total amount lost by wear) x (original percentage of imadocloprid) = amount of imidacloprid lost by wear, and: (total amount lost by wear) x (original percentage of flumethrin) = amount of flumethrin lost by wear. The table below shows that for the cat collar most of the imidacloprid is released by diffusion (the total amount released by wear is approximately 10-14% for 28 days and about 42% for 240 days), while most of the flumethrin is released by wear (the mean total percentage released by wear in the 5 cat studies below which ran for 238-241 days is 99.46%).

Study	Body	Study	Mean	Plastic	Amount	Amount of	Amount in mg	Amount in mg
Number	weight	Duration	collar	weight	of	flumethrin	of	of flumethrin
	range in	(Days)	weight	loss (mg)	lmidaclo	released	imidacloprid	released by
	kg		loss (mg)		prid	(mg)	released by	wear (% total
					released		wear and %	released)
					(mg)		total	
146.156	3.2-5.4	238	2024.44	1518.97	433.1	72.37	179.64 (41.48)	80.04 (110.6)
146.164	2.56-4.22	30	1198.75	860.75	295.58	42.43	100.67 (34.06)	45.30 (106.8)
	2.28-5.14	240	2160.0	1634.56	435,3	90.14	191.18 (43.92)	86.03 (95.44)
146.159	2.4-4.7	60	907.33	634.99	235.60	36.74	72.61 (30.82)	33.34 (90.75)
146.303	3.7-4.7	238	1798.75	1340.35	394.45	63.95	158.52 (40.19)	70.63 (110.44)
146.747	3.6-5.7	28	458.75	239.71	205.34	13.7	27.38 (13.33)	12.29 (89.73)
146.266	3.5-4.1	2	33.33	N.V.	54.67	1.53	N,C.	N.C.
	3.4-5.1	7	133.33	16.36	109.0	7.97	1.93 (1.77)	0.86 (10.82)
	3.4-5.1	14	266.67	103.57	149.5	13.60	12.25 (8.19)	5.46 (40.13)
	3.4-5.1	28	366.67	160.01	195.53	11.13	18.92 (9.68)	8.43 (75.75)
	3.5-5.1	56	633.33	344.69	266.87	21.77	40.77 (15.28)	18.16 (83.43)
	3.3-3.7	84	1000.00	648.2	312.4	39.40	76.66 (24.54)	34.16 (86.69)
146.045	4.6-6.0	241	2197.0	1656.37	411.21	129.42	195.89 (47.64)	87.28 (67.44)
146.155	2.5-3.6	240	1804.0	1334.52	407.48	62.00	157.83 (38.73)	70.32 (113.42)
146,100	2.38-5.8	226ª	1502.5ª	1294.77 ^a	177.54ª	30.19ª	33.98 (19.14)	30.59 (101.31)
	2.58-3.36	226 ⁶	1696.25 ⁶	1315.76 ^b	349.89 ⁶	30.60 ^b	70.93 (20.27)	31.92 (104.31
	2.28-4.36	226°	1725.0°	1402.13°	297.44°	25.43°	159.79 (53.72)	35.95 (141.37)

Data calculated from information (Tables) on p. 36, 37, 38, 39, 40, 41, 42

^aCollar supposedly contained 2.5% Imidacloprid and 2.25% Flumethrin and this reviewer's calculations above are based on that composition; however, column 6 of the Table on p. 44 of MRID 48240140 indicates the collar contained 10.1% Imidacloprid and column 7 indicates it contained 4.5% Flumethrin.

^bCollar supposedly contained 5.0% lmidacloprid and 2.25% Flumethrin and this reviewer's calculations above are based on that composition; however, column 6 of the Table on p. 44 of MRID 48240140 indicates the collar contained 10.1% lmidacloprid and column 7 indicates it contained 4.5% Flumethrin.

^cCollar supposedly contained 10.0% Imidacloprid and 2.25% Flumethrin and this reviewer's calculations above are based on that composition; however, column 6 of the Table on p. 44 of MRID 48240140 indicates the collar contained 10.1% imidacloprid and column 7 indicates it contained 4.5% Flumethrin.

Dog studies:

Dosage rates in dog studies (from Table 6 on p. 8 of MRID 48240140):

Study Number	Breed & (body weight	Study Duration	lmidacloprid	Flumethrin exposure
-	range in kg)	(Days)	exposure (mg/kg/day)	(mg/kg/day)
146.165	Mongrel (11.6-19.4)	30	1.62	0.20
		238	0.33	0.11
146.306	Beagle (9.4-13.6)	238	0.52	0.18
146.161	Mix (8.4-20.2)	60	0.89	0.07
152.151	Beagle (8.7-13.4)	60	1.37	0.15
152.149	Beagle puppies (1.5-	23	2.44	0.36
	2.9 on study day 0)	30	2.21	0.42
		60	0.97	0.28
146.737	Beagle (8.7-11,7)	28	2.25	0.20
146.158	Beagle (8.8-12.8)	245	0.52	0.11
146.390	Beagle (6.6-20.4)	240	0.35	0.09
146.592	Beagle (8.3-13.5)	240	0.37	0.13
146,269	Mongrel (7.1-21.5)	90	0.70	0.32
146.607	Beagle (10.0-13.1)	91	0.97	0.18

The table below shows that for the dog collar most of the imidacloprid is released by diffusion (the total amount released by wear is approximately 8-22% for 28-30 days and about 29-61.5%, with a mean of ~44% for 238-245 days), while most of the flumethrin is released by wear (the mean total percentage released by wear in the 5 dog collar studies below which ran for 238-245 days was 64.4%).

Study	Body	Study	Mean	Plastic	Amount	Amount of	Amount in mg	Amount in mg
Number	weight	Duration	collar	weight	of	flumethrin	of	of flumethrin
	range in	(Days)	weight	loss (mg)	1midaclo	released	imidacloprid	released from
	kg)	1	loss (mg)		prid	(mg)	released from	wear (% total
					released		wear and %	released)
			ļ <u>.</u>		(mg)		lotal	
146.164	(11.6-	30	2145.7	1342.5	715.74	87.49	155.26 (21.69)	70.57 (80.66)
	19.4)	240	6921.4	5155.95	1310.19	455.26	596.31 (45.51)	271.05 (59.54)
146.158	(8.8-	245	5136.0	3481.85	1358.7	295.45	406.76 (29.94)	178.97 (60.58)
	12.8)						_	
146.306	(9.4-	238	6238.8	4458.65	1321.25	458.9	520.87 (39.42)	229.18 (49.94)
	13.6)							
146.362/	(10.0-	91	3498.3	2319.43	998.3	180.57	268.25 (26.87)	104.37 (57.8)
146.607	13.1)						_	
146.737	(9.1-	28	1142.5	445.99	640.61	55.9	51.58 (8.05)	23.45 (41.95)
	11.0)							
146.390	(10.4-	240	5718.0	4297.67	1126.98	303.35	500.90 (44.45)	220.39 (72.65)
	18.2)							
146.269	(7.22-	90	3696.25#	2621.89	796.3	278.06	303.23 (38.08)	137.83 (49.57)
	21.48)							
146.161	(10.36-	60	1633.75	797.53	797.61	38.61	92.24 (11.56)	41.93 (108.59)
	17.56)							
146.592	(8.3-	240	6467.14	5156.91	969.07	341.16	596.42 (61,5)	271.10 (79.46)
	13.5)							

Data calculated from information (Tables) on p. 45, 46, 47, 48, 49, 50, 51, 52, and 53.

#No weight loss reported for collar from one dog (CC0CE2); data from this dog not included in calculations by the EPA reviewer.

For the dog studies that ranged from 238-245 days the mean collar weight loss was 6096.27 (range: 5136.0-6921.4) mg; the mean plastic (matrix) weight loss was 4510.21 (range: 3481.85-5156.91) mg; the mean total amount of imidacloprid released per collar was 1217.24 (range: 969.07-1358.7) mg; and the mean total amount of flumethrin released per collar was 370.82 (range: 295.45-458.9) mg. The approximate amount of imidacloprid released per collar from wear was 524.25 (range: 406.76-596.42) mg and the approximate amount of flumethrin released per collar from wear was 234.14 (range: 178.97-271.1) mg.

The following summarizes the dosages given in Tables 5 and 6 on p. 8 of MRID 48240140:

Short-Term (28-91 day) Cat & Kitten Studies:	Imidacloprid exposure (mg/kg/day): 2.08, 1.44, 1.13, 3.04, 1.27, 1.62,	Flumethrin exposure (mg/kg/day): 0.12, 0.10, 0.18, 0.44, 0.20, 0.32,
Kitten Studies.	3.72*, 1.91*, 0.71 [Mean = 1.88]	0.20^* , 0.14^* , 0.05 [Mean = 0.19]
Long-Term (238-245 day) Cat	lmidacloprid exposure (mg/kg/day):	Flumethrin exposure (mg/kg/day):
Studies:	0.56, 0.39, 0.42, 0.33, 0.60 Mean =	0.12, 0.06, 0.07, 0.10, 0.09 [Mean =
	0.46	0.088]
Short-Term (23-91 day) Dog &	Imidacloprid exposure (mg/kg/day):	Flumethrin exposure (mg/kg/day):
Puppy Studies:	1.62, 0.89, 1.37, 2.44**, 2.21**,	0.20, 0.07, 0.15, 0.36**, 0.42**,
	0.97**, 2.25, 0.70, 0.97 [Mean =	0.28**, 0.20, 0.32, 0.18 Mean =
	1.49]	0.24]
Long-Term (238-245 day) Dog	lmidacloprid exposure (mg/kg/dau):	Flumethrin exposure (mg/kg/day):
Studies:	0.33, 0.52, 0.52, 0.35, 0.37 [Mean =	0.11, 0.18, 0.11, 0.09, 0.13 Mean =
	0.42]	0.12]

^{*}Kitten study

Reviewer's Conclusions:

The dosage rates from a \sim 10 g cat collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (28-91 day) Cat & Kitten Studies: Imidacloprid: Mean dosage rate = 1.88 mg/kg/day (range: 0.71-3.72 mg/kg/day). Flumethrin: Mean dosage rate = 0.19 mg/kg/day (range: 0.05-0.44 mg/kg/day).

Long-term (238-245 day) Cat Studies: Imidacloprid: Mean dosage rate = 0.46 mg/kg/day (range: 0.33-0.60 mg/kg/day). Flumethrin: Mean dosage rate = 0.088 mg/kg/day (range: 0.06-0.12 mg/kg/day).

The dosage rates from a \sim 35 g dog collar containing \sim 10% Imidacloprid and \sim 4.5% Flumethrin were the following:

Short-term (23-91 day) Dog & Puppy Studies: Imidacloprid: Mean dosage rate = 1.49 mg/kg/day (range: 0.70-2.44 mg/kg/day). Flumethrin: Mean dosage rate = 0.24 mg/kg/day (range: 0.07-0.42 mg/kg/day).

Long-term (238-245 day) Dog Studies: Imidacloprid: Mean dosage rate = 0.42 mg/kg/day (range: 0.33-0.52 mg/kg/day). Flumethrin: Mean dosage rate = 0.12 mg/kg/day (range: 0.09-0.18 mg/kg/day).

^{**}Puppy study

This report is classified as acceptable (Non-Guideline). It provides useful information regarding the rates of release of the two active ingredients from a collar containing $\sim \! 10\%$ Imidacloprid and $\sim \! 4.5\%$ Flumethrin and the exposure to cats and dogs wearing this collar.

ACUTE TOX ONE-LINERS:

1. **DP BARCODE:** 392118

2. PC CODES: 129099 (Imidacloprid); 036007 (Flumethrin)

3. CURRENT DATE: December 29, 2011

4. TEST MATERIAL: Dog & Cat Collars containing ~10% Imidacloprid & ~4.5% Flumethrin

Study/Species/Lab Study # / Date	MR1D	Results	Tox. Cat.	Core Grade
Dosages & release rates of actives (review compilation)/cats & dogs/Bayer Animal Health, Monheim, Germany/PNR 1427/June 28, 2010	48240140	Short-term (28-91 day) Cat & Kitten Studies: Imidacloprid: Mean dosage rate = 1.88 mg/kg/day (range: 0.71-3.72 mg/kg/day). Flumethrin: Mean dosage rate = 0.19 mg/kg/day (range: 0.05-0.44 mg/kg/day). Long-term (238-245 day) Cat Studies: Imidacloprid: Mean dosage rate = 0.46 mg/kg/day (range: 0.33-0.60 mg/kg/day). Flumethrin: Mean dosage rate = 0.088 mg/kg/day (range: 0.06-0.12 mg/kg/day). The dosage rates from a ~35 g dog collar containing ~10% Imidacloprid and ~4.5% Flumethrin were the following: Short-term (23-91 day) Dog & Puppy Studies: Imidacloprid: Mean dosage rate = 1.49 mg/kg/day (range: 0.70-2.44 mg/kg/day). Flumethrin: Mean dosage rate = 0.24 mg/kg/day (range: 0.07-0.42 mg/kg/day). Long-term (238-245 day) Dog Studies: Imidacloprid: Mean dosage rate = 0.42 mg/kg/day (range: 0.33-0.52 mg/kg/day). Flumethrin: Mean dosage rate = 0.12 mg/kg/day (range: 0.09-0.18 mg/kg/day).	n/a	A (non- Guideline)

Core Grade Key: A = Acceptable, S = Supplementary, U = Unacceptable, W = Waived



ARONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460



OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

OFFICE OF PESTICIDE PROGRAMS REGISTRATION OIVISION (7505P)

DATE OUT: October 11, 2011

ACTION CODE: 570

STORAGE STABILITY (830.6317) & CORROSION CHARACTERISTICS (830.6320) REVIEW SUBJECT:

ACCELERATED STUDY []; ONE YEAR STUDY [X[; OVER I YEAR STUDY []]

MP[] EP[X] EUP[]

DP BARCODE No.: 388440 DECISION No.: 440307

REG. No.:11556-RLL MRID No(s): 484165-01

William Herald / Microbiologist (MS) / CHEMIST, REHS / Registered Sanitarian Product Chemistry Team
Technical Review Branch/RD (7505P)

BeWanda Alexander / Richard Gehken, RM 10
Insecticide Branch / RD (7505P) PRODUCT NAME: PNR1427 INSECTICIDE COMPANY: BAYER HEALTHCARD LLC

FROM:

TO:

I. CONCLUSIONS:

STORAGE STABILITY (830.6317):

[X] ACCEPTABLE

[] UNACCEPTABLE*

[] UPGRADEABLE*

40CFRI58.190 DATA REQUIREMENT: [X] SATISFIED [] NOT SATISFIED

CORROSION CHRACTERISTICS (830.6320):

[X] ACCEPTABLE

[] UNACCEPTABLE*

[] UPGRADEABLE*

40CFR158,190 DATA REQUIREMENT: [X] SATISFIED [] NOT SATISFIED

* If unacceptable or upgradeable describe the deficiency and provide recommendations

Comments & Recommendations:



EN CONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

OFFICE OF PESTICIDE PROGRAMS REGISTRATION DIVISION (7505P)

IL STUDY SUMMARY

A. STUDY CONDUCTED UNDER US GLP/OECD GUIDELINES
[X] Yes [] No

B. PRODUCT INFORMATIO

Active ingredients:

Lahel claims Nominal concentrations (%):

Flumethrin	4.5%
Imidacloprid	10.0%

Initial concentrations of the AIs (%) used in the study:

Flumethrin	4.656% (average)
Imidacloprid	10.13% (average)

Lower certified limits (%) based on AI % in the study:

Flumethrin	4.422%
Imidacloprid	9.62%

C. EXPERIMENTAL PARAMETERS

Temperature: Ambient room temperatures for one year.

Duration of study: [X] 1 year Types of containers: Plastic bags.

Analysis at intervals: [X] 0 (initial); [X] 3 months; [X] 6 months

[X] 9 months; and [X] 12 months.

D. ANALYTICAL METHOD

Method	DETECTOR
High Pressure Liquid chromatography (HPLC)	UV/VIS (268nm)

E. RESULTS

- 1) Compared to the initial concentrations of the active ingredients in the study, the report shows that the AIs% remained will within the statutory parameters required in Title 40 CFR § 158.350 during the 3rd, 6th, 9th and 12th month testing periods while stored at amhient room temperatures.
- 2) The study reported that there was no observed corrosive effect from the test substance; the collar remained a solid gray throughout the study. No corrosive effects during the study were observed. There were no corrosion of the packaging was observed. All of the packaging remained intact and no leaking or deforming of the package was noticed.



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

OFFICE OF PESTICIDE PROGRAMS REGISTRATION DIVISION (7505P)

DP BAR CODE NO.: 385540

FILE SYMBOL NO.: 11556-RLL DECISION NO.: 440307

PC Code(s): 129099,036007

ACTION CODE: R110.0

FOOD Use: No

NON-FOOD Use: Yes

DATE OUT:

October 11, 2011

SUBJECT:

End Use Product Chemistry Review

Product Name: PNR 1427 Insecticide

FROM:

Hari Mukhoty

Product Chemistry Team

Technical Review Branch / Registration Division (7505P)

TO:

BeWanda Alexander / Richard Gebken PM - 10

Insecticide Branch / Registration Division (7505P)

Company Name:

Bayer HealthCare LLC

Formulation Type: Solid

INTRODUCTION:

The Registrant has submitted one basic CSF (dated: 08/25/2010), two amended CSFs (Dated: 08/25/2010) as alternate formulations (Alt. #1 & #2) to the aforesaid basic and has proposed a product specific label for registration of the aforesaid products under EPA File Symbol No. 11556-RLL.

TRB has been requested to evaluate the product chemistry data required for the registration of the proposed products.

SUMMARY OF FINDINGS:

- Name of Active Ingredient(s): Imidacloprid (10.0%), Flumethrin (4.50%).
- 2. Has the registrant claimed substantial similarity to registered product? [[Yes [X] No [] NA If yes: EPA Reg. No.
- 3. The source material(s) of the active ingredient(s) is/are registered with the Agency. The source of the active ingredient Flumethrin is not, as of this date, registered with the Agency. The nominal concentration of this active ingredient (4.50%) has been tentatively calculated based on the claimed purity of the chemical by the registrant to be 96.2%.
- 4. All inert ingredients have been screened by IIAB on 10/06/2010 and have been found to be approved for non-food uses only.
- 5. The CSFs of the proposed basic and alternate formulations have been filled out completely and correctly based on the claimed purity of the active ingredient Flumethrin.

	FILE SYMBOL NO.: 11556-RLL ACTION CODE: R110.0 NON-FOOD Use: Yes	DECISION NO.: 440307
6. Confidential Statement of Formul	la(s):	
[X] Basic - Dated: 08/25/2010	re-subr	mitted - Dated: NA
[X] Alternate-#1 Dated:	08/25/2 0 10 re-sub	mitted: Dated: NA
Alternate CSF(s) complies with 4	0CFR §152.43; [X] Yes [] No	NA [].
7. Product label		
a. Ingredient statement: Non Notice 91-2) [X]Yes	ninal concentration o f Al listed on	CSF(s) concur with product label (PR
Is the sub statement in compliance v	with PR Notice 97-6?	
] X] Yes [] No -Uses the term "C , if not, explain below:	Other Ingredients"	
b. Health related sub statemen	its:	
Petroleum distillate at > 10%; [] \\ Methanol at > 4%; [] \\ Sodium Nitrate / Sodium Nitrite []	Yes []No [X [NA	
c. Physical chemical hazard stateme flammability, explosive potential or e		nent per 40 CFR §156.78 for:
[]Yes]X]No		
Total Release Fogger PR Notice 98-	6 (40 CFR 156.78 d): [[Yes []	No [X] NA
d. Label requires an additional Stora point of view; if yes explain below:	ge and D isposal statement: [] Yes	s [X] No – from product chemistry

Final decision of overall label acceptance will be made by the PM.

DP BAR CODE NO.: 385540

FILE SYMBOL NO.: 11556-RLL DECISION NO.: 440307

PC Code(s): 129099,036007 FOOD Use: No

ACTION CODE: R110.0 NON-FOOD Use: Yes

8. Group A: Product Chemistry Data

TRB's determination of the acceptability of the data for the proposed product is listed in the tables below.

Guideline No.	Study Title		Dafa subr	nitt ed	TRB's Assessment	MRID Nos.
			Yes	No	of Data	482401-01
8 3 0.155 0	Product Identity & Co	omposition	х		Α	#
830.1600	Description of materials used to produce the product		х		A	t c
830.165 0	Description of formulation process		х		Α	ř.
830.1670	Discussion on the for impurities	ion on the formation of			Α	#
	Certified limits	Standard certified Limits	х		A	- 61
830.175 0	(158.350)	Propose d limits			N/A	
830.1800	Enforcement Analytical Method #		х		А	44

A = Acceptance, NA = Not Acceptable, G = Data Gap, W = Waiver Request, I = In Progress, N/A = Not Applicable # = HPLC using UV detector set at 268 nm DP BAR CODE NO.: 385540 PC Code(s): 129099,036007

)

FILE SYMBOL NO.: 11556-RLL DECISION NO.: 440307

FOOD Use: No

ACTION CODE: R110.0 NON-FOOD Use: Yes

9. Group B:

Guideline No.	Study Title	Value or Qualitative Description	TRB's Assessment of Data	MRID Nos. 482401-01
830.6303	Physical State	Solid	A	4
830.6315	Flammability	Product is solid	A	ti .
8 30.6316	Explodability	Product does not contain any explosive ingredient	A	tt
830. 7 000	pH	The product is no dispersible	Α	31.
830.7300	Density (Bulk Density)	1.044	Α	u

A = Acceptance, NA = Not Acceptable, G = Data Gap, W = Waiver request, N/A = Not applicable, I = In progress

CONCLUSIONS:

- 1. TRB has reviewed the CSFs for the proposed basic (dated: 08/25/2010) and alternate formulations and has found them to be acceptable provided the product chemistry data for the source of the active ingredient Flumerthrin Technical is found to be acceptable for registration. The CSFs are attached with this review and can be located in OPPIN CHEM DOCS.
- 2. Product chemistry Group A and Group B data, with the exception of one year storage stability (830.6317) & corrosion characteristics (830.6320) are satisfied and acceptable.
- 3. The registrant must generate one year storage stability (830.6317) and corrosion characteristics (830.6320) data on the proposed product. It is required that the observations be made at 0, 3, 6, 9, and 12 month intervals. The results must be submitted to the Agency in electronic and hard copy format.
- 4. The proposed label was screened as it pertains to the product chemistry requirements. The final review of the proposed label and uses are the purview of the PM team.



Approved OMB No. 2070-0060

		DATA I	MATRIX - CO	NFIDENTI	AL VERSION	
Date: November 3	, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 1 of 18
Bayer Health Care, Animal Health Div P.O. Box 390 Shawnee Mission,	Product: PNR1427 Insecticide Flumethrin Technical (pages 1 - 7) Imidacloprid Technical (pages 8 - 14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)		
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

Flumethrin Active Ingredient Specific (Pages 1 - 7)										
Product Chemist	try, Section 158/300									
830.1550	Product identity and Composition	48240201	11556	OWN	23979 (BR 2625)					
830.1600	Description of materials used to produce the product	48240201	11556	OWN	23979 (BR 2625)					
830, 1620	Description of production process	48240201	11556	OWN	23979 (BR 2625)					
830,1650	Description of formulation process					N.A EP Only				
830,1670	Discussion on formation of impurities	48240201	11556	OWN	23979 (BR 2625)					
830,1700	Preliminary analysis	48240201	11556	OWN	23979 (BR 2625)					
830,1750	Certified of limits	48240201	11556	OWN	23979 (BR 2625)					
830,1800	Enforcement method	48240201	11556	OWN	23979 (BR 2625)					
830,1900	Submittal of samples					Samples available upon request				
830.6302	Color	48240202	11556	OWN	23980 (BR 2624)					
830,6303	Physical state	48240202	11556	OWN	23980 (BR 2624)					
830.6304	Odor	48240202	11556	OWN	23980 (BR 2624)					
830.6313	Stability	48240202	11556	OWN	23980 (BR 2624)					
830.6314	Oxidizing / reducing action	48240202	11556	OWN	23980 (BR 2624)					
830.6315	Flammability	48240202	11556	OWN	23980 (BR 2624)					
830.6316	Explodability	48240202	11556	OWN	23980 (BR 2624)					
830,6317	Storage stability	48240202	11556	OWN	23980 (BR 2624)					
830,6319	Miscibility	48240202	11556	OWN	23980 (BR 2624)					
830.6320	Corrosion characteristics	48240202	11556	OWN	23980 (BR 2624)					
830.6321	Dielectric breakdown volt	48240202	11556	OWN	23980 (BR 2624)					
830.7000	pH	48240202	11556	OWN	23980 (BR 2624)					



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response

		DATA	MATRIX - CO	NEIDENT	AL VERSION	
Date: November	3, 2010					Page 2 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidaclopaid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRED Number	Submitter	Status	Report Number	Comments
830.7050	UV/Visible absorption	48240202	11556	OWN	23980 (BR 2624)	
830.7100	Viscosity	48240202	11556	OWN	23980 (BR 2624)	N.A Not a liquid
830.7200	Melting point	48240202	11556	OWN	23980 (BR 2624)	
830.7220	Boiling point	48240202	11556	OWN	23980 (BR 2624)	
830.7300	Density, bulk-density, or specific gravity	48240202	11556	OWN	23980 (BR 2624)	
830.7370	Dissociation constant in water	48240202	11556	OWN	23980 (BR 2624)	N.A Does not dissociate
830.7520	Particle size, fiber length, and diameter distribution	48240202	11556	OWN	23980 (BR 2624)	
830.7550 830.7560 830.7570	Partition coefficient (n-octanol/water)	48240202	11556	OWN	23980 (BR 2624)	
830.7840 830.7860	Water solubility	48240202	11556	OWN	23980 (BR 2624)	
830-7950	Vapor pressure	48240202	11556	OWN	23980 (BR 2624)	
Terrestrial and	aquatic non-target organisms data requirements, Sec	tion 158.630				
850.2100	Avian oral toxicity					N.A.
850.2200	Avian dietary toxicity			Ţ		N.A.
850.2400	Wild mammal toxicity			}		N-A.
850.2300	Avian reproduction					N.A.
850.2500	Simulated or actual field testing	l				N.A.
850.1075	Freshwater fish toxicity]			N.A.
850.1010	Acute toxicity freshwater invertebrates					N.A.
850-1025 850-1035 830-1045 830-1055 830-1075	Acute toxicity estuarine and marine organisms					N.A.
850.1300	Aquatic invertebrates life cycle (freshwater)	·	- 	+		N.A.



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting borden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA			AL VERSION	
ate: November			EPA Reg No	./File Symb	ol: 11556-RLL	Page 3 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• ls	lumethrin Te nidaeloprid T	NR1427 Insecticide chnical (pages 1 -7) Technical (pages 8 -14) acticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
uideline eference iumber	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
850.1350	Aquatic invertebrates life cycle (saltwater)		<u> </u>	T		N.A.
850-1400	Fish early-life stage (freshwater)		T			N.A.
850.1400	Fish early-life stage (saltwater)					N.A.
850.1500	Fish life cycle					N.A.
850.1710 850.1730 850.1850	Aquatic organisms bioavailability, biomagnifications, toxicity					N.A.
850.1950	Simulated or actual field testing for aquatic organisms					N.A.
850.1735	Whole sediment: acute freshwater invertebrates					N.A.
850.1740	Whole sediment: acute marine invertebrates					N.A.
850.3020	Honey bee acute contact toxicity					N.A.
850.3030	Honey bee toxicity of residues on foliage		<u> </u>			N.A.
850.3040	Field testing for pollinators	<u>L</u>	<u> </u>			N.A.
oxicology, Sect	ion 158.500			11 <u>11</u>		
870.1100	Acute oral toxicity - rat	48240203	11556	OWN	76064 (ID 23940)	
		48240204	11556	OWN	14838	Supplemental
		48240205	11556	OWN	18186	Sopplemental
870.1200	Acute dermal toxicity	48240206	11556	OWN	76065 (ID 23941)	
		48240207	11556	OWN	14837	Supplemental
870.1300	Acute inhalation toxicity - rat	48240208	11556	OWN	16302	
		48240209	11556	OWN	17815	Pilot study

48240210

11556

17817

OWN



Approved OMB No. 2070-0060

		DAIA	MATRIX – CO	MEIDENTI	AL VERSION		
ate: November	3, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 4 of 18	
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• In	lumethrin Te nidacloprid T	NR1427 Insecticide chnical (pages 1 -7) 'echnical (pages 8 -t4) cticide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)	
Suideline Leference Jumber	ference		Submitter	Status	Report Number	Comments	
870.2400	Primary eye irritation – rabbit	48240211	11556	OWN	33853	Waiver request	
		48240212	11556	OWN	14967	Supplemental Study	
870.2500	Primary demaal irritation	48240213	11556	OWN	76066 (ID 23942)		
870.2600	Dermal sensitization	48240214	11556	OWN	14561	***************************************	
870.6100	Delayed neurotoxicity (acute) - hen					N.R Not an organophosphate	
870.6200	Acute neurotoxicity - rat	48240215	11556	OWN	201861 (ID 32545)	N.R Not an organophosphate	
870.3100	90-day oral - rodent			<u> </u>		No oral exposure	
870.3150	90-day feeding - non-rodent					N.R Nonfood use	
870.3200	21-day dermal - rabbit/rat					N.R Nonfood use	
870.3250	90-day dermal toxicity	48240216	11556	OWN	32570		
		48240217	11556	OWN	30932	Pilot study for 32570	
		48240218	11556	OWN	30931	Pilot study for 32570 and 30932	
870.3465	90-day inhalation	48240219	11556	OWN	18177	1	
870.6100	28-day delayed neurotoxicity - hen					N.R Not an organophosphate	
870.6200	90-day neurotoxicity - rat	48240220	11556	OWN	201706 (ID 32054)		
870.4100	Chronic oral toxicity - rodent	48240221	11556	OWN	19360	Listed as study type 870.4300 (combined)	
		48240222	11556	OWN	15285	Pilot study for ID 19360	
870.4200	Carcinogenicity – rat	48240221	11556	OWN	19360	Listed as study type 870.4300 (combined)	
		48240222	11556	OWN	15285	Pilot study for ID 19360	
870.4200	Carcinogenicity - mouse	48240223	11556	OWN	19383	See protocol discussion	
···		48240224	11556	OWN	18255	Pilot study for ID 19383	
870.3700	Developmental toxicity - rat	48240225	11556	OWN	18968		
870.3700	Developmental toxicity - rabbit	48240226	11556	OWN	35286		



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), 11 S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC.

20460. Do not se	ncluding suggestions for reducing the burden to: and the form to the address.	Director, OPPE Information	Management i	Division (213	7), U.S. Environmental Protection	Agency, 401 M Street, S.W., Washington, DC
		DATA I	MATREX - CO	NFIDENTI	AL VERSION	
Date: November	3, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 5 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• tr	lumethrin Tea nidacloprid T	NRI427 Insecticide Chnical (pages 1 -7) Pechnical (pages 8 - t4) Cticide (pages 15 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
870.3800	Reproduction and fertility effects	48240227	11556	OWN	32775	
		48240228	11556	OWN	13252	Pilot study for 32775
	•	48240229	11556	OWN	30322	Pilot study for 32775
		48240230	11556	OWN	30686	Pilot study for 32775
		48240231	11556	OWN	30517	Supplement to 30686
870.6300	Developmental neurotoxicity	48240232	11556	OWN	201747 (ID 32365)	
870.5100	Bacterial reverse mutation assay	48240233	11556	OWN	I4173	
		48240234	11556	OWN	14174	
		48240235	11556	OWN	30687	
870.5300	In vitro mammalian cell assay	48240236	11556	OWN	15461	
870.5375		48240237	11556	OWN	31492	
		48240238	11556	OWN	74691 (ID 16145)	
	ļ	48240239	11556	OWN	31489	
870,5385	In vitro cytogenetics	48240240	11556	OWN	30951	
870.5395	,	48240241	11556	OWN	15198	
870.5550	Unscheduled DNA Synthesis	48240242	11556	OWN	14867	
870.7485	Metabolism and pharmacokinetics	48240243	11556	OWN	14368	
	1	48240244	11556	OWN	22813	
		48240245	11556	OWN	30971	
		48240246	11556	OWN	15839	Cattle - Supplemental Study
	İ	48240247	11556	OWN	22818	Sheep - Supplemental Study
		48240248	11556	OWN	22819	Sheep - Supplemental Study
		48240249	11556	OWN	15987	Cattle - Supplemental Study
870.7200	Companion animal safety					N.A. for EP Only
870,7600	Dermal penetration		i			N.R See Risk Assessment



Approved OMB No. 2070-0060

20460. Do not se	including suggestions for reducing the burden to: Director and the form to the address.	n, OTTE Imorniano	al latente Eculcut 1	>14121011 (E1.	77, 0.3. Environmental Protection	Agency, 101 M Succe, S.W., Washington, DC
		DATA	MATRIX - CO	NEIDENTI	AL VERSION	
Date: November	3,2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 6 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• 1n	lumethrin Te nidacloprid T	NR1427 Insecticide chnical (pages 1 -7) fechnical (pages 8 -14) ccticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
870.7800	Immunotoxicily	48240250	11556	OWN	35217	
875.2400	Post-Application Exposure (Dermal)					N.A. EP Only
None	1998 EMEA Summary/Overview on Flumethtrin	48240251	11556	OWN	35038	Requested by Agency in Pre-Reg Meeting of 11/11/06
Environmental	Fate, Section 158.1300					
835.2120	Hydrolysis	}		<u> </u>		N.A.
835.2240	Photodegradation - water					N.A.
835.2410	Photodegradation - soil					N.A.
835.2370	Photodegradation - air					N.A.
835.4100	Aerobic soil melabolism					N.A.
835.4200	Angerobic soil metabolism					N.A.
835.4300	Aerobic aquatic metabolism		<u> </u>			N.A.
835.4400	Anaerobic aquatic metabolism			Ţ		N.A.
835.1230						N.A.
835,1240	Leaching / adsorption/desorption					
835.1410	Volatility - laboratory					N.A.
835.8100 835.6100	Volatility - field Terrestrial field dissipation			.}	 	NA.
835.6200	Aquatic (sediment)			<u> </u>	 	N.A.
835.6300	Forestry			<u> </u>		N.A.
835.6400	Combination and tank mixes	-	 	 		N.A.
835,7100	Ground water moniloring	1	·			N.A.



Approved OMB No. 2070-0060

		DATA	MATRIX - CO	NFIDENT	IAL VERSION	
Date: Novembe	er 3, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 7 of 18
Animal Health I P.O. Box 390	ayer Health Care, LLC nimal Health Division O. Box 390 hawnee Mission, KS 66201-0390			lumethrin Te nidaeloprid T	NRI427 Insecticide chnical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

	Nature of residue - plants	N.A.
	Nature of residue - livestock and poultry	N.A.
	Residue analytical method - plants	N.A.
	Residue analytical method - animal	N.A.
	Storage slability	N.A.
	Magnitude of residues - meat/milk/poultry/egg	N.A.
	Magnitude of residue - crop field trials	N.A
	Magnitude of residue - processed food/feed	N.A.
	Method validation/ multiresidue method	N.A.
None	Benefits Reports	N,A:
None	Dietary Analysis	N.A.
810.3300	Treatments to control pests of humans and pets	N.A. for EP Only



Approved OMB No. 2070-0060

		DATA	MATRIX CO	NFIDENTI	AL VERSION		
Date: November 3, 2010 Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 18)			Page 8 of 18	
						Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-3)	
Guideline Reference Number	Guldeline Study Name	MRID Number	Submitter	Status	Report Number	Comments	

		Imidacloprid Ac	tive Ingre	edient Sp	pecific (Pages 8 – 14)
Product Chemi	stry, Section 158.240				
• ••		42055302	264	PER	BR 1759 (TGAI)
61-1	Chemical identity	43306001	264	PER	BR 1879 (TGAI)
		42055302	264	PER	BR 1759 (TGAI)
		43306001	264	PER	BR 1879 (TGAI)
61-2	Statement of Composition	42270801	264	PER	BR 1785 (TGAI)
61-3	Formation of impurities	42055302	264	PER	BR 1759 (TGAI)
		42055303	264	PER	BR 1760 (TGAI)
	1	43306002	264	PER	BR 1880 (TGAI)
62-1	Preliminary analysis	42270802	264	PER	BR 1786 (TGAI)
		42055303	264	PER	BR 1760 (TGAI)
62-2	Certification of limits	43306002	264	PER	BR 1880 (TGAI)
		42055303	264	PER	BR 1760 (TGAI)
		43213001	264	PER	BR 1874 (TGAI)
62-3	Analytical method	43306002	264	PER	BR 1880 (TGAI)
63-1	Chemical and Physical Properties	42055304	264	PER	BR 1761 (TGAI)
63-2	Appearance	42055304	264	PER	BR 1761 (TGAI)
63-3	Physical state	42055304	264	PER	BR 1761 (TGAI)
63-4	Odor	42055304	264	PER	BR 1761 (TGAI)
63-5	Melting point	42055304	264	PER	BR 1761 (TGAI)
63-6	Boiling point	42055304	264	PER	BR 1761(TGAI)
63-7	Density	42055304	264	PER	BR 1761 (TGAI)



Approved OMB No. 2070-0060

20460. Do not se	and the form to the address.					
		DATA	MATRIX - CO	NFIDENT	IAL VERSION	
Date: November	EPA Reg No	/File Symb	ol: 11556-RLL	Page 9 of 18		
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide • Flumethrin Technical (pages 1 -7) • Imidacloprid Technical (pages 8 -14) • PNR1427 Insecticide (pages t5 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Yumber	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
63-8	Solubility	42055304	264	PER	BR 1761 (TGAI)	
63-9	Vapor pressure	42055304	264	PER	BR 1761 (TGAI)	
63-10	Dissociation constant	12035001		1	200.101 (10.11)	N.A Does not dissociate
63-11	Octanol / water partition	42055304	264	PER	BR 1761 (TGAI)	1777
63-12	рН	42055304	264	PER	BR 1761 (TGAI)	
63-13	Stability	42055304	264	PER	BR 1761 (TGAI)	
63-14	Oxidizing / reducing action					N.A No oxidative or reductive characteristics
63-15	Flammability	42055304	264	PER	BR 1761 (TGAI)	· · · · · · · · · · · · · · · · · · ·
63-16	Explodability	42055304	264	PER	BR 1761 (TGAI)	
63-17	Storage stability	42055304	264	PER	BR 1761 (TGAI)	
63-18	Viscosity			<u> </u>		N.A Solid
63-19	Miscibility		<u> </u>			N.A Solid
63-20	Corrosion characteristics	42055304	264	PER	BR 1761 (TGAI)	
63-21	Dielectric breakdown volt			·		N.A Solid
64-I	Submittal of samples				Samples available upon request	
Viidlife and Ac	uatic Organisms, Section 158.490					
71-1	Acute avian oral - quail/duck					N.A.
71-2(a)	Avian dietary - quail					N.A.
71-2(b)	Avian dietary - duck					N.A.
71-3	Wild mammal toxicity					N.A.
71-4(a)	Avian reproduction - quail					N.A.
71-4(b)	Avian reproduction - duck	_				N.A.
71-5	Simulated or actual field study					N.A.
72-1(a)	Fish toxicity - bluegill					N.A.



Approved OMB No. 2070-0060

20460. Do not se	and the form to the address.					, , , , , , , , , , , , , , , , , , , ,
		DATA N	MATRIX - CO	NFIDENT	AL VERSION	
Date: November 3, 2010				/File Symb	oi: 11556-RLL	Page 10 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide • Flumethrin Technical (pages 1-7) • Imidacloprid Technical (pages 8-14) • PNR1427 Insecticide (pages 15-18)			Ingredient: Flumethrin (CAS 69770-45-2 Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
72-1(b)	Fish toxicity bluegil! - tep	<u></u>				N.A.
72-2(a)	Invertebrate toxicity - Daphnia					N.A.
72-2(b)	Invertebrate toxicity - Amphipods					N.A.
72-2(e)	Acute aquatic invertebrate toxicity - Chironomids					N.A.
72-3(a)	Estuarine / marine loxicity - fish					N.A.
72-3(b)	Estuarine / marine toxicity - mollusk					N.A.
72-3(c)	Estuarine/marine toxicity - shrimp					N.A.
72-4(a)	Early life stage - fish					N.A.
72-4(b)	Life cycle invertebrate					N.A.
72-7	Simulated or actual field study					N.A.
None	Foliar half-life and distribution for potatoes					N.A.
None	Runoff and Erosion predictions for apple/potato/cotton					N.A.
None	Risk assessment for apple/potato/cotton					N.A.
Toxicology, Sec	tion 158.340					
81-1	Acute oral toxicity rat	42055331	264	PER	Report No. 100040 (TGAI)	
81-2	Acute dermal toxicity, rat/rabbit	42055332	264	PER	Report No. 100041 (TGAI)	
		42055333	264	PER	Report No. 99806 (TGAI)	
81-3	Acute inhalation toxicity, rat	42286101	264	PER	Report No. 99806-1 (TGAI)	
81-4	Primary eye irritation - rabbit	42055334	264	PER	Report No. 99679 (TGAI)	
81-5	Primary dermal irritation - rabbit	42055335	264	PER	Report No. 99804 (TGAI)	
81-6	Dermal sensitization - guinea pig	42055336	264	PER	Report No. 99800 (TGAI)	



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA N	MATRIX - CO	NFIDENT	AL VERSION	<u> </u>
ate: November	3, 2010		EPA Reg No	Æile Symb	ol: 11556-RLL	Page 11 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• ln	umethrin Te tidacloprid 1	NR1427 Insecticide chnical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
uideline eference iumber	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
		43170301	264	PER	Report No. 106348	
		43285801	264	PER	Report No. 106348-1	
81-8(SS)	Acute neuratoxicily	42770301	264	PER	Report No. 103979	
82-1(a)	90-day feeding - rodent	42256327	264	PER	Report No. 100036	
82- 1(b)	90-day feeding - non-rodent	42256328	264	PER	Report No. 100176	
		42256329	264	PER	Report No. 100688	
82-2	21-day dermal - rabbit/rat	48024009	264	PER	Report No. M-357205	
82-5(b)	90 day neurotoxicity - mammal	43286401	264	PER	Report No. 106356	
		42256331	264	PER	Report No. 100652	
		42256332	264	PER	Report No. 101931	
		42256333	264	PER	Report No. 102658	
83-1(a)	Chronic feeding toxicity - rodent	42256334	264	PER	Report No. 99672	
83-1(b)	Chronic feeding toxicity - non-rodent	42273002	264	PER	Report No. 100015	
		42256331	264	PER	Report No. 100652	
		42256332	264	PER	Report No. 101931	
		42256333	264	PER	Report No. 102658	
83-2(a)	Oncogenicity - rat	42256334	264	PER	Report No. 99672	
		42256335	264	PER	Report No. 100693	
		42256336	264	PER	Report No. 101929	
83-2(b)	Oncogenicity - mouse	42256337	264	PER	Report No. 99808	
83-3(a)	Developmental toxicity - rat	42256338	264	PER	Report No. 98571	
83-3(b)	Developmental toxicity - rabbit	42256339	264	PER	Report No. 98572	

42256340

264

PER

Report No. 100647

Two generation reproduction - rat

83-4



Approved OMB No. 2070-0060

20400. Do not ser	nd the form to the address.	DATA?	MATRIX CO	NEIDENE	IAL VERSION	
Date: November 3, 2010						Page 12 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 – 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Namc	MRID Number	Submitter	Status	Report Number	Comments
					T	
		42256341	264	PER	Report No. 101276	
0.4.0/->		42256342	264	PER	Report No. 98584	
84-2(a)	Gene mutation (ames test)	42256343	264	PER	Report No. 98570	
1	Į.	42256344	264	PER	Report No. 100021	
		42256345	264	PER	Report No. 99262	
		42256346	264	PER	Report No. 99257	
		42256347	264	PER	Report No. 102652	
		42256348	264	PER	Report No. 102654	
84-2(b)	Structural chromosomal aberration	42256349	264	PER	Report No. 102655	
		42256350	264	PER	Report No. 99676	
		42256351	264	PER	Report No. 101275	
		42256352	264	PER	Report No. 98573	
84-4	Other genoloxic effects	42256353	264	PER	Report No. 102653	
!		42256354	264	PER	Report No. 101999	
	1	42256355	264	PER	Report No. 87264	
		42256356	264	PER	Report No. 87265	
85-1	General metabolism	42256357	264	PER	Report No. 102617	
870.7200 (86-1)	Domestic Animal Safety					N.A. for EP Only
95-9	Efficacy			 		N.A. for EP Only
	, Section 158.540		<u></u>			
122-2	Aquatic plant growth		1	T		N.A.
123-2	Aquatic plant growth		 			N.A.
141-1	Honey bee acute contact			 		N.A.



Approved OMB No. 2070-0060

20460. Do not se	nd the form to the address.					
		DATA :	MATRIX CO	NFIDENT	IAL VERSION	
Date: November	3, 2010		EPA Reg No	/File Symb	el: 11556-RLL	Page 13 of 18
Animal Health Di P.O. Box 390	Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, K\$ 66201-0390		Product: PNRI427 Insecticide • Flumethrin Technical (pages 1 -7) • Imidacloprid Technical (pages 8 -14) • PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
141-2	Honey bee residue on foliage		T	<u> </u>		N.A.
	ion, Section 158.390		<u></u>	<u> </u>		
		42256386	264	PER	Report No. 94273	
230-236	Mixer/loader/applicator exposure	43790701	11556	OWN	Report No. 106743	
Environmental	Fate, Section 158,290	-A				
161-1	Hydrolysis	T	T ·			N.A.
161-2	Photodegradation - water	<u> </u>	<u> </u>			N.A.
16t-3	Photodegradation - soil		 			N.A.
162-1	Aerobic soit metabolism		T			N.A.
162-2	Anerobic soil metabolism					N.A.
162-3	Anaerobic aquatic metabolism					N,A.
163-1	Leaching / adsorption/desorption	1	†			N.A.
164-1	Terrestrial field dissipation	1.				N.A.
165-1	Confined rotational crop		1			N.A.
165-2	Field rotational crop					N.A.
166-1	Ground water - small prospective		T			N.A.
None	Environmental fate summary					N.A.
Residue, Section	158.240					
171-4(a)	Nature of residue - plants	T				N.A.
171-4(b)	Nature of residue - livestock and poultry					N.A.
171-4(c)	Residue analytical method - plants					N.A.
171-4(d)	Residue analytical method - animal					N.A.
171-4(e)	Storage slability					N.A.
171-4(j)	Magnitude of residues - meat/milk/poultry/egg	<u> </u>	<u> </u>	<u> </u>		NA.
171-4(k)	Magnitude of residue - crop field trials			<u> </u>		N.A.
171-4(1)			l		1	N.A.



Approved OMB No. 2070-0060

		DATA	MATRIX - CC	NFIDENT	AL VERSION	
Date: November	3,20t0		EPA Reg No	/File Symb	el: 11556-RLL	Page 14 of 18
Bayer Health Can Animal Health Di P.O. Box 390 Shawnee Mission			Product: PNR1427 Insecticide • Flumethrin Technical (pages t -7) • Imidscloprid Technical (pages 8 -14) • PNR1427 Insecticide (pages 15 - 18)		chnical (pages t -7) Technical (pages 8 -14)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
	Magnitude of residue - processed food/feed			J		
171-4(m)	Method validation/ multiresidue method					N.A
None	Benefits Reports					N.A.
None	Dietary Analysis					N.A.



Approved OMB No. 2070-0060

		DATA	MATRIX CO	NEIDENTI	AL VERSION	
Date: November 3, 2010			EPA Reg No	/File Symb	ol: tt556-RLL	Page 15 of 18
Bayer Health Car Animal Health D P.O. Box 390 Shawnee Mission			1 "			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

PNR 1427 Insecticide End-Use Product Specific (Pages 15 – 18)										
Product Chemistry, Section 158.240										
830.1550	Product identity and Composition	48240101	11556	OWN	33752					
830.1600	Description of materials used to produce the product	48240101	11556	OWN	33752					
830.1620	Description of production process	48240101	11556	OWN	33752					
830.1650	Description of formulation process	48240101	11556	OWN	33752					
830.1670	Discussion on formation of impurities	48240101	11556	OWN	33752					
830.1700	Preliminary analysis					N.A. TGAI Only				
830.1750	Certified of limits	48240101	11556	OWN	33752					
830.1800	Enforcement method	48240101	11556	OWN	33752					
830.1900	Submittal of samples					Samples available upon request				
830.6302	Color	48240101	1 1556	OWN	33752					
830.6303	Physical state	48240101	11556	OWN	33752					
830.6304	Odor	48240101	11556	OWN	33752					
830.6313	Stability			Ť ·		N.A. – TGAI Only				
830.6314	Oxidizing / reducing action					N.A EP not contain an oxidizing or reducing agent				
830.6315	Flammability					N.R This product is not considered a combustible liquid, because the closed up flashpoint for all the ingredients is > 199°F.				
830.6316	Explodability					N.R. – This product does not contain any explosive ingredients.				
830.6317	Storage stability					Pending; Available 3/31/2011				
830.6319	Miscibility .					N.R This product is not an emulsifiable type				



Approved OMB No. 2070-0060

20460. Do not send	the form to the address.				,,	
		DATA I	MATRIX - CO	NFIDENTI	AL VERSION	
Date: November 3.	Date: November 3, 2010 Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			./File Symb	ol: 11556-RLL	Page 16 of 18
Animal Health Div P.O. Box 390				iumethrin Te nidacloprid T	NR1427 Insecticide chnical (pages 1 -7) Technical (pages 8 -14) cticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) ImIdacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
830.6320	Corrosion characteristics	<u> </u>	T	····	1	Pending; Available 3/31/2011
830,6321	Dielectric breakdown volt					N.A Not intended use around electrical equipment
830,7000	pH					N.A product not soluble in water and therefore pH not required.
830.7050	UV/Visible absorption		<u> </u>	<u> </u>		N.A. – TGAI Only
830.7100	Viscosity					N.A. — This product is a solid and viscosity is not applicable.
830.7200	Melting point			<u> </u>		N.A TGA1 Only
830.7220	Boiling point			<u> </u>		N.A. – TGAI Only
830.7300	Density, bulk-density, or specific gravity		<u> </u>	<u> </u>		
830.7370	Dissociation constant in water			<u> </u>		N.A. – TGAI Only
830.7520	Particle size, fiber length, and diameter distribution					N.A. – Nonfiberous product
830.7550 830.7560 830.7570	Partition coefficient (n-octanol/water)					N.A. – TGAl Only
830.7840 830.7860	Water solubility					N.A. – TGAI Only
830.7950	Vapor pressure					N.A. – TGAI Only
Toxicology, Section	n 158.500				. 	
870.1100	Acute oral toxicity - rat	48240102	11556	OWN	33854	Waiver request
870.1200	Acute dermal toxicity	48240103	11556	OWN	33855	Waiver request
870.1300	Acute inhalation toxicity - rat	48240104	11556	OWN	33856	Waiver request
870.2400	Primary eye irritation - rabbtt	48240105	11556	OWN	33857	Waiver request
870.2500	Primary dermal irritation	48240106	11556	OWN	33749	
870.2600	Dermal sensitization	48240107	t1556	OWN	33750	
870.6100	Delayed neurotoxicity (acute) - hen		1	T		N.R Not an organophosphate



Approved OMB No. 2070-0060

		DATA i	MATRIX CC	INFIDENTI	AL VERSION	
Date: November 3, 2010				/File Symb	ol: 11556-RLL	Page 17 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			+ li	lumethrin Te nidacloprid T	NRI427 Insecticide chnical (pages 1 -7) 'echnical (pages 8 -14) cticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
870.6200	Acute neurotoxicity - rat			<u> </u>		N.R Not an organophosphate
870.3100	90-day oral - rodent		<u> </u>			N.R.
870.3200	21-day dermal - rabbit/rat					N.R Non-food use
870.3250	90-day dermal		<u> </u>			N.R Collar not affect uptake
870.7200	Companion animal safety	48240108	11556	OWN	33800	Adult cat safety study
		48240108	11556	OWN	33826	Amendment to adult cat study 33800
		48240109	11556	OWN	33805	Adult dog safety study
		48240110	11556	OWN	33806	Puppy safety study
		48240111	11556	OWN	33824	Kitten safety study
		48240112	11556	OWN	33822	Reflector study (puppy)
	İ	48240113	11556	OWN	33823	Reflector study (kitten)
		48240114	11556	OWN	35986	Reflector study (adult cat)
		48240115	11556	OWN	35637	Reflector Study (adult dog)
Product Perform	nance, Section 158.400					
810.3300	Treatments to control pests of humans and pets					
		48240116	11556	OWN	33801	Fleas and ticks (dogs)
		48240117	11556	OWN	33802	Fleas and ticks (cats)
		48240118	11556	OWN	33803	Efficacy with bathing and water immersion against ticks and fleas
		48240119	11556	OWN	35630	Fleas and ticks (Ixodes ricinis) (cats)
		48240120	11556	OWN	35631	Adult and larvacidal flea control; repellency and tic control (dogs)
		48240121	11556	OWN	35635	Adult and larvacidal fleas, ticks study (cats)
		48240122	11556	OWN	35644	Field studies fleas and ticks (cats)
		48240123	11556	OWN	35645	Field studies- fleas and ticks (dogs)



Approved OMB No. 2070-0060

	end the form to the address,				<u> </u>	
		DATA			AL VERSION	
			EPA Reg No			Page 18 of 18
			• lr	lumethnin Te nidacioprid T	NR1427 Lusecticide chnical (pages 1 -7) Pechnical (pages 8 -14) acticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-3)
Guideline Reference Kumber	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
<u></u>	Treatments to control pests of pets (cont'd)	48240124	11556	OWN	35980	Speed of kill for fleas (cats)
		48240125	11556	OWN	35987	Speed of kill for fleas (dogs)
		48240126	11556	OWN	33464	Ixodes Bridging study
		48240127	11556	OWN	35981	Ticks [Ixodes ricinis] (cats)
		48240128	11556	OWN	35979	Ticks [Ixodes ricinis] (dogs)
		48240129	11556	OWN	35982	Repellency and control of ticks (dogs)
		48240130	11556	OWN	33467	Juvenile Ticks
		48240131	11556	OWN	33694	Lice (Trichodectes canis)
		48240132	11556	OWN	33691	Sercoptic mange
		48240133	11556	OWN	36172	Hair clipping study - Repellency and efficacy
		48240134	11556	OWN	15962	Hair clipping study
		48240135	11556	OWN	35642	Serum and haircoat kinetics in cats
		48240136	11556	OWN	35643	Serum and halrcoat kinetics in dogs
·····		48240137	11556	OWN	15749	Advantage Efficacy against C. canis
Miscellaneous		1,000,000				
None	Benefits Document (In the Public Interest)	48240138	11556	OWN	33860	Submitted w/ Flumethrin Technical Application
None	ORE Risk Assessment	48240139	11556	OWN	33861	
None	Release Rate Compitation	48240140	11556	OWN	35992	
None	Soluble Surface Content of Collar	48240141	11556	OWN	35118	<u>l</u>



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

December 02, 2011

OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

BAYER HEALTHCARE LLC PO.BOX: 390

SHAWNEE MISSION, KS 66201-0390

Report of Analysis for Compliance with PR Notice 86-5

Thank you for your submittal of 30-NOV-11. Our staff has completed a preliminary analysis of the material. The results are provided as follows:

Your submittal was found to be in full compliance with the standards for submission of data contained in PR Notice 86-5. A copy of your bibliography is enclosed, annotated with Master Record ID's (MRIDs) assigned to each document submitted. Please use these numbers in all future references to these documents. Thank you for your cooperation. If you have any questions concerning this data submission, please raise them with the cognizant Product Manager, to whom the data have been released.

Bayer HealthCare Animal Health

Via Federal Express

November 29, 2011

Document Processing Desk (ADDL DATA - NO REGFEE)
Office of Pesticide Programs (7504P)
U.S. Environmental Protection Agency
Room S-4900, One Potomac Yard
2777 South Crystal Drive
Arlington, VA 22202-4501

Attention: Mr. Richard Gebken/PM10

Registration Division (7505P)

Subject: PNR1427 Insecticide (EPA File Symbol 11556-RLL)

Amendments to Companion Animal Safety Studies

Dear Mr. Gebken:

Please find enclosed two respective amendments to currently on-file companion animal safety studies on adult cats and adult dogs. The enclosed amendments provide additional information about the required studies, as requested in a teleconference on this subject with the Agency on October 20, 2011 (Dr. Byron Backus and Ms. BeWanda Alexander.) The main objective of these amendments is to appropriately recalculate the exposure of the target animals to the levels of the two active ingredients released from the collars worn by the pets during the study.

We will update the respective Data Matrix and resubmit it after we receive the MRID numbers back from the Agency. If you have any questions, please do not hesitate to call me at 913-268-2751.

Sincerely,

Douglas AuSpilker. Ph. D.

Manager, EPA Regulatory Affairs

Doug.Spilker@Bayer.com

Enclosures:

1. Bayer Report No. 33967 – Adult Dogs (3 copies)

2. Bayer Report No. 33968 - Adult Cats (3 copies)



Bayer HealthCare LLC Animal Health P.O. Box 390 Shawnee Mission, KS 66201-0390

Transmittal Document

1. Name and Address of Submitter

Bayer HealthCare LLC

Animal Health Division

Box 390

Shawnee Mission, Kansas 66201-0390

Douglas A. Spilker, Ph.D.

Manager, EPA Regulatory Affairs

(913) 268-2751

2. Regulatory Action in Which this Package is Submitted

> Additional Information for the Pending Application for Registration of "PNR1427 Insecticide"; File Symbol 11556-RLL

3. Transmittal Date

November 29, 2011

4. List of Submitted Studies:

MRID No.

Volume

1

48674701

"Final Report Amendment 1 to Bayer Report 33805 (MRID 48240109) - Safety of PNR 1427 in Adult

Dogs," Bayer Report No. 33967, Harish M. Chopade,

16 pp.

48674702

2 "Final Report Amendment 2 to Bayer Report 33800

(MRID 48240108) - Safety of PNR 1427 in Adult Cats," Bayer Report No. 33968, Harish M. Chopade,

16 pp.

Page 1 of 1

Memorandum

Date:	12/06/11
To:	, Regulatory Manager
From:	Information Services Branch, ITRMD
indicati	our receipt of this data submission is not an ion that MRIDs for the enclosed studies have osted to OPPIN.
from t	e expect that it will be approximately 5 days he above date before the study-level data is ble in OPPIN.
•	you have any questions about this process, contact Teresa Downs (305-5363).
This is	a: fully accepted submission partially accepted submission

484185-00

Bayer HealthCare LLC Animal Health P.O. Box 390

Shawnee Mission, KS 66201-0390

Bayer HealthCare

Animal Health

Via Federal Express

March 10, 2011

Document Processing Desk (ADDL DATA - NO REGFEE)
Office of Pesticide Programs (7504P)
U.S. Environmental Protection Agency
Room S-4900, One Potomac Yard
2777 South Crystal Drive
Arlington, VA 22202-4501

Attention:

Mr. Richard Gebken/PM10

Registration Division (7505P)

Subject:

PNR1427 Insecticide (EPA File Symbol 11556-RLL)

Dear Mr. Gebken:

Please find enclosed a study providing data to fulfill the data requirements of one year storage stability (OPPTS GL No. 830.6317) and corrosion characteristics (OPPTS GL No. 830.6320) in support of the pending registration of the subject product. As requested, please also find an electronic version of this report on the enclosed CD. Please note that the title of the report refers to "M915 Insecticide," the previous code name for the product, but the formulation being the same.

I will update the respective Data Matrix and resubmit it after I receive the MRID number back from the Agency.

If you have any questions, please do not hesitate to call me at 913-268-2751.

Sincerely/

Douglas A. Spilker. Ph. D.

Manager, EPA Regulatory Affairs

Doug.Spilker@Bayer.com

Enclosures:

1. Bayer Report No. 33906 (3 copies paper; 1 copy CD)

cc; B. Alexander (EPA) - email

84

Transmittal Document

1. Name and Address of Submitter

Bayer HealthCare LLC Animal Health Division

Box 390

Shawnee Mission, Kansas 66201-0390

Douglas A. Spilker, Ph.D.

Manager, EPA Regulatory Affairs

(913) 268-2751

2. Regulatory Action in Which this Package is Submitted

Submission of one year storage stability (830.6317) and corrosion characteristics (830.6320) report, in support of the pending registration of PNR1427 Insecticide (EPA File Symbol 11556-RLL)

3. <u>Transmittal Date</u>

March 10, 2011

4. <u>List of Submitted Studies</u>:

MRID No. Volume

1

48416501

 Evaluation of Stability and Corrosion Characteristics of M915 Insecticide, OPPT 830.6317 and 830.6320;
 Bayer Report No. 33906, Rose, J., 24 pp. (3 paper copies; 1 CD)



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

October 6, 2010

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

BAYER HEALTHCARE LLC ANIMAL HEALTH DIVISION PO Box 390 SHAWNEE MISSION, KS 66201-0390

Report of Analysis for Compliance with PR Notice 86-5

Thank you for your submittal of 24-SEP-10. Our staff has completed a preliminary analysis of the material. The results are provided as follows:

Your submittal was found to be in full compliance with the standards for submission of data contained in PR Notice 86-5. A copy of your bibliography is enclosed, annotated with Master Record ID's (MRIDs) assigned to each document submitted. Please use these numbers in all future references to these documents. Thank you for your cooperation. If you have any questions concerning this data submission, please raise them with the cognizant Product Manager, to whom the data have been released.

Bayer HealthCare Animal Health

BAYER BAYER

Via Federal Express

September 23, 2010

Document Processing Desk (REGFEE) Office of Pesticide Programs (7504P) U.S. Environmental Protection Agency Room S-4900, One Potomac Yard 2777 South Crystal Drive Arlington, VA 22202-4501

Attention:

Mr. Richard Gebken/PM10

Registration Division (7505P)

Subject:

Application for Registration of a New Active Ingredient

(PRIA R110): Flumethrin Technical (CAS No. 69770-45-2)

Application for Registration of a Combination (Flumethrin + Imidacloprid) End-Use Product: *PNR1427 Insecticide*

Dear Mr. Gebken:

With this application, the enclosed data and labeling, Bayer HealthCare LLC, Animal Health Division (BAH) is requesting the registration of a new technical active ingredient – "Flumethrin Technical" containing flumethrin (CAS No. 69770-45-2). A second application for registration of PNR1427 Insecticide end-use product (flea and tick pet collar) is being submitted concurrently with this application for registration of the technical active ingredient. The flumethrin technical active ingredient, which is also the manufacturing-use product, is for formulation purposes ONLY into products with indoor, non-food uses. The "specific use pattern" on domestic animals, according to the Pesticide Use Index, is determined to be Group Number 99 "Indoor – Non-Food."

The proposed Flumethrin Technical is considered a "new" active ingredient in that it is "...not currently contained as an active ingredient in any EPA registered pesticide product." The ultimate use of this technical active ingredient is for formulation into pesticide products on pets (cats and dogs), which are considered indoor use patterns by the Agency. No flumethrin-containing end-use products are proposed that would be used on or come into contact with food and/or feed items. Therefore as described in the PRIA Decision Tree, the application for registration of this new active ingredient – Flumethrin Technical - falls under the action code R110: "Nonfood use; Indoor." Furthermore, it is our understanding that all indoor non-food use products included with this technical active

Bayer HealthCare LLC Animal Health P.O. Box 390 Shawnee Mission, KS 66201-039 ingredient application are covered by the base fee in this category, if submitted simultaneously. The application for the end-use product, *PNR1427 Insecticide*, is being submitted simultaneously with the technical product application, and therefore there should be no additional PRIA fee for the *PNR1427 Insecticide* application.

Flumethrin, a new active ingredient, is intended as a Technical/Manufacturing Use Product for formulating insecticides for indoor uses (on domestic animals; cats and dogs). Flumethrin Technical is proposed for use in combinations with other EPA-registered active ingredients (such as imidacloprid). PNR1427 Insecticide is a new pesticide end-use product combining two active ingredients, imidacloprid and flumethrin, in a pet collar formulation. It is intended for the prevention and treatment of public health pests, such as ticks and fleas, on kittens, cats, puppies and dogs.

The Agency is not unfamiliar with this active ingredient and end-use product, as Bayer Healthcare has had several pre-registration meetings and/or teleconferences with the Agency to discuss these registration actions and the specific 40 CFR Part 158 requirements for these products. Detailed overviews of the two actions are attached to the respective Applications for Pesticide Registration (EPA Form No. 8570-1), and the Bayer-EPA interactions will be referenced in the respective sections of these overviews, and copies of referenced documents provided. We request that copies of the two applications with attachments be forwarded to the respective review groups, as we think this information could be quite helpful during their review processes.

Information regarding the benefits of this new active ingredient-containing product is contained in the document entitled: "Benefits of Flumethrin Active Ingredient and the Imidacloprid/Flumethrin Collar for Cats and Dogs (PNR1427), Bayer report No. 33860," which should allow the Agency to make the determination that "...the use of the pesticide will not cause any unreasonable risk to the environment; and the use of the pesticide is in the public interest."

If you have any questions, please do not hesitate to call me at 913-268-2751.

Sincerely,

Douglas A. Spilker. Ph. D.

Manager, EPA Regulatory Affairs

Doug.Spilker@Bayer.com

Enclosures:

1. Copy of Check – Check No. 2000542090 (\$209,475.00), cover letter, dated 9/20/10, and delivery confirmation, dated 9/21/2010

2. Application for Registration - Flumethrin Technical

- a. Administrative Volume (Volume 1 on Transmittal Document)
 - i. Cover letter (Extra Copy)
 - ii. Copy of PRIA Payment (Check No. 2000542090)
 - iii. Application for Registration Flumethrin Technical (Form 8570-1), 10pp. w/ 6 attachments
 - iv. Transmittal document
 - v. Confidential Statement of Formula, dated 11/15/2008 (2 copies)
 - vi. Certification with Respect to Citation of Data (Form 8570-34)
 - vii. Data Matrix (CONFIDENTIAL) "Flumethrin Active Ingredient Specific, dated 9/20/2010," 7pp.
 - viii. Data Matrix (PUBLIC) "Flumethrin Active Ingredient Specific, dated 9/20/2010," 7pp.
 - ix. Product label, dated 9/20/2010 (3 copies)
- b. Bayer Reports ID Nos. 23979, 23980, 23940, 14838, 18186, 23941, 14837, 16302, 17815, 17817, 33853, 14967, 76066, 14561, 32545, 32570, 30932, 30931, 18177, 201706, 19360, 15285, 19383, 18255, 18968, 35286, 32775, 13252, 30322, 30686, 30517, 32365, 14173, 14174, 30687, 15461, 31492, 74691, 31489, 30951, 15198, 14867, 14368, 22813, 30971, 15839, 22818, 22819, 15987, 35217, 35038 (3 copies each)

3. <u>Application for Registration – end-use product PNR1427</u> Insecticide

- a. Administrative Volume (Volume 1 on Transmittal Document)
 - i. Cover letter (Extra Copy)
 - ii. Application for Registration PNR1427 Insecticide (Form 8570-1), 17pp. w/ 7 attachments
 - iii. Confidential Statements of Formula (3) Basic, Alt 1, and Alt 2, dated 8/25/2010; 2 copies each)
 - iv. Transmittal Document
 - v. Certification with Respect to Citation of Data (Form 8570-34)

- vi. Letter of Authorization from Bayer CropScience (for imidacloprid), dated 9/7/2010
- vii. Data Matrix (CONFIDENTIAL) PNR1427 Insecticide: "Flumethrin Active Ingredient Specific (pages 1-7), Imidacloprid Active Ingredient Specific (pages 8-14), and PNR1427 Insecticide Specific (pages 15-18); dated 9/20/2010," total pages – 18
- viii. Data Matrix (PUBLIC) PNR1427 Insecticide: "Flumethrin Active Ingredient Specific (pages 1-7), Imidacloprid Active Ingredient Specific (pages 8-14), and PNR1427 Insecticide Specific (pages 15-18); dated 9/20/2010," total pages -18
- ix. Product label, dated 9/20/2010 (3 copies)
- b. Bayer Reports ID Nos. 33752, 33854, 33855, 33856, 33857, 33749, 33750, 33800, 33826, 33805, 33806, 33824, 33822, 33823, 35986, 35637, 33801, 33802, 33803, 35630, 35631, 35635, 35644, 35645, 35980, 35987, 33464, 35981, 35979, 35982, 33467, 33694, 33691, 36172, 15962, 35642, 35643, 15749, 33860, 33861, 35992, 35118 (3 copies each)

TRANSMITTAL DOCUMENT

Name and Address of Submitter:

Bayer HealthCare LLC

Animal Health Division

Box 390

Shawnee Mission, Kansas 66201-0390

Regulatory action in support of

Application for registration of

which this package is submitted:

PNR1427 Insecticide

EPA Reg. No./File Symbol:

Company Number: 11556- XXX

Alternate Test Material Names:

N/A

Transmittal Date:

September 23, 2010

Box Count:

19 - 24

Volume Number	Citation	MRID Number
1	Administrative Materials - Cover letter (Extra Copy) - Application for Pesticide Registration (with Attachments) - Confidential Statement of Formula (2 copies) - Transmittal Document - Certification with respect to Citation of Data (8570-34) - Letter of Authorization from Bayer CropScience (imidacloprid) - Data Matrix (CONFIDENTIAL) - Data Matrix (PUBLIC) - Product Label (3 copies)	
1) E 2	Rose, J.E., 2009, Chemistry Evaluation of M915 Insecticide, 33752 (1 book, 3 copies).	48240101
^() ¹ 3	Chopade, H., 2010, Request for Waiver from the Requirement of Acute Oral Toxicity Study – PNR 1427 Insecticide, 33854 (1 book, 3 copies).	48240102
√ ()√ 4	Chopade, H., 2010, Request for Waiver from the Requirement of Acute Dermal Toxicity Study – PNR 1427 Insecticide, 33855 (1 book, 3 copies).	48240103
7 ₅ 5	Chopade, H., 2010, Request for Waiver from the Requirement of Acute Inhalation Toxicity Study – PNR 1427 Insecticide, 33856 (1 book, 3 copies).	48240104
·6	Chopade, H., 2010, Request for Waiver from the Requirement of Acute Eye Irritation Toxicity Study – PNR 1427 Insecticide, 33857 (1 book, 3 copies).	48240105
, _, , + 7	Durando, J., 2009, Primary Skin Irritation Study in Rabbits, 33749 (1 book, 3 copies).	48240106

Volume Number	Citation	MRID Number
8	Durando, J., 2009, Dermal Sensitization Study in Guinea Pigs (Buehler Method), 33750 (1 book, 3 copies).	48240107
9	Madsen, T.J., 2010, Safety of PNR 1427 in adult cats, 33800 (1 book, 3 copies).	48240108
10	Madsen, T.J., 2010, Amendment to Bayer Report No.33800- Safety of PNR1427 in Adult Cats, 33826 (1 book, 3 copies).	
11	Madsen, T.J., 2010, Safety of PNR 1427 in Adult Dogs, 33805 (1 book, 3 copies).	48240109
12	Madsen, T.J. & Chopade, H., 2010, Safety of PNR1427 in Puppies, 33806 (2 books, 3 copies).	48240110
13	Madsen, T.J., 2010, Safety of PNR 1427 in Kittens, 33824 (2 books, 3 copies).	48240111
t4	Madsen, T.J., 2010, Safety of PNR1427 With Reflectors in Puppies, 33822 (1 book, 3 copies).	48240112
15	Madsen, T.J., 2010, Safety of PNR1427 with Reflectors in Kittens, 33823 (1 book, 3 copies).	48240113
16	Delport, P.C., 2010, Target animal safety with a PNR 1427 collar with and without reflectors when applied once to adult cats, 35986 (1 book, 3 copies).	48240114
17	Bach, T., 2010, Target Animal Safety With A 10% Imidacloprid + 4.5% Flumethrin Collar With or Without Reflector Clips Applied Once To Adult Dogs, 35637 (1 book, 3 copies).	48240115
18	Everett, W.R., Davis, W.L., & Settje, T.L., 2010, Efficacy of PNR1427 Against Tick (Dermacentor variabilis, Rhipicephalus sanguineus) and Flea Infestations on Dogs, 33801 (1 book, 3 copies).	48240116
19	Everett, W.R., Davis, W.L., & Settje, T.L., 2010, Efficacy of PNR1427 Against Tick (Amblyomma americanum) and Flea Infestations on Cats, 33802 (1 book, 3 copies).	48240117
20	Everett, W.R., Davis, W.L., & Settje, T.L., 2010, Evaluation of the Effects of Shampooing or Water Immersion on the Efficacy of PNR1427 Against Flea (Ctenocephalides felis) and Tick (Dermacentor variabilis, Rhipicephalus sanguineus) Infestations on Dogs, 33803 († book, 3 copies).	48240118
21	Strube, K., Stanneck, D., Schroeder, I., & Kruedewagen, E., 2010, Efficacy of a 10% imidacloprid / 4.5% flumethrin collar against experimental tick (Ixodes ricinus) and flea (Ctenocephalides felis) infestations in cats, 35630 (1 book, 3 copies).	48240119

Volume Number	Citation	MRID Number
22	Strube, K., Stanneck, D., Schroeder, I., & Kruedewagen, E., 2010, Efficacy of a 10% imidacloprid / 4.5% flumethrin collar against experimental tick (Ixodes ricinus and Rhipicephalus sanguineus) and flea (Ctenocephalides felis) infestations in dogs, 35631 (1 book, 3 copies).	48240120
23	Wolken, S., & Stanneck, D., 2010, Efficacy of a 10% imidacloprid / 4.5% flumethrin collar against experimental tick (Ixodes ricinus) and flea (Ctenocephalides felis) infestations in cats, 35635 (1 book, 3 copies).	48240121
24	Rass, J. & Stanneck, D., 2010, Evaluation of the Efficacy, Persistency and Safety of "Imidacloprid 10%/Flumethrin 4.5% Collar" in Cats Naturally Infested with Fleas and/or Ticks in a Multi-Centric Clinical Field Study in the EU, 35644 (1 book, 3 copies).	48240122
25	Rass, J. & Stanneck, D., 2010, Evaluation of the Efficacy, Persistency and Safety of "Imidacloprid 10%/Flumethrin 4.5% Collar" in Dogs Naturally Infested with Fleas and/or Ticks in a Multi-Centric Clinical Field Study in the EU, 35645 (1 book, 3 copies).	48240123
26	Strube, K. & Schroeder, I., 2010, Onset of Efficacy of a 10% Imidacloprid/ 4.5% Flumethrin Collar on Cats When Experimentally Infested with the Cat Flea Ctenocephalides felis (C. felis), 35980 (1 book, 3 copies).	48240124
27	Kok, D.J., 2010, Onset of Efficacy of an Imidacloprid/Flumethrin Collar Formulation Against Fleas (Ctenocephalides felis) on Dogs, 35987 (1 book, 3 copies).	48240125
28	Turberg, A. & Settje, T., 2010, Comparative in-vitro study of flumethrin efficacy against two Ixodes species in a glass vial contact assay, 33464 (1 book, 3 copies).	48240126
29	Strube, K., 2010, Onset of efficacy of a 10% Imidacloprid/ 4.5% flumethrin collar on cats when experimentally infested with <i>Ixodes ricinus (l. ricinus)</i> , 35981 (1 book, 3 copies).	48240127
30	Ketzis, J. & Schroeder, I., 2010, A controlled, randomized study to confirm the efficacy of Imidacloprid/Flumethrin containing collars against artificially induced infestations of Ixodes ricinus on beagles, 35979 (1 book, 3 copies).	48240128
31	Strube, K., 2010, Onset of Efficacy of a 10% Imidacloprid/ 4.5% Flumethrin Collar on Dogs when Experimentally Infested with <i>Ixodes ricinus</i> and <i>Rhipicephalus sanguineus</i> , 35982 (1 book, 3 copies).	48240129

Volume	Citation	MRID Number
Number 32	Turberg, A., 2010, Comparative in-vitro study of efficacy of a 1: 1.85 flumethrin: imidacloprid mixture against larvae, nymphs and adults of I. ricinus and R. sanguineus and larvae and adults of D. reticulatus ticks in a glass vial contact assay, 33467 (1 book, 3 copies).	
33	Ketzis, J. & Stanneck, D., 2010, A Controlled, Randomized Study to Confirm the Efficacy of Imidacloprid/Flumethrin Containing Collars Against a Natural Infestation of Dog Lice (<i>Trichodectes canis</i>) on Mixed Bred and Purebred Dogs, 33694 (1 book, 3 copies).	48240131
34	Fourie, J.J., 2010, Evaluation of the Efficacy of an Imidacloprid/Flumethrin Collar Formulation on Dogs with Naturally Acquired Infestations of <i>Sarcoptes scabiei</i> , 33691 (1 book, 3 copies).	48240132
35	Kruedewagen, E., 2010, In-vitro Efficacy of Hair Coat Samples From Cats and Dogs Treated with Imidacloprid 10%/Flumethrin 4.5% Collars Against Ticks (<i>R. sanguineus</i>), 36172 (1 book, 3 copies).	48240133
36	Gyr, P. & Hopkins, T., 1995, Residues of BAY 17391 10% w/v Spot-on in the Coat of Dogs at Various Times After Treatment, 15962 (1 book, 3 copies).	48240134
37	Delport, P.C., 2010, Serum and Hair Coat Kinetics of an Imidacloprid 10%/Flumethrin 4.5% Collar in Cats, 35642 (1 book, 3 copies).	8240135
38	Delport, P.C., 2010, Serum and Hair Coat Kinetics of an Imidacloprid 10%/Flumethrin 4.5% Collar in Dogs, 35643 (1 book, 3 copies).	240136
39	Jacobs, D.E., 1995, Imidacloprid Spot-on 10% (BAY t 7391) for the Control of Fleas on Dogs - Clinical Field Study, 15749 (1 book, 3 copies).	48240137
40	Spilker, D.A., & Davis, W.L., 2010, "Benefits of Flumethrin Active Ingredient and the Imidacloprid/Flumethrin Collar for Cats and Dogs (PNR1427)", 33860 (1 book, 3 copies).	48240138
41	Lunchick, C., 2010, Occupational and Residential Exposure and Risk Assessment for PNR 1427 Dog and Cat Collars Formulated with Imidacloprid and Flumethrin, 33861 (1 book, 3 copies).	48240139
42	Stanneck, D., 2010, Dosage of the imidacloprid 10%/flumethrin 4.5% collar and release of the active ingredients over time in cats and dogs – Review Compilation, 35992 (1 book, 3 copies).	48240140

Volume Number	Citation	MRID Number
43	Kruedewagen, E., 20 t0, Soluble Surface Content of Flumethrin and Imidacloprid of a Collar Containing 10% Imidacloprid plus 4.5% Flumethrin After Beeing Worn by Cats for Different Time Periods, 35118 (1 book, 3 copies).	48240141

Company Official:

Douglas A. Spilker, Ph.D., Manager

EPA Regulatory Affairs

Company Name:

Bayer HealthCare LLC Animal Health Division

Company Contact:

Douglas A. Spilker, Ph.D. Phone: (913) 268-2751 Fax: (913) 268-2135 Email: doug.spilker@bayer.com



Approved OMB No. 2070-0060

		DATA	MATRIX - CO	NFIDENT	AL VERSION	
Date: November 3, 2010			EPA Reg No	./File Symb	ol: 1556-RLL	Page 1 of 18
Bayer Health Care Animal Health Div P.O. Box 390 Shawnee Mission,	noision		• in	umethrin Te aidacloprid T	NR1427 Insecticide chnical (pages 1 -7) Technical (pages 8 -14) octicide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

		Flumethrin Ac	tive Ingre	dient Sp	pecific (Pages 1 – 7)	
Product Chemis	try, Section 158.300					
830.1550	Product identity and Composition	48240201	11556	OWN	23979 (BR 2625)	
830.1600	Description of materials used to produce the product	48240201	11556	OWN	23979 (BR 2625)	
830.1620	Description of production process	48240201	11556	OWN	23979 (BR 2625)	
830.1650	Description of formulation process					N.A EP Only
830.1670	Discussion on formation of impurities	48240201	11556	OWN	23979 (BR 2625)	
830.1700	Preliminary analysis	48240201	11556	OWN	23979 (BR 2625)	
830.1750	Certified of limits	48240201	11556	OWN	23979 (BR 2625)	
830.1800	Enforcement method	48240201	11556	OWN	23979 (BR 2625)	
830.1900	Submittal of samples		· · · · · · · · · · · · · · · · · · ·	<u> </u>		Samples available upon request
830,6302	Color	48240202	11556	OWN	23980 (BR 2624)	
830,6303	Physical state	48240202	11556	OWN	23980 (BR 2624)	
830.6304	Odor	48240202	11556	OWN	23980 (BR 2624)	
830,6313	Stability	48240202	11556	OWN	23980 (BR 2624)	
830.6314	Oxidizing / reducing action	48240202	11556	OWN	23980 (BR 2624)	
830.6315	· Flammability	48240202	11556	OWN	23980 (BR 2624)	
830.6316	Explodability	48240202	11556	OWN	23980 (BR 2624)	
830,6317	Storage stability	48240202	11556	OWN	23980 (BR 2624)	
830.6319	Miscibility	48240202	11556	OWN	23980 (BR 2624)	
830.6320	Corresion characteristics	48240202	11556	OWN	23980 (BR 2624)	
830,6321	Dielectrie breakdown volt	48240202	11556	OWN	23980 (BR 2624)	
830,7000	pH .	48240202	11556	OWN	23980 (BR 2624)	



Approved OMB No. 2070-0060

ZU40U. L/O not sen	d the form to the address.	D		A 1911 P. F12 1941	The same of the sa	
Data Manager 2	2010	DATA !			AL VERSION	
	Date: November 3, 2010			./File Symb		Page 2 of 18
Animal Health Div P.O. Box 390	Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390		• 1r	umethrin Te nidacloprid T	NRI427 Insecticide chnical (pages 1 -7) Technical (pages 8 -14) cticide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guidelinc Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
830.7050	UV/Visible absorption	48240202	11556	OWN	23980 (BR 2624)	
830.7100	Viscosity	48240202	11556	OWN	23980 (BR 2624)	N.A. – Not a liquid
830.7200	Melting point	48240202	11556	OWN	23980 (BR 2624)	14.V. – 1401 g trďano
830.7200 830.7220	Boiling point	48240202	11556	OWN	23980 (BR 2624)	
830.7300	Density, bulk-density, or specific gravity	48240202	11556	OWN	23980 (BR 2624)	
830.7370	Dissociation constant in water	48240202	11556	OWN	23980 (BR 2624)	N.A Does not dissociote
830.7520	Particle size, fiber length, and diameter distribution	48240202	11556	OWN	23980 (BR 2624)	1111 2 22 101 2 22 2 2 2 2 2 2 2 2 2 2 2
830.7550 830.7560 830.7570	Partition coefficient (n-octanol/water)	48240202	11556	OWN	23980 (BR 2624)	
830.7840 830.7860	Water solubility	48240202	11556	OWN	23980 (BR 2624)	
830.7950	Vapor pressure	48240202	11556	OWN	23980 (BR 2624)	
	quatic non-target organisms data requirements, Sec	tion 158.630				
850.2100	Avian oral toxicity					N.A.
850.2200	Avian dietary toxicity					N.A.
850,2400	Wild mammal toxicity		Ţ			N.A.
850.2300	Avian reproduction					N.A.
850.2500	Simulated or actual field testing					N.A.
850.1075	Freshwater fish toxicity					N.A.
850.1010	Acute toxicity freshwater invertebrates			1		N.A.
850.1025 850.1035 830.1045 830.1055 830.1075	Acute toxicity estuarine and marine organisms					N.A.
850.1300	Aquatic invertebrates life cycle (freshwater)		1			N.A.



Approved OMB No. 2070-0060

Date: November	3, 2010		EPA Reg No	./File Symb	ol: 11556-RLL	Page 3 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• In	lemethn'n Te nidacloprid T	NR1427 Insecticide choical (pages 1 -7) Fechical (pages 8 -14) ecticide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
850.1350	Aquatic invertebrates life cycle (saltwater)					N.A.
850.1400	Fish early-life stage (freshwater)					N.A.
850.1400	Fish early-life stage (saltwater)					N.A.
850.1500	Fish life cycle					N.A.
850.1710 850.1730 850.1850	Aquatic organisms bioavailability, biomagnifications, toxicity					N.A.
850-1950	Simulated or actual field testing for aquatic organisms					N.A.
850.1735	Whole sediment: acute freshwater invertebrates					N.A.
850.1740	Whole sediment: acuse marine invertebrates					N.A.
850.3020	Honey bee scute contact toxicity					N.A.
850.3030	Honey bee toxicity of residues on foliage					N.A.
850.3040	Field testing for pollinators					N.A.

870.1100	Acute oral toxicity - rat	48240203	11556	OWN	76064 (ID 23940)	
	İ	48240204	11556	OWN	14838	Supplemental
		48240205	11556	OWN	18186	Supplemental
870,1200 Acute dermal toxicity	Acute dermal toxicity	48240206	11556	OWN	76065 (ID 23941)	
		48240207	11556	OWN	14837	Supplemental
870.1300	Acute inhalation toxicity - rat	48240208	11556	OWN	16302	
		48240209	t1556	OWN	17815	Pilot study
					Pilot study	
		48240210	11556	OWN	17817	



Approved OMB No. 2070-0060

		······································	T			
Date: November 3, 2010 Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			EPA Reg No	-		Page 4 of 18
			• In	lumethrin To	NR1427 Insecticide chnical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
870.2400	Primary eye irritation - rabbit	48240211	11556	lown	33853	Waiver request
	, , , , , , , , , , , , , , , , , , , ,	48240212	11556	OWN	14967	Supplemental Study
870.2500	Primary dermal irritation	48240213	11556	OWN	76066 (ID 23942)	
870.2600	Dermal sensitization	48240214	11556	OWN	14561	
870.6100	Delayed neurotoxicity (acute) - hen					N.R Not an organophosphate
870.6200	Acute neurotoxicity - rat	48240215	11556	OWN	201861 (ID 32545)	N.R Not an organophosphate
870,3100	90-day oral - rodent					No oral exposure
870.3150	90-day feeding - non-rodent				***	N.R. – Nonfood use
B70.3200	21-day dermal - rabbit/rat					N.R Nonfood use
870.3250	90-day dermal toxicity	48240216	11556	OWN	32570	
		48240217	11556	OWN	30932	Pilot study for 32570
		48240218	11556	OWN	30931	Pilot study for 32570 and 30932
870.3465	90-day inhalation	48240219	11556	OWN	18177	
870.6100	28-day delayed neurotoxicity - hen					N.R Not an organophosphate
870.6200	90-day neuroloxicity - rat	48240220) 1556	OWN	201706 (ID 32054)	
870.4100	Chronic oral toxicity - rodent	48240221	11556	OWN	19360	Listed as study type 870.4300 (combined)
		48240222	11556	OWN	15285	Pilot study for ID 19360
870.4200	Carcinogenicity - rat	48240221	11556	OWN	19360	Listed as study type 870.4300 (combined)
		48240222	11556	OWN	15285	Pilot study for ID 19360
870,4200	Carcinogenicity - mouse	48240223	11556	OWN	19383	See protocol discussion
	<u> </u>	48240224	11556	OWN	18255	Pilot study for ID 19383
870.3700	Developmental toxicity - rat	48240225	11556	OWN	18968	
870,3700	Developmental toxicity - rabbit	48240226	11556	OWN	35286	



Approved OMB No. 2070-0060

		DATA :	MATRIX - CO	NFIDENTI	AL VERSION	
Date: November 3, 2010			EPA Reg No	./File Symb	ol: 11556-RLL	Page 5 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390		Product: PNR1427 Insecticide Flumethrin Technical (pages 1 - 7) Imidacloprid Technical (pages 8 - 14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)	
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

870.3800	Reproduction and fertility effects	48240227	11556	OWN	32775	
	1	48240228	11556	OWN	13252	Pilot study for 32775
	1	48240229	11556	OWN	30322	Pilot study for 32775
		48240230	11556	OWN	30686	Pilot study for 32775
	,	48240231	11556	OWN	30517	Supplement to 30686
870.6300	Developmental neurotoxicity	48240232	11556	OWN	201747 (ID 32365)	
870.5100	Bacterial reverse mulation assay	48240233	11556	OWN	14173	
		48240234	11556	OWN	14174	
		48 24 02 35	11556	OWN	30687	
870.5300	In vitro mammalian cell assay	48240236	11556	OWN	15461	
870.5375		48240237	11556	OWN	31492	
	1	48240238	11556	OWN	74691 (ID 16145)	
		48240239	11556	OWN	31489	
870.5385	In vitro cytogenetics	48240240	11556	OWN	30951	
870,5395		48240241	11556	OWN	15198	
870,5550	Unscheduled DNA Synthesis	48240242	11556	OWN	14867	
870.7485	Metabolism and pharmacokinetics	48240243	11556	OWN	14368	
		48240244	11556	OWN	22813	
		48240245	11556	OWN	30971	
		48240246	11556	OWN	15839	Cattle - Supplemental Study
	48240247	11556	OWN	22818	Sheep - Supplemental Study	
	48240248	11556	OWN	22819	Sheep - Supplemental Study	
	48240249	11556	OWN	15987	Cattle - Supplemental Study	
870.7200	Companion animal safety					N.A. for EP Only
870.7600	Dermal penetration			T		N.R See Risk Assessment



Approved OMB No. 2070-0060

nd the form to the address.					
	DATA	MATRIX - CO	NFIDENT	AL VERSION	
			/Flie Symb	ol; 11556-RLL	Page 6 of 18
			lumethrin Te nidacloprid 1	chnical (pages 1 -7) Fechnical (pages 8 -14)	Ingredient: Flumethrin (CAS 69770-45-2) lmidacloprid (CAS 138261-41-3)
Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
Immunotoxicity	48240250	11556	OWN	1 35217	
					N.A. EP Only
1998 EMEA Summary/Overview on Flumethtrin	48240251	11556	OWN	35038	Requested by Agency in Pre-Reg Meeting of 11/11/06
'ate, Section 158.1300				•	
Hydrolysis					N.A.
Photodegradation - water					N.A.
Photodegradation - soil					N.A.
Photodegradation - air			<u> </u>		N.A.
Aerobic soil metabolism		<u> </u>			N.A.
Anaerobic soil metabolism		<u> </u>			N.A.
Aerobic aquatic metabolism					N.A.
Anaerobic aquatic metabolism					N.A.
			t		N,A,
	<u> </u>		<u> </u>		
					N.A.
			<u> </u>		N.A.
		<u> </u>			N.A.
	 	<u> </u>	<u> </u>		N.A.
		.	ļ		N.A.
Ground water monitoring	<u> </u>		↓		N.A.
3 2 3	Guideline Study Name Immunotoxicity Post-Application Exposure (Dermal) 1998 EMEA Summary/Overview on Flumethtrin ate, Section 158.1300 Hydrolysis Photodegradation - water Photodegradation - soil Photodegradation - air Aerobic soil metabolism Anaerobic soil metabolism Anaerobic aquatic metabolism Anaerobic aquatic metabolism Leaching / adsorption/desorption Volatility - field Terrestrial field dissipation Aquatic (sediment) Forestry Combination and tank mixes	DATA 3, 2010 3, LLC vision KS 66201-0390 Guideline Study Name Immunotoxicity 48240250 Post-Application Exposure (Dermal) 1998 EMEA Summary/Overview on Flumethtrin 48240251 ate; Section 158.1300 Hydrolysis Photodegradation - water Photodegradation - soil Photodegradation - soil Photodegradation - air Aerobic soil metabolism Anaerobic soil metabolism Anaerobic aquatic metabolism Leaching / adsorption/desorption Volatility - laboratory Volatility - field Terrestrial field dissipation Aquatic (sediment) Forestry Combination and tank mixes	DATA MATRIX - CO 3, 2010 EPA Reg No LLC vision RS 66201-0390 Guideline Study Name MRID Number Immunotoxicity Post-Application Exposure (Dermal) 1998 EMEA Summary/Overview on Flumethtrin At Section 158.1300 Hydrolysis Photodegradation - water Photodegradation - soil Photodegradation - air Acrobic soil metabolism Anaerobic soil metabolism Anaerobic aquatic metabolism Anaerobic aquatic metabolism Leaching / adsorption/desorption Volatility - laboratory Volatility - field Terrestrial field dissipation Aquatic (sediment) Forestry Combination and tank mixes	DATA MATRIX - CONFIDENTI 3, 2010 EPA Reg No/File Symb 5, LLC vision RS 66201-0390 Fundation Te Imidaclopind	DATA MATRIX ~ CONFIDENTIAL VERSION 3,2010 EPA Reg No./File Symbol: 11556-RLL



Approved OMB No. 2070-0060

		DATA ?	MATRIX - CO	NFIDENTI	AL VERSION	
Date: November 3	, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 7 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethin Technical (pages 1 -7) Imidaclopid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Fiumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

	Nature of residue - plants	N.A.
	Nature of residue - livestock and poultry	N.A.
	Residue analytical method - plants	N.A.
	Residue analytical method - animal	N.A.
	Storage stability	N.A.
	Magnitude of residues - meat/milk/poultry/egg	N.A.
	Magnitude of residue - crop field trials	N.A.
	Magnitude of residue - processed food/feed	N.A.
··· <u>'' ···</u>	Method validation/ multiresidue method	N.A.
None	Benefits Reports	N,A,
None	Dietary Analysis	N.A.
310.3300	Treatments to control pests of humans and pets	N.A. for EP Only



Approved OMB No. 2070-0060

		DATA	MATRIX – CO	NFIDENT	AL VERSION	
Date: November 3, 2010			EPA Reg No	./File Symb	ol: 11556-RLL	Page 8 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

	Imidacloprid Active Ingredient Specific (Pages 8 – 14)									
Product Chemi	stry, Section 158.240									
		42055302	264	PER	BR 1759 (TGAI)					
61-1	Chemical identity	43306001	264	PER	BR 1879 (TGAI)					
		42055302	264	PER	BR 1759 (TGAI)					
		43306001	264	PER	BR 1879 (TGAI)					
61-2	Statement of Composition	42270801	264	PER	BR 1785 (TGAI)					
61-3	Formation of impurities	42055302	264	PER	BR 1759 (TGAI)					
		42055303	264	PER	BR 1760 (TGAI)					
		43306002	264	PER	BR 1880 (TGAI)					
62-1	Preliminary analysis	42270802	264	PER	BR 1786 (TGAI)					
:		42055303	264	PER	BR 1760 (TGAI)					
62-2	Certification of limits	43306002	264	PER	BR 1880 (TGAI)					
,		42055303	264	PER	BR 1760 (TGAI)					
	1	43213001	264	PER	BR 1874 (TGAI)					
62-3	Analytical method	43306002	264	PER	BR 1880 (TGAI)					
63-1	Chemical and Physical Properties	42055304	264	PER	BR 1761 (TGAI)					
63-2	Арреагалсе	42055304	264	PER	BR 1761 (TGAI)					
63-3	Physical state	42055304	264	PER	BR 1761 (TGAI)					
63-4	Odor	42055304	264	PER	BR 1761 (TGAI)					
63-5	Melting point	42055304	264	PER	BR 1761 (TGAI)					
63-6	Boiling point	42055304	264	PER	BR 1761(TGA1)					
63-7	Density	42055304	264	PER	BR 1761 (TGAI)					



Approved OMB No. 2070-0060

20460. Do not se	nd the form to the address.					
		DATA	MATRIX – CO	DNFIDENT	IAL VERSION	
Date: November			EPA Reg No	/File Symb	ol: 11556-RLL	Page 9 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390		11 • [lumethrin Te nidacloprid	NR1427 Insecticide chnical (pages 1 -7) Technical (pages 8 -14) ecticide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)	
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
63-8	Solubility	42055304	264	PER	BR 1761 (TGAI)	
63-9	Vapor pressure	42055304	264	PER	BR 1761 (TGAI)	
63-10	Dissociation constant		<u> </u>			N.A Does not dissociate
63-11	Octanol / water partition	42055304	264	PER	BR 1761 (TGAI)	
63-12	ρH	42055304	264	PER	BR 1761 (TGAI)	
63-13	Stability	42055304	264	PER	BR 1761 (TGAI)	
63-14	Oxidizing / reducing action		<u> </u>			N.A No oxidative or reductive characteristics
63-15	Flanmability	42055304	264	PER	BR 1761 (TGAI)	
63-16	Explodability	42055304	264	PER	BR 1761 (TGAI)	
63-17	Storage stability	42055304	264	PER	BR 1761 (TGAI)	
63-18	Viscosity					N.A Solid
63-19	Miscibility					N.A Solid
63-20	Corrosion characteristics	42055304	264	PER	BR 1761 (TGAI)	
63-21	Dielectric breakdown volt					N.A Solid
64-1	Submittal of samples				Samples available upon request	
Wildlife and Aq	uatic Organisms, Section 158.490					
71-1	Acute avian oral - quail/duck					N.A.
71-2(a)	Avian dietary - quail					N.A.
71-2(b)	Avian dietary - duck					N.A.
71-3	Wild mammal toxicity					N.A.
71-4(a)	Avian reproduction - quail					N.A.
71-4(b)	Avian reproduction - duck			<u> </u>		N.A.
71-5	Simulated or actual field study					N.A.
72-1(a)	Fish toxicity - btuegill					N.A.



Approved OMB No. 2070-0060

		DATA I	MATRIX - CO	NFIDENTI	AL VERSION	<u></u>
Date: November 3, 2010				File Symb	ol: 11556-RLL	Page 10 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• In	umethrin Te nidacloprid T	NR1427 Insecticide chnical (pages t -7) 'echnical (pages 8 -14) cticide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
72-1(b)	Fish toxicity bluegill - tep		<u> </u>	T		N.A.
72-2(a)	Invertebrate toxicity - Daphnia					N.A.
72-2(b)	Invertebrate toxicity - Amphipods					N.A.
72-2(c)	Acute aquatic invertebrate toxicity - Chironomids			l		N.A.
72-3(a)	Estuarine / marine toxicity - fish		1			N.A.
72-3(b)	Estuarine / marine toxicity - mollusk		<u> </u>			N.A.
72-3(e)	Estuarine/marine toxicity - shrimp			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		N.A.
72-4(a)	Early life stage - fish					N.A.
72-4(b)	Life cycle invertebrate					N.A.
72-7	Simulated or actual field study]		N.A.
None	Foliar half-life and distribution for potatoes					N.A.
None	Runoff and Erosion predictions for apple/potato/cotton		[N.A.
None	Risk assessment for apple/potato/cotton					N.A.
Toxicology, Sect	ion 158.340					
81-1	Acute oral toxicity rat	42055331	264	PER	Report No. 100040 (TGAI)	
81-2	Acute dermal toxicity, rat/rabbit	42055332	264	PER	Report No. 100041 (TGAI)	
		42055333	264	PER	Report No. 99806 (TGAI)	
81-3	Acute inhalation toxicity, rat	42286101	264	PER	Report No. 99806-1 (TGAI)	
81-4	Primary eye irritation - rabbit	42055334	264	PER	Report No. 99679 (TGAI)	
81-5	Primary dermal irritation - rabbit	42055335	264	PER	Report No. 99804 (TGAI)	
81-6	Dermal sensitization - guinea pig	42055336	264	PER	Report No. 99800 (TGAI)	



Approved OMB No. 2070-0060

		DATA I	MATRIX - CO	NFIDENTI	AL VERSION	<u></u>	
Date: November 3	, 2010		EPA Reg No	Ælle Symb	ol: 11556-RLL	Page 11 of 18	
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3	3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments	

		43170301	264	PER	Report No. 106348
		43285801	264	PER	Report No. 106348-1
81-8(SS)	Acute neurotoxicity	42770301	264	PER	Report No. 103979
82-1(a)	90-day feeding - rodent	42256327	264	PER	Report No. 100036
82-1(b)	90-day feeding - non-rodent	42256328	264	PER	Report No. 100176
- ··-		42256329	264	PER	Report No. 100688
82-2	21-day dermal - rabbit/rat	48024009	264	PER	Report No. M-357205
82-5(b)	90 day neurotoxicity - mammal	43286401	264	PER	Report No. 106356
		42256331	264	PER	Report No. 100652
		42256332	264	PER	Report No. 101931
		42256333	264	PER	Report No. 102658
83-1(a)	Chronic feeding toxicity - rodent	42256334	264	PER	Report No. 99672
83-1(ъ)	Chronic feeding toxicity - non-rodent	42273002	264	PER	Report No. 100015
		42256331	264	PER	Report No. 100652
		42256332	264	PER	Report No. 101931
		42256333	264	PER	Report No. 102658
83-2(a)	Oncogenicity - rat	42256334	264	PER	Report No. 99672
		42256335	264	PER	Report No. t00693
		42256336	264	PER	Report No. 101929
83-2(b)	Oncogenicity - mouse	42256337	264	PER	Report No. 99808
83-3(a)	Developmental toxicity - rat	42256338	264	PER	Report No. 98571
83-3(b)	Developmental toxicity - robbit	42256339	264	PER	Report No. 98572
83-4	Two generation reproduction - rat	42256340	264	PER	Report No. 100647



Approved OMB No. 2070-0060

		DATA	MATRIX – CO	NFIDENT	AL VERSION	
Date: November	3, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 12 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, K\$ 66201-0390			• 1n	lumethrin Te nidacloprid I	NR1427 Insecticide chnical (pages 1 -7) 'echnical (pages 8 -14) cticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number			Submitter	Status	Report Number	Comments
<u></u>		42256341	264	PER	Report No. 101276	
		42256342	264	PER	Report No. 98584	
84-2(a)	Gene mutation (ames test)	42256343	264	PER	Report No. 98570	
B4-2(4)	Oche mutatori (anes test)	42256344	264	PER	Report No. 100021	
		42256345	264	PER	Report No. 99262	
		42256346	264	PER	Report No. 99257	
		42256347	264	4	<u> </u>	
		<u> </u>	264	PER	Report No. 102652	
84-2(Ь)		42256348		PER	Report No. 102654	
54-2(D)	Structural chromosomal aberration	42256349	264	PER	Report No. 102655	
		42256350	264	PER	Report No. 99676	
		42256351	264	PER	Report No. 101275	
0.4	Other transfer of the second	42256352	264	PER	Report No. 98573	
84-4	Other genotoxic effects	42256353	264	PER	Report No. 102653	
		42256354	264	PER	Report No. 101999	
		42256355	264	PER	Report No. 87264	
		42256356	264	PER	Report No. 87265	
85-1	General metabolism	42256357	264	PER	Report No. 102617	
870,7200						N.A. for EP Only
(86-1)	Domestic Animal Safety					
95-9	Efficacy					N.A. for EP Only
	i, Section 158.540					
122-2	Aquatic plant growth					N.A.
123-2	Aquatic plant growth					N.A.
141-1	Honey bee acute contact			1		N.A.



Approved OMB No. 2070-0060

		DATA !	MATRIX - CO	NFIDENT	IAL VERSION	
Date: November	Date: November 3, 2010			File Symb	ol; 11556-RLL	Page 13 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390		Product:			Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-3)	
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Submitter Status Report Number		Conuments
141-2	Honey bee residue on foliage	<u> </u>		ļ		N.A.
Reentry Protecti	on, Section 158:390				•	
		42256386	264	PER	Report No. 94273	
230-236	, Mixer/loader/applicator exposure	43790701	11556	OWN	Report No. 106743	
Environmental I	ate, Section 158.290					
161-1	Hydrolysis					N.A.
161-2	Photodegradation - water					N.A.
161-3	Photodegradation - soil					N.A.
162-1	Acrobic soil metabolism					N.A.
162-2	Anerobic soil metabolism			<u> </u>		N.A.
162-3	Anaerobic aquatic metabolism	1				N.A.
163-I	Leaching / adsorption/desorption					N.A.
164-1	Terrestrial field dissipation					N.A.
165-1	Confined rotational crop					N.A.
165-2	Field rotational crop			1		N.A.
166-l	Ground water - small prospective					N.A.
None	Environmental fate summary					N.A.
Residue, Section	158.240					
171-4(a)	Nature of residue - plants			Ĭ		N.A.
171-4(b)	Nature of residue - livestock and poultry	· · ·				N.A.
171-4(c)	Residue analytical method - plants					N.A.
171-4(d)	Residue analytical method - animal					N.A.
171-4(e)	Storage stability					N.A.
171-4(j)	Magnitude of residues - meat/milk/poultry/egg		 _			N.A.
171-4(k)	Magnitude of residue - crop field trials					N.A.
171-4(1)			İ			N.A.



Approved OMB No. 2070-0060

		DAT	A MATRIX - CO	NEIDENT	IAL VERSION		
Date: November	3, 2010		EPA Reg No	/File Symi	ol: 11556-RLL	Page 14 of 18	
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• Lo	lumethrin To nidacloprid	NRI427 Insecticide chnical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-2	
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments	
<u></u>	Magnitude of residue - processed food/feed			T .			
(71-4(m)	Method va(idation/ multiresidue method			T -		N.A.	
None	Benefits Reports			T		N.A.	
None	Dietary Analysis			1		N.A.	



Approved OMB No. 2070-0060

DATA MATRIX - CONFIDENTIAL VERSION								
Date: November 3, 2010			EPA Reg No	/File Symb	ol: 11556-RLL	Page 15 of 18		
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)		
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments		

	PNR 1	427 Insecticid	e End-Use	Produc	t Specific (Pages 15 -	18)
Product Chemis	try, Section 158.240					
830.1550	Product identity and Composition	48240101	11556	OWN	33752	
830.1600	Description of materials used to produce the product	48240101	11556	OWN	33752	
830.1620	Description of production process	48240101	11556	OWN	33752	
830.1650	Description of formulation process	48240101	11556	OWN	33752	
830.1670	Discussion on formation of impurities	48240101	11556	OWN	33752	
830,1700	Preliminary analysis					N.A. TGAI Only
830,1750	Certified of limits	48240101	11556	OWN	33752	
830,1800	Enforcement method	48240101	11556	OWN	33752	
830.1900	Submittal of samples	·····				Samples available upon request
830.6302	Color	48240101	11556	OWN	33752	
830.6303	Physical state	48240101	11556	OWN	33752	
830.6304	Odor	48240101	11556	OWN	33752	
830,6313	Stability					N.A TGAI Only
830.6314	Oxidizing / reducing action					N.A EP not contain an oxidizing or reducing agent
830.6315	Flammability					N.R. – This product is not considered a combustible liquid, because the closed up flashpoint for all the ingredients is > 199°F.
830.6316	Explodability					N.R. – This product does not contain any explosive ingredients.
830.6317	Storage stability			<u> </u>		Pending; Available 3/31/2011
830.6319	Miscibility					N.R This product is not an emulsifiable type



Approved OMB No. 2070-0060

		DATA	MATRIX CO	NFIDENTI	AL VERSION	
Date: November 3, 2010			EPA Reg No	/File Symb	ol: 11556-RLL	Page 16 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 - 14) PNR1427 Insecticide (pages 15 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter Status Report Number		Report Number	Comments
830.6320	Corrosion characteristics		T	Γ		Pending; Available 3/31/2011
830.6321	Dielectric breakdown volt		 	<u> </u>		N.A. – Not intended use around electrical equipment
830.7000	pH					N.A. – product not soluble in water and therefore pH not required.
830.7050	UV/Visible absorption					N.A. – TGAI Only
830.7100	Viscosity					N.A.—This product is a solid and viscosity is not applicable.
830.7200	Melting point					N.A TGAI Only
830.7220	Boiling point					N.A. – TGAI Only
830.7300	Density, bulk-density, or specific gravity					
830.7370	Dissociation constant in water					N.A. – TGAI Only
830,7520	Particle size, fiber length, and diameter distribution					N.A. – Nonfiberous product
830.7550 830.7560 830.7570	Partition coefficient (n-oclanol/water)					N.A. – TGAl Only
830.7840 830.7860	Water solubility					N.A TGAI Only
830.7950	Vapor pressure	· · · · · · · · · · · · · · · · · · ·				N.A. – TGAI Only
Toxicology, Sect	ion 158.500					
870.1100	Acute oral toxicity - rat	48240102	11556	OWN	33854	Waiver request
870.1200	Acute dermal toxicity	48240103	11556	OWN	33855	Waiver request
870.1300	Acute inhalation toxicity - rat	48240104	11556	OWN	33856	Waiver request
870,2400	Primary eye irritation - rabblt	48240105	11556	OWN	33857	Waiver request
870,2500	Primary dermal irritation	48240106	11556	OWN	33749	
870,2600	Dermal sensitization	48240107	11556	OWN	33750	
870,6100	Delayed neurotoxicity (acute) - hen			T		N.R Not an organophosphate



Approved OMB No. 2070-0060

20460. Do not sen	d the form to the address.						
		DATA	MATRIX - CO	ONFIDENTI	AL VERSION		
Date: November 3		EPA Reg No	/File Symb	ol: 11556-RLL	Page 17 of 18		
Bayer Health Care, Animal Health Div P.O. Box 390 Shawnee Mission,	rision		• ir	PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages t5 - 18)		Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)	
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments	
870.6200	Acute neurotoxicity - rat		<u> </u>	T	E	N.R Not an organophosphate	
870,3100	90-day oral - rodent		 			N.R.	
870,3200	21-day dermal - rabbit/rat					N.R Non-food use	
870.3250	90-day dermal					N.R Collar not affect uptake	
870.7200	Companion animal safety	48240108	11556	OWN	33800	Adult cat safety study	
	Companion analysis sales	48240108	11556	OWN	33826	Amendment to adult cat study 33800	
		48240108	11556	OWN	33805	Adult dog safety study	
		48240110	11556	OWN	33806	Puppy safety study	
		48240111	11556	OWN	33824	Kitten safety study	
		48240112	11556	OWN	33822	Reflector study (puppy)	
		48240113	11556	OWN	33823	Reflector study (kitten)	
		48240114	11556	OWN	35986	Reflector study (adult cat)	
		48240115	11556	OWN	35637	Reflector Study (adult dog)	
Product Perform	ance, Section 158,400		1		1		
810.3300	Treatments to control pests of humans and pets						
		48240116	11556	OWN	33801	Fleas and ticks (dogs)	
		48240117	11556	OWN	33802	Fleas and ticks (cats)	
	:	48240118	11556	OWN	33803	Efficacy with bathing and water immersion against ticks and fleas	
		48240119	11556	OWN	35630	Fleas and ticks (Ixodes ricinis) (cats)	
		48240120	11556	OWN	35631	Adult and larvacidal flea control; repetiency and tick control (dogs)	
		48240121	11556	OWN	35635	Adult and larvacidal fleas, ticks study (cats)	
		48240122	11556	OWN	35644	Field studies - fleas and ticks (cats)	
		48240123	11556	OWN	35645	Field studies- fleas and ticks (dogs)	



Approved OMB No. 2070-0060

		DATA	MATRIX CO	NFIDENTI	IAL VERSION	
Date: Novembe	r 3, 2010		EPA Reg No	/File Symb	ol: 11556-RLL	Page 18 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390		• In	lumethrin Te aldacloprid T	NR1427 Iusecticide chnical (pages 1 -7) Fechnical (pages 8 -14) acticide (pages 15 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)	
Guldeline Reference Number	ference Number		Submitter	Status	Report Number	Comments
	Treatments to control pests of pets (cont'd)	48240124	11556	OWN	35980	Speed of kill for fleas (cats)
		48240125	11556	OWN	35987	Speed of kill for fleas (dogs)
1		48240126	11556	OWN	33464	Ixodes Bridging study
		48240127	11556	OWN	35981	Ticks [Ixodes ricinis] (cats)
		48240128	11556	OWN	35979	Ticks [Ixodes ricinis] (dogs)
		48240129	11556	OWN	35982	Repellency and control of ticks (dogs)
		48240130	11556	OWN	33467	Juvenile Ticks
		48240131	11556	OWN	33694	Lice (Trichodectes canis)
		48240132	11556	OWN	33691	Sarcoptic mange
		48240133	11556	OWN	36172	Hair clipping study - Repellency and efficacy
		48240134	11556	OWN	15962	Hair clipping study
		48240135	11556	OWN	35642	Serum and haircoat kinetics in cats
		48240136	11556	OWN	35643	Serum and haircoat kinetics in dogs
		48240137	11556	OWN	15749	Advantage Efficacy against C. canis
Miscellaneous						
None	Benefits Document (In the Public Interest)	48240138	11556	OWN	33860	Submitted w/ Flumethrin Technical Application
None	ORE Risk Assessment	48240139	11556	OWN	33861	
None	Release Rate Compitation	48240140	11556	OWN	35992	
None	Soluble Surface Content of Collar	48240141	11556	OWN	35118	

25 Ang 11556-RLL (csubm. fopending product -> office up botz

Memorandum

Date:	08 / 24 / 11
To:	PM 10 , Regulatory Manager
From:	Information Services Branch, ITRMD
indication	on that MRIDs for the enclosed studies have sted to OPPIN.
from th	expect that it will be approximately 5 days to above date before the study-level data is le in OPPIN.
_	ou have any questions about this process, ontact Teresa Downs (305-5363).
This is a	a: ☐ fully accepted submission ☐ partially accepted submission ☐ rejected submission



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

August 22, 2011

OFFICE OF CHEMICAL SAFETY AND POLLUTION PREVENTION

BAYER HEALTHCARE LLC

PO.BOX: 390

SHAWNEE MISSION, KS 66201-0390

Report of Analysis for Compliance with PR Notice 86-5

Thank you for your submittal of 18-AUG-11. Our staff has completed a preliminary analysis of the material. The results are provided as follows:

Your submittal was found to be in full compliance with the standards for submission of data contained in PR Notice 86-5. A copy of your bibliography is enclosed, annotated with Master Record ID's (MRIDs) assigned to each document submitted. Please use these numbers in all future references to these documents. Thank you for your cooperation. If you have any questions concerning this data submission, please raise them with the cognizant Product Manager, to whom the data have been released.

Administrative Materials

Bayer Animal Health



Bayer HealthCare LLC Animal Health P.O. Box 390

Shawnee Mission, KS 66201-0390

Via Federal Express

September 20, 2010

U.S. Bank Government Lockbox 979074 1005 Convention Plaza SL-MO-C2-GL St. Louis, MO 63197

(314) 418-4990

Subject:

U.S. Environmental Protection Agency

PRIA Registration Service Fee - New Active Ingredient

R110: Nonfood Use; Indoor

Bayer Product: Flumethrin Technical

Bayer Company No. 11556

Dear Sir or Madam:

Please find enclosed the appropriate PRIA Service fee for the subject application for registration of *Flumethrin Technical* (Bayer Reg. No. 11556-XXX) and the respective end-use product *PNR1427 Insecticide* being submitted to the appropriate address at the Environmental Protection Agency in Washington D.C.

If you have any questions, please do not hesitate to call (913-268-2751).

Sincerely,

Douglas A. Spilker. Ph. D.

Manager, EPA Regulatory Affairs

Doug.Spilker.b@Bayer.com

Enclosure: Check No. 2000542090 (\$209,475.00)

21-Day Screen Completed by Contractor

21-Day Expires on 10-15-10

Jacket # 11556 - RLL MRID# 482401

Content Screen: Recommended to Pass/Fail

86-5 Review: Passed/Failed/NA

Transfer This Jacket to:

STEPHEN SCHAIBLE

PM-13

PRIA 2 – 21 Day Content Screen Review Worksheet (EPA/OPP Use Only) 3/23/09

21 Day Screen Start Date:	9-2	4-10		
Experts In-Processing Signature:	MF	HARRINGTON	Date 9-29-/0	Fee Paid: Yes
Division management contacted on			Date	

Application Form (EPA Form 8570-1)(link to form) signed & co			Local	1!	i		
including package type	Application Form (EPA Form 8570-1)(link to form) signed & complete including package type						
Confidential Statement of Formula all boxes completed, form sidated (EPA Form 8570-4) (Link to form)	X		 				
a) All inerts (link to http://www.epa.gov/opprd001/inerts/), including fragrances, approved for the proposed uses (see Footnote A)							
Certification with Respect to Citation of Data (EPA Form 8570 form) completed and signed (N/A if 100% repack)	ink to	X					
Certificate and data matrix consistent		X					
If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B)	no						
Formulator's Exemption Statement (EPA Form 8570-27) (Link		THE STATE OF THE S	7 7777	X			
	nal	×					
a) Selective Method (Fee category experts use)	yes >	no					
b) Cite-All (Fee category experts use)							
c) Applicant owns all data (Fee category experts use)							
	dated (EPA Form 8570-4) (Link to form) a) All inerts (link to http://www.epa.gov/opprd001/inerts/), including fragrances, approved for the proposed uses (see Footnote A) Certification with Respect to Citation of Data (EPA Form 8570 form) completed and signed (N/A if 100% repack) Certificate and data matrix consistent If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B) If applicable, is there a letter of Authorization for exclusive use or Formulator's Exemption Statement (EPA Form 8570-27) (Link completed and signed (N/A if source is unregistered or applicant of technical) Data Matrix (EPA Form 8570-35) (Link to form) both internal arcopies (PR 98-5) (Link to PR 98-5) completed and signed (N/A if repack) a) Selective Method (Fee category experts use)	dated (EPA Form 8570-4) (Link to form) a) All inerts (link to http://www.epa.gov/opprd001/inerts/), including fragrances, approved for the proposed uses (see Footnote A) Certification with Respect to Citation of Data (EPA Form 8570-34) (Link form) completed and signed (N/A if 100% repack) Certificate and data matrix consistent If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B) If applicable, is there a letter of Authorization for exclusive use only. Formulator's Exemption Statement (EPA Form 8570-27) (Link to form completed and signed (N/A if source is unregistered or applicant owns the technical) Data Matrix (EPA Form 8570-35) (Link to form) both internal and extencopies (PR 98-5) (Link to PR 98-5) completed and signed (N/A if 100% repack) a) Selective Method (Fee category experts use) b) Cite-All (Fee category experts use) c) Applicant owns all data (Fee category experts use)	a) All inerts (link to http://www.epa.gov/opprd001/inerts/), including fragrances, approved for the proposed uses (see Footnote A) Certification with Respect to Citation of Data (EPA Form 8570-34) (Link to form) completed and signed (N/A if 100% repack) Certificate and data matrix consistent If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B) If applicable, is there a letter of Authorization for exclusive use only. Formulator's Exemption Statement (EPA Form 8570-27) (Link to form) completed and signed (N/A if source is unregistered or applicant owns the technical) Data Matrix (EPA Form 8570-35) (Link to form) both internal and external copies (PR 98-5) (Link to PR 98-5) completed and signed (N/A if 100% repack) a) Selective Method (Fee category experts use) b) Cite-All (Fee category experts use) c) Applicant owns all data (Fee category experts use)	a) All inerts (link to http://www.epa.gov/opprd001/inerts/), including fragrances, approved for the proposed uses (see Footnote A) Certification with Respect to Citation of Data (EPA Form 8570-34) (Link to form) completed and signed (N/A if 100% repack) Certificate and data matrix consistent If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B) If applicable, is there a letter of Authorization for exclusive use only. Formulator's Exemption Statement (EPA Form 8570-27) (Link to form) completed and signed (N/A if source is unregistered or applicant owns the technical) Data Matrix (EPA Form 8570-35) (Link to form) both internal and external copies (PR 98-5) (Link to PR 98-5) completed and signed (N/A if 100% repack) a) Selective Method (Fee category experts use) b) Cite-All (Fee category experts use) c) Applicant owns all data (Fee category experts use)	a) All inerts (link to http://www.epa.gov/opprd001/inerts/), including fragrances, approved for the proposed uses (see Footnote A) Certification with Respect to Citation of Data (EPA Form 8570-34) (Link to form) completed and signed (N/A if 100% repack) Certificate and data matrix consistent If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B) If applicable, is there a letter of Authorization for exclusive use only. Formulator's Exemption Statement (EPA Form 8570-27) (Link to form) completed and signed (N/A if source is unregistered or applicant owns the technical) Data Matrix (EPA Form 8570-35) (Link to form) both internal and external copies (PR 98-5) (Link to PR 98-5) completed and signed (N/A if 100% repack) a) Selective Method (Fee category experts use) b) Cite-All (Fee category experts use) c) Applicant owns all data (Fee category experts use)		

7	Is the data package consistent with PR Notice 86-5 (link to PRN 86-5)	X	
8	Notice of Filing (link to http://www.epa.gov/pesticides/regulating/tolerance_petitions.htm) included with petitions (link to http://www.epa.gov/pesticides/regulating/tolerances.htm)	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	7
9	If applicable for conventional applications, reduced risk rationale (link to http://www.epa.gov/opprd001/workplan/reducedrisk.html)		 \times
100 mm. m. m. m. m. m. m. m. m. m. m. m. m.	Required Data (link to http://www.epa.gov/pesticides/regulating/data_requirements.htm) and/or data waivers. See Footnote C. a) List study (or studies) not included with application	THE PARTY OF THE P	

Comments:

PEGISTRANT NOTIFIED OF 86-5 DEFICIENCIES, & CORRECTED THEM PRIOR TO CLOSE OF BUSINESS ON 10/5/10. ALL STUDIES HOW PASS 86-5 REVIEW.

MRID 482401

* N/A – Not Applicable

Footnotes

A. During the 21 day initial content review, all CSFs will be reviewed to determine whether all inerts listed, including fragrances, are approved for the proposed uses. If an unapproved inert is identified, the applicant must either 1) resolve the inert issue by, for example, removing the inert, substituting it with an approved inert, submitting documentation that EPA approved the inert for the proposed pesticidal uses, correcting mistakes on the CSF, etc. or 2) provide the data to support OPP approval of the inert or 3) withdraw the application. Removing or substituting an inert ingredient will require a new CSF and may require submission of data. All information, forms, data and documentation resolving the inert issue must have been received by the Agency or the application withdrawn within the 21 day period, otherwise, the Agency will reject the application as described below.

To successfully complete this aspect of the 21 day initial content screen, applicants are strongly encouraged to verify that all inert ingredients have been approved for the application's uses even if a product is currently registered by consulting the inert Web

site [link to http://www.epa.gov/opprd001/inerts/lists.html] and if the inert is not approved, to obtain the necessary inert approval prior to submitting an application to register a pesticide product containing that inert ingredient. Some inert ingredients are no longer approved for food uses or certain types of uses. The name and/or CAS number on a CSF must match the name and CAS number on this web site. Simple typographical errors in the name or CAS number have resulted in processing delays.

If an inert is not listed on the inert ingredient web site and the applicant believes that the inert has been approved, the applicant should contact the lnert Ingredient Assessment Branch (IIAB) at inertsbranch@epa.gov and resolve the issue. Copies of the correspondence with IIAB resolving the issue should accompany the application. All new inerts except PIP inerts are reviewed by IIAB. The IIAB should also be contacted for any questions on what supporting data needs to be submitted for and the Agency's inert review process. Questions on PIP inerts should be directed to the Chief of Microbial Pesticides Branch [Link to http://www.epa.gov/oppbppd1/biopesticides/contacts_bppd.htm].

When a brand, trade, or proprietary name of an inert ingredient is listed on a CSF, additional information such as an alternate name of the inert, CAS number or other information [link to http://www.epa.gov/opprd001/inerts/tips.pdf] must also be included to enable the Agency to determine if it has been approved. Each component of an inert mixture (including a fragrance) must be identified. In some cases, the supplier of the mixture or fragrance may need to provide this information to the Agency. Prior to the Agency's receipt of an application, applicants must arrange with a proprietary mixture or fragrance supplier to provide the component information to the Agency or promptly upon EPA's request. If the inert ingredients in a proprietary blend (including fragrances) cannot or are not identified or provided within the 21-day content review period, the Agency will reject the application.

During the 21 day content review, applicants should submit information to the individual identified by the Agency when the applicant is informed of an unapproved inert.

Unapproved Inerts Identified on CSFs

All applications except conventional new products and PIPs

Once an unapproved inert is identified on a CSF, the Agency will contact the applicant with the following options:

- Correct the application by, for instance, correcting the inert's identity or CAS
 number, providing documentation that the inert has been approved, or
 removing the unapproved inert from the CSF or replacing it with one that is
 approved for the application's uses; or
- Submit the information and data needed for the Agency to approve the unapproved inert. If this option is selected and implemented, the Agency may request an extension in the PRIA decision review timeframe to accommodate the inert review/approval process;

3. Withdraw the application (the Agency retains 25% of the full fee for the fee category estimated); or

If none of these options is selected and implemented by the applicant within the 21 day content review period, the Agency will reject the application and retain 25% of the full fee of the category identified.

Conventional New Product Applications

When the Registration Division identifies an unapproved inert on a CSF with an application for a new product that the applicant has not identified as requiring an inert approval (R311, R312 or R313), it will contact the applicant with the following options:

- 1. Correct the application by, for instance, correcting the inert's identity or CAS number, providing documentation that the inert has been approved, or removing the unapproved inert from the CSF or replacing it with one that is approved for the application's uses; or
- 2. Submit the information and data needed for the Agency to approve the unapproved inert, including any required petition to establish or amend a tolerance or exemption from a tolerance. (This option may change the PRIA category for the application, which could require a longer decision review time and a larger fee. If additional fees are due, they must be received by the Agency within the 21 day content review period.)
- 3. Withdraw the application (the Agency retains 25% of the full fee for the fee category estimated); or

If none of the above options is selected and implemented during the 21-day content-review period, the Agency will reject the application and retain 25% of the appropriate fee for the new product-inert approval category.

PIP Applications

When the Biopesticide and Pollution Prevention Division identifies an unapproved inert on a PIP CSF and a request to approve the inert does not accompany the application, it will contact the applicant with the following options:

- 1. Correct the application by, for instance, correcting the spelling or name of the inert to that in 40 CFR 174, or providing documentation that the inert has been approved; or
- 2. Submit the information and data needed for the Agency to approve the unapproved inert. If an inert ingredient tolerance exemption petition is required, the petition must be received by the Agency and the B903 fee paid within the 21 day period. If this option is selected and implemented, the Agency will discuss harmonizing the timeframe for both actions.

3. Withdraw the application (the Agency retains 25% of the full fee for the fee category estimated); or

If none of the above options is selected and implemented during the 21 day content review period, the Agency will reject the application and retain 25% of the fee.

- B. A policy on documentation of offers to pay is still being developed, however, for a me-too or fast track (similar/identical) new product, R300 or A530, an application without the necessary authorizations of offers to pay will be placed into either R301 or A531. The Agency recommends that authorizations of offers to pay be submitted with other PRIA applications to avoid delays in the Agency's decision.
- C. Biopesticide applicants are advised to contact the Agency and discuss study waivers prior to submitting their application to the Agency. Documentation of such discussions should be submitted with the study waiver.



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

September 28, 2010

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

OPP Decision Number: D-440307

EPA File Symbol or Registration Number: 11556-RLL

Product Name: PNR1427 INSECTICIDE

EPA Receipt Date: 24-Sep-2010 EPA Company Number: 11556

Company Name: BAYER HEALTHCARE LLC

DOUGLAS A. SPILKER, PH.D. BAYER HEALTHCARE LLC ANIMAL HEALTH DIVISION PO Box 390 SHAWNEE MISSION, KS 66201-0390

SUBJECT: Receipt of Registration Application Subject to Registration Service Fee

Dear Registrant:

The Office of Pesticide Programs has received your application and certification of payment. If you submitted data with this application, the results of the PRN-86-5 screen will be communicated separately. During the administrative screen, the Office of Pesticide Programs has determined that this Action is subject to a Pesticide Registration Service Fee as defined in the Pesticide Registration Improvement Act.

The Action has been identified as Action Code: R110.0

NEW AI; NON-FOOD USE; INDOOR;

No additional payment is due at this time.

If you have any questions, please contact the Pesticide Registration Service Fee Ombudsman at (703) 308-9362.

Sincerely,


Front End Processing Staff

Information Technology & Resources Management Division

Fee for Service



This package includes the following	for Division
 New Registration Amendment Studies? □ Fee Waiver? volpay % Reduction: 	○ AD ○ BPPD ○ RD Risk Mgr. 13
Receipt No. S- EPA File Symbol/Reg. No. Pin-Punch Date:	882827 11556-RLL 9/24/2010
This item is NOT subject to Action Code: Requested: R	o FFS action. Parent/Child Decisions: S883754/11556-R
Inert Cleared for Intended Use Reviewer:	Uncleared Inert in Product Date: 9/28/00



FEE FOR SERVICE

Please read instructions on reverse before a letting form.	Form Appro)Vi	MB No. 207	0-0060	Print Form
United States		×	Registrat		OPP Identifiar Number
Environmental Protection A Washington, DC 20460	Agency		Amendm Other	ent	
Application f	or Pesticide - Sect	ion			
1. Compony/Product Number	2. EPA Product Mans Richard Gebken		······································		
4. Company/Product (Nama) PNR1427 Insecticide	PM#	Mone Restricted			
5. Name and Address of Applicant (Include ZIP Code)					
Bayer HealthCare LLC, Animal Health Division P.O. Boc 390	(b)(i), my product is to:	6. Expedited Review. (n accordance with FIFRA Section 3(c)(3) b)(i), my product is similar or identical in composition and labeling to:			
5hawnee Mission, K5 6620}-0390	EPA Reg. No	EPA Reg. No			
Check if this is a new address	Product Name _				
	Section - II				
Amendment - Explain below. Final printed labels in response to Agency letter dated Me Too" Application.					
Notification - Explain below.	Other - Expl	ain De			
Explanation: Use additional page(s) If necessary. (For section I an	nd Section II.				:
Application for registration of a new end-use product, contain					
and a new AI - Flumethrin Technical (CAS No. 69770-45-2). The concurrently with this end-use application. No PRIA fee require		ion o	f Flumethrin	Technica Technica	al is being submitted
concentently with this end use application from the regame	ed (see detainment).				
S	Section - III				
Material This Product Will Be Peckaged In:					
·	eter Soluble Peckeging		2. Type of C		
Yes You	Yes			Metal Plastic	
X No X No Der II "Yes" No. per II	× No "Yes" No. per		4	Gless Paper	
	ackego wgt container		()~~~~~~~	Other (S	pecify)
3. Location of Net Contents Information 4. Size(s) Retail Co	ontainer	5. Lo	cetion of Latel	Directio	n¢
Label Container 0.44/1.6 oz		x		g accom	penying product
6. Menner in Which Label is Affixed to Product Lithograph Paper glued Stendiled	Other				
S	iection - IV				
1. Contect Point (Complete items directly below for identification of individual to be contacted, if necessary, to process this application.)					
Name Douglas A. Spilker, Ph.D. Tite Mar	nager, EPA Reg. Affairs			elephone 913) 268	No. (Inciujule Areo Code) 3-2751
Certification certify that the stetements I have made on this form and all attachments thereto are true, accurate and complete. acknowledge that any knowlingly talsa or misleading statement may be punishable by fine or imprisonment or, , , , , , both under applicable law.					
2. Signature Digla A-Gilla Mar	tie nager, EPA Regulatory Afi	fairs		, , , , , , , , , , , , , , , , , , ,	3 3 3 3 5 3
4. Typed Name 5. Da	ête .		<u></u>		7 7 3 3 3 3 9 7 5
Douglas A. Spilker, Ph.D.	23 Sept 2	910)	}	3 3 3 5 , 3 > 3 2 7

Application for Pesticide Registration (Continued) - PNR1427 Insecticide, EPA Reg. No. 11556-XXX

	Application Organization	Page
	Application for registration (Form 8570-1)	1
A.	PRIA Determination	2
В.	Introduction	2
C.	Product Profile	3
D.	Product Chemistry	6
E.	Acute Toxicity	7
F.	Efficacy	8
G.	Companion Animal Safety	12
H.	Occupational/Residential Exposure	14
I.	Label Development	15
J.	Ecological Effects	16
K.	Discussion of Other Requirements	16
L.	Benefits/Public Interest	16
M.	Data Compensation	16
N.	List of Attachments & Attachments 1 -7	17 -

With this application, the enclosed data and labeling, Bayer HealthCare LLC, Animal Health Division (BAH) is requesting the registration of a new end-use product, *PNR1427 Insecticide*, containing two active ingredients – the currently registered **Imidacloprid Technical** (EPA Reg. No. 264-755; CAS No. 138261-41-3) and a new active ingredient **flumethrin** (CAS No. 69770-45-2). The application for registration of *Flumethrin Technical* is being submitted concurrently with this end-use application for registration. The "specific use pattern" on domestic animals, according to the Pesticide Use Index, is determined to be Group Number 99 "Indoor – Non-Food." Several pre-registration meetings and/or teleconferences to discuss this registration action and the specific 40 CFR Part 158 requirements were held with the Agency, and will be referenced in the respective sections of this overview, and copies of referenced documents enclosed.

A. PRIA 2 DETERMINATION

The proposed *PNR1427 Insecticide* is being submitted as a formulated end-use product simultaneously with the application for registration of the new active ingredient – flumethrin technical active ingredient under the action code R110: "Nonfood use; Indoor." As described in the PRIA Decision Tree "All indoor non-food uses included in the application are covered by the base fee for the application in this category if submitted simultaneously." Therefore, since this application for the end-use product, *PNR1427 Insecticide* is being submitted simultaneously with the technical product application, there should be no additional PRIA fee for this application, there should be no additional PRIA fee for this application.

B. INTRODUCTION

The imidacloprid/flumethrin collar is a new pesticide product combining two active ingredients, 10% imidacloprid and 4.5% flumethrin in a pet collar formulation. It is intended for the prevention and treatment of ectoparasites of cats and dogs. The proposed ectoparasiticide claims include the control and treatment of ticks: American dog ticks (Dermacentor variabilis), Blacklegged (deer) ticks (Ixodes scapularis), Brown dog ticks (Rhipicephalus sanguineus), and Lone

Star ticks (Amblyomma americanum). The label also includes claims for prevention and treatment of fleas (Ctenocephalides felis, C. canis, and Pulex irritans) on cats and dogs, and lice on dogs (Trichodectes canis) and for use in the treatment of Sarcoptic mange on cats and dogs. Additionally, data included in the field studies showed it to be effective against several European tick species, including Ixodes ricinus. All of the aforementioned pests are considered public health pests by the Agency, so efficacy data supporting these claims are enclosed with this application.

The active ingredients are released constantly from the collar in very small amounts and remain on the animal's skin and hair coat throughout an 8-month treatment period.

Two different sizes of collars have been developed. A small one (38 cm long, 12.5g/0.44 oz.) is for use on cats as well as for small dogs up to 18 lbs. (8 kg) body weight. A large collar (70 cm long, 45g/1.6 oz.) of the same formulation is for use on dogs above 18 lbs. (8 kg) body weight. The collar is fastened once around the animal's neck. Any excess length extending beyond an inch (2 cm) is directed to be cut off. After application of the collar, three optional reflector clips (contained in a separate pouch) may be fixed permanently to the collar to increase the pet's visibility in the dark.

In the United States, imidacloprid is an established insecticide and is registered by the Environmental Protection Agency in the spot-on products Advantage[®] Topical Solution and Advantage II for dogs and cats since 1996 and 2010, respectively. It is also used in the EPA-registered combination spot-on products with permethrin for use on dogs (K9 Advantix[®] and K9 Advantix II).

Flumethrin, the proposed acaricidal compound in the formulated product, is being submitted simultaneously with this application for registration as a new active ingredient by the Environmental Protection Agency. Flumethrin active ingredient is authorized in the European Union since 1986 and is used for companion and food producing animals (cats, dogs, cattle, sheep, goats, horses, and bees). Flumethrin containing products authorized in Europe are Bayticol® EC, Bayticol® Pour-on, Bayvarol® Strips and Kiltix® collar.

Bayer has worked to combine the excellent efficacy of imidacloprid for flea treatment and control, with flumethrin for tick prevention into an easy to administer, single administration per ectoparasitic season, low exposure, topical product with excellent pet tolerance.

C. PRODUCT PROFILE - Imidacloprid 10%/flumethrin 4.5% collar

Product: PNR1427 Insecticide **Active Ingredients:** Imidacloprid, flumethrin

Form: Pet collar

Strengths: 10% imidacloprid, 4.5% flumethrin

Presentation: Package containing 1 collar packed into a pouch made of a laminated

PETP/ PE foil with a separate pouch containing 3 reflectors.

Package Size: Two different collar sizes:

Small: 38 cm for cats, and dogs \leq 18 lbs. (8kg)

Large: 70 cm dogs > 18 lbs. (8kg)

Target Species: Cats, Dogs

Imidacloprid - active ingredient

Chemical structure

INN Name	Imidacloprid	CAS No.	138261-41-3		
IUPAC Names	1-(6-Chloro-3-pyri ylideneamine	1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine			
Laboratory Codes	NTN 33893, Bay 7	NTN 33893, Bay T 7391, Confidor			
Molecular Formula	C ₉ H ₁₀ ClN ₅ O ₂	C ₉ H ₁₀ ClN ₅ O ₂			
Structural Formula	CI N Relative molecular	NH NO ₂ mass: 255.7 g/mol			
Classification	Ectoparasiticide; Agonist at the nicotinergic acetycholine receptor				

The function of imidacloprid in the present formulation for cats and dogs is as an ectoparasiticide, especially fleas. Following application of the product (collar), imidacloprid remains on the outer surface of the animal's skin and fur enabling it to come into contact with the targeted parasites and kill them. Imidacloprid interacts with the nicotinic acetylcholine receptors (nAChRs) on the post-synaptic membrane.

Flumethrin - active ingredient

Chemical structure

INN Name	Flumethrin	CAS No.	69770-45-2		
TUPAC Names	(±)α-cyano-4-fluoro-3-phenoxybenzyl-3(β,4-dichlorostyryl)-2,2-dimethylcycloproprane carboxylate				
Laboratory Codes/Synonyms	Flumethrine; FLU; PNR1427; Bayticol P; Bayticol P techn.; Bayticol P active ingredient; Bayticol P Wirkstoff; BAY Vq 1950				
Empirical Formula	C ₂₈ H ₂₂ Cl ₂ FNO ₃	——————————————————————————————————————	——————————————————————————————————————		
Structural Formula	į	CH ₃ O CN CN r mass: 510.4 g/mol	F		
Classification	Ectoparasiticide; s (Type II)	ynthetic pyrethroid	of the α -dyano group,		

Flumethrin is an α-cyano (type II)-pyrethroid which has been registered since 1986 in the EU for on animal use.

As the compound class is very well described and known, only a short summary for this specific compound is given: Like all α-cyano or type II pyrethroids, flumethrin acts at the sodium channels of nerves, causing the channels to remain open for longer, thus extending the period of sodium influx. This results in repeated, shorter or longer phases of nerve impulses being emitted. A secondary effect is the release of neurotransmitters, such as GABA, acetylcholine and dopamine.

Imidacloprid and flumethrin formulated as a 10%: 4.5% collar

Characteristics of the end-use product form

The imidacloprid/flumethrin collar is a grey (alternate colors – red or yellow), odorless collar containing 10% (w/w) imidacloprid and 4.5% (w/w) flumethrin for fastening around the neck of cats and dogs. The collar provides a long term broad spectrum parasiticidal activity by combining the insecticidal active ingredient imidacloprid with the acaricidal active ingredient flumethrin. The patented Bayer collar matrix system ensures that both active ingredients are slowly and continuously released from the collar towards the animal thereby avoiding peak concentrations and ensuring that acaricidal /insecticidal concentrations of both active ingredients are present in the cat's or dog's hair coat during the entire efficacy period of 8 months. The active ingredients spread from the site of direct contact over the entire pet surface.

The collar is available in 2 different sizes, one small collar of 38 cm long (0.44 oz./12.5g) for cats, as well as for dogs up to 18 lbs. (8 kg) body weight, and one large collar of 70 cm long (1.6 oz./45 g) for dogs of more than 18 lbs. (8 kg) body weight.

The imidacloprid/flumethrin collar is intended to be potentially marketed in four (4) presentations as shown in the table below. Since the companion animal safety studies with the small collar show excellent tolerance in both dogs and cats, it may be desirable to market a single collar for optional use on either small dogs or cats.

Size of Collar	Presentation
Small Collar (38 cm; 12.5gm)	 For cats For dogs ≤ 18 lbs. (8 kg) For cats and dogs ≤ 18 lbs. (8 kg)
Large Collar (70 cm; 45gm)	• For dogs > 18 lbs. (8 kg)



Optional Snap-on Reflectors: In addition to the foil pouch containing the collar, the outer package will also contain 3 reflector clips in a separate pouch. As an option, these reflector clips

5 6 3 3 3

Inert ingredient information may be entitled to confidential treatment

Bay. JaithCare LLC, Animal Health Division September 23, 2010

can be fixed permanently by the pet owner to the collar to increase the animal's visibility at night. The reflectors are regarded as a useful add-on, as they may help protect pets from, for example, being hit by cars in the dark. It has been shown that these optional reflector clips have no negative impact on companion animal safety or efficacy of the product; please refer to the Companion Animal Safety section of the application. Once the reflectors are affixed to the collar, they cannot be removed and are discarded with the expired collar.

In a pre-registration teleconference with the Agency on March 24, 2009 (see Attachment 1) the composition and potential regulatory requirements for these reflectors were discussed. Bayer proposed that no product chemistry information should be required for these reflectors. The Agency's response was that "This is acceptable to the Agency since the reflector is a device, will not be a part of the collar package (i.e. in separate bag), and contains no active ingredients." Therefore, no product chemistry or other specific information on the reflectors is enclosed with this application.

Although we have included warnings on the label that this product contains small parts which may be a potential choking hazard, these statements have been included on a voluntary basis. It is our understanding that since this product (pet collar with reflectors) will not be marketed to children as a toy, the requirements of the Consumer Product Safety Commission do not apply (Personal communication; J. Boja [CPSC] via J. Wishneff [Consumer Specialty Products Association]; Jan. 15, 2010).

D. PRODUCT CHEMISTRY

The insecticide formulation is a plastic matrix which contains the active ingredients. Three Confidential Statements of Formula (1 basic; 2 alternates) are enclosed with this application. The three versions of the Confidential Statements of Formula for the collars vary only by the different pigments they contain, and are proposed as having a gray color red color or yellow color

Therefore, the three respective variations of the formulation include:

Basic CSF -

Gray (PNR Basic)

Alternate 1 -

Red (PNR 1427 Alt 1 - R)

Alternate 2 -

Yellow (PNR 1427 Alt 2 – Y)

In the teleconferences with the Agency (B. Alexander and S. Mathur) on Jan. 12, 2010 and March 1, 2010, we were given guidance that: a) each formula with a different dye color must have its own CSF, and b) because of the nature of the collar, "N/A" (not applicable) should appear in the "Box 7: Bulk Density", but that the respective density information should appear in Part B of the Product Chemistry requirements. The enclosed information and reports reflect this guidance.

All of the inert ingredients listed on the Confidential Statements of Formula are listed in the Agency document "Inert Ingredients Permitted for Use in Nonfood Use Pesticide products, Last Updated March 28, 2010" or are proprietary blends previously evaluated and found acceptable by the Agency for use as an inert in nonfood use pesticide products. Please note that the formulation contains the proprietary blend from were notified by the EPA - Inert Ingredient Assessment Branch (see Attachment 2) that "

3 3 3 2 2

Inert ingredient information may be entitled to confidential treatment

Bay. althCare LLC, Animal Health Division September 23, 2010

Please also note, at the time of the aforementioned 09/15/2008 email, was not approved for use in nonfood use pesticides; subsequently it was approved and now appears on "Inert Ingredients Permitted for Use in Nonfood Use Pesticide products, Last Updated March 28, 2010."

In the Pre-registration teleconference with the Agency on March 24, 2009 (see Attachment 1), Dr. Mathur gave us direction on how the flumethrin isomer ratio should be expressed on the label. The enclosed draft labeling reflects that guidance. However, direction was also given in the aforementioned teleconference that only the nominal value of the flumethrin technical needs to be reported on the Confidential Statement of Formula (CSF) for the end-use product; that is, no isomers need listing. The enclosed CSFs reflect this guidance.

Two (2) copies of each of the three (3) Confidential Statements of Formula (CSF) for this product are enclosed.

The **product chemistry data** to support the registration of this end-use product are found in Bayer Report ID No. 33752, entitled "Product Chemistry for M915 Insecticide (Imidacloprid + Flumethrin Collar)." Please note that the study to fulfill the requirements for a) **one-year storage stability study** (GL No. 830.6317) and b) **corrosion characteristics** (GL No. 830.6320) using the finished product is in progress (start date – 10/28/2009) and should be available for submission by 3/31/2011, well before the Agency has completed their review of this action. We request that the timing of this supplemental submission to the Agency be acceptable. As has been the Agency's previous policy, the timely submission of these data should not delay the review process.

E. ACUTE TOXICITY

The acute toxicity studies normally associated with a new formulation were not conducted because they are not practical or necessary for the pet collar product. In explanation, the physical nature of the proposed product, which is a plastic pet collar, is not a practical test article for the conduct of the "6-pack" toxicity studies (Guidelines 870.1100 – 870.2600).

BAH planned to request a waiver of 5 of the 6 studies required for the end-use product due to physical characteristics of the collar (solid plastic material). This was done previously for a similar test article - cattle ear tags. We proposed to conduct only an acute dermal irritation study with the final collar product. The studies for which a waiver was planned included: Acute oral toxicity – rat (GL No. 870.1100), acute dermal toxicity (GL No. 870.1200), acute inhalation toxicity – rat (GL No. 870.1300), primary eye irritation toxicity – rabbit (GL No. 870.2400), dermal sensitization (GL No. 870.2600).

However, as described in the meeting minutes from a teleconference with the Agency on March 30, 2009 (see Attachment 3), the Agency's response to this proposal was that this plan is reasonable (that is, to submit appropriate waiver requests) except for the omission of the dermal sensitization requirement. A dermal sensitization study should be conducted using ground collar material (may be frozen and then ground). Such a study was conducted and submitted as Bayer Report ID No. 33750.

In addition, the Agency asked in the aforementioned teleconference that we include information on the release rate of the active ingredient from the collar in our justification for the waiver of the acute oral toxicity data requirement. This information is referenced in the enclosed waiver request identified as Bayer Report ID No. 33854.

The following acute toxicity studies and/or official waiver request documents required to support the proposed product are enclosed and are titled:

EPA Guideline Number	uideline Report ID		Toxicity Category	
870.1100	33854	Request for Waiver from the Requirement of Acute Oral Toxicity Study – PNR1427 Insecticide	NA	
870.1200	33855	Request for Waiver from the Requirement of Acute Dermal Toxicity Study – PNR1427 Insecticide	NA	
870.1300	33856	Request for Waiver from the Requirement of Acute Inhalation Toxicity Study – PNR1427 Insecticide	NA	
870.2400	33857	Request for Waiver from the Requirement of Acute Eye Irritation Toxicity Study – PNR1427 Insecticide	NA	
870.2500	33749	Primary Skin Irritation Study in Rabbits	ΙV	
870.2600	33750	Dermal Sensitization Study in Guinea Pigs (Buehler Method)	Negative	
		Overall Tox Category (Signal Word)	IV Caution	

F. EFFICACY

The imidacloprid/flumethrin pet collar is designed for use on cats and dogs for the prevention and treatment of ectoparasites and remains effective for 8 months even after bathing or swimming. A pre-registration meeting was held with the Agency on September 14, 2006 (see Attachment 4) in order to obtain Agency guidance on the necessary studies required to receive acceptance of the desired performance claims. Since all of the proposed pests are considered public health pests by the Agency, efficacy data supporting these claims are enclosed with this application. Please note that some trials evaluate performance on more than one pest.

Although specific claims appear on the proposed label, in general, the main efficacy claims include:

- Treatment and prevention of flea infestations, which may also aid in the prevention of flea allergy dermatitis (FAD).
- Flea larvae in the pet's immediate surroundings are killed following contact with a treated animal.

- Kills fleas fast, based on times found in the respective residual control and "onset of efficacy" studies.
- Acaricidal and repellent efficacy against tick infestations of the brown dog tick
 (Rhipicephalus sanguineus), Lone Star tick (Amblyomma americanum), American dog
 tick (Dermacentor variabilis), and Black-legged/Deer tick (Ixodes scapularis), with
 efficacy against larvae, nymphs, and adult ticks. As specified in the "Product
 Performance Test Guidelines (OPPTS 810.3300) Treatments to Control Pests of
 Humans and Pets," these data support a "general tick claim" in additional to the specific
 tick itemization on the product label.
- Field study reports additionally include efficacy against the European tick species (Rhipicephalus turanicus, Ixodes ricinus, and Ixodes hexagonus).
- In dogs only, treatment of lice infestations (Trichodectes canis)
- Aid in the treatment of sarcoptic manage
- · "Waterproof" after swimming or bathing
- Duration of efficacy 8 months

1. Efficacy against fleas

Eight (8) efficacy studies have been performed in cats and dogs to confirm the efficacy of the imidacloprid 10%/flumethrin 4.5% collar against cat fleas (*Ctenocephalides felis*) - six (6) controlled laboratory studies (3 cat/3 dog) and two controlled field studies (1 cat/1 dog). Additionally the aim of the field studies was to show the prevalence of concurrent flea and tick infestations in cats and dogs and to show the efficacy against other important flea species which are not available for laboratory studies.

Efficacy against adult cat fleas (Ctenocephalides felis): Six (6) laboratory efficacy studies included evaluation of the insecticidal activity of the imidaeloprid/flumethrin collar against adult cat fleas (Ctenocephalides felis) on dogs (Bayer Report ID Nos.33801, 33803 and 35631) and on cats (33802, 35630 and 35635) as well as in two European field trials for both cats (35644) and dogs (35645). Efficacy was excellent (\geq 90%) in all studies throughout the 8-month testing period. The percentage flea control in the field studies was also excellent with most observations \geq 95% control.

Efficacy against Ctenocephalides canis and Pulex irritans: In the dog field study (35645), 12% of the fleas identified in the baseline infestations were C. canis. The collar was as efficacious against these fleas as it was against C. felis. Further in support of this claim, imidacloprid levels have been found in the hair coat of collared dogs (see 35643) to exceed by far the imidacloprid levels in the hair of Advantage® (imidacloprid spot-on) treated dogs (15962). Since Advantage® spot-on was shown to have >95% efficacy for at least 32 days against C. canis (15749), this provides solid support for a C. canis claim for the collar.

In the same field study (ID 35645), 3.6% of the fleas identified in the baseline infestations were *P. irritans*, and the collar also was efficacious against this flea. *P. irritans* is not bred and kept under laboratory conditions, eliminating the opportunity to evaluate efficacy in a controlled laboratory study. However the field study supports efficacy against this flea.

The general flea efficacy of the collar on cats and dogs has been demonstrated in the multiple studies submitted, and is supported by the dog hair coat kinetic values discussed above. Fleas tend to not be extremely host specific, and both species can be found regularly on cats and dogs. Therefore the label claim for the control of *C. canis* and *P. irritans* on cats and dogs is supported.

<u>Flea larvacidal efficacy:</u> In two of the adulticidal flea efficacy studies referenced above (35631 and ID 35635), additional larval development evaluations were made to confirm the larvicidal efficacy of the product. The results of these studies confirm that imidacloprid/flumethrin collars have a marked flea larvicidal efficacy that is transferred to the animal's environment throughout the eight month efficacy period.

Onset of efficacy claims for fleas: Efficacy against fleas on both cats (35980) and dogs (35987) started immediately after treatment, resulting in 99.8 to 100% efficacy at the first 24h post-treatment count and lasted generally at >95%/24h after re-infestation for the duration of 8 months.

Re-infesting flea claims: In one cat study (33802) and one dog study (33801) additionally a "speed of kill" efficacy evaluation was conducted at day 7 post-treatment, counting fleas at 2, 6, and 12 hours after re-infestation of adult fleas. Excellent efficacy results (100%), at even the 2h count, showed that the fleas are killed extremely quickly on the pet. This suggests that flea allergy dermatitis curative efficacy can be expected to be excellent.

2. Efficacy against ticks (Cats & Dogs)

Five controlled studies on cats and dogs, plus three *in vitro* studies, were conducted to demonstrate the acaricidal and repellent efficacy of the imidacloprid 10%/flumethrin 4.5% collar against tick infestations of the brown dog tick (*Rhipicephalus sanguineus*), Lone Star tick (Amblyomma americanum), American dog tick (*Dermacentor variabilis*) and *Ixodes spp.*, with efficacy against larvae, nymphs and adult ticks.

In most studies, the curative efficacy on ticks that were already on the animal at the time of treatment (counts conducted at 48 hours post collar application) was usually below an efficacy of 90%, although clearly above 50% in the vast majority of the studies. This is not surprising as pyrethroids generally seem to have limited efficacy on partially engorged ticks that have already been on the host for several days at the time of treatment. To address this situation, information on the proposed label instructs pet owners that "Ticks already on the [(dog)(cat)] prior to treatment may not be killed immediately after collar application and may remain attached and visible. Therefore removal of ticks already on the [(dog)(cat)] at the time of application is recommended."

Therefore, only the preventive tick efficacy will be discussed here, where the animals were exposed to ticks after treatment or together with the treatment. The label reflects this use pattern.

General control of ticks (adults): In the three studies (33801, 33803 and 35631) running for the full duration of the label claim, the preventive efficacy against the brown dog tick (Rhipicephalus sanguineus) was above 90% for eight months. Excellent performance against this tick was also found in the European field studies (35644 and 35645). Both studies (33801 and 33803), testing the effectiveness of the collar on the American dog tick (Dermacentor variabilis) showed excellent performance, with efficacies above 90% for eight months. Efficacy against the

Lone Star tick (Amblyomma americanum) in cats was shown to be 100% throughout 8 months (33802).

<u>Tick larvacidal/juvenile efficacy:</u> A comparative *in-vitro* study (33467) of efficacy of a flumethrin: imidacloprid (1: 1.85) mixture was conducted against larvae, nymphs, and adults of *I. ricinus* and *R. sanguineus*, and larvae and adults of *D. reticulatus* ticks in a glass vial contact assay. Results showed the susceptibility of tick larvae and nymphs against the imidacloprid/flumethrin mixture under evaluation is higher than that of adult ticks. Therefore, these data support the extension of the adult tick claim to "adult, nymphs, and larvae."

Onset of efficacy claims for ticks: The 6-hr efficacy evaluation (repel and/or kill) against reinfesting brown dog ticks on dogs (35631 and 35982) and *Ixodes ricinis* ticks on cats (35630, 35635 and 35981) was consistently above 97%, starting at day 2 (after the first 48h efficacy counts). The aforementioned studies, except 35981 and 35982, were conducted for 8 months.

<u>Control of Ixodes spp.:</u> The control/repellency of the black-legged/deer tick (Ixodes scapularis) is very important in the United States as these ticks serve as the vector for Lyme disease. As demonstrated in the aforementioned tick efficacy studies, the flumethrin component of the proposed collar is very effective against all tick species tested. Therefore, the collar could be speculated to be very effective against this tick species as well.

On March 19, 2009 in a pre-registration meeting, we notified the Agency of the short supply of black-legged/deer ticks for appropriate testing against this tick. Please note, BAH requested permission from the Agency (see Attachment 5 for correspondence) to substitute a similar tick species, *Ixodes ricinus*, for *I. scapularis*. The PERC responded (via M. Suarez, email 10/15/09) that "After discussion with the PERC, we are not inclined to consider Ix. ricinis as a substitute for Ix. scapularis. A better option would be to use wild caught Ix. scapularis from an area known to have a low incidence of Lyme disease." After pursuing the option recommended by the PERC, we received feedback from the contract research laboratories on their hesitancy to work with wild ticks due to the potential risk of exposing the test animals and laboratory workers to Lyme disease. Bayer respects their concern, and therefore this option was not possible.

As stated above, the collar has been shown to be very effective against a similar tick species (*I. ricinus*) in European testing on both cats (35630, 35635, and 35981) and dogs (35631, 35979, and 35982). Therefore, in lieu of specific testing on *I. scapularis*, we request the Agency to accept the black-legged/deer tick efficacy claim based on bridging data comparing *in vitro* susceptibility of these two tick species plus the European trials using the product against *I. ricinus*, a similar tick species.

In the bridging study, a coated glass vial contact assay (33464) was used to confirm the comparability concerning flumethrin susceptibility of two adult *Ixodes scapularis* tick strains reared in the laboratory, but originating from two different locations (Rhode Island and Connecticut) and one Laboratory strain of *Ixodes ricinus* originally found in the Berlin area in Germany. The effective concentration (EC) was evaluated by measuring tick knock down effects after 24 and 48 hours contact time. The lethal dose (LD) was evaluated by measuring tick mortality after 48 hours contact time. Inferential statistical analyses did not reveal significant differences in the susceptibility of the two Ixodes tick species towards flumethrin. Based on the review of this bridging study, comparing the susceptibility of *I. ricinus* to *I. scapularis*, in concert with the very effective results against *I. ricinus* in the European studies on both cats and

dogs, we request the Agency to reconsider the PERC decision and accept the black-legged/deer tick claims on the proposed label.

- 3. "Waterproof" after swimming or bathing: This aspect of the product usage was investigated in the already mentioned shampooing/immersion study (33803) conducted according to the protocol reviewed by the Agency (Decision No. 408242; MRID 47718601) using fleas and two species of ticks. Dogs were either shampooed with a non-medicated shampoo or immersed for five minutes in a water tank including three times of complete rinsing of the head at one week before the next scheduled flea/tick infestation. The collars were left on the test animals for the full duration of the study. Efficacy evaluation was done as usual, at 24h post re-infestation with fleas and 48h post re-infestation with ticks. The results of the study show that multiple shampooings have only a negligible effect on flea and tick efficacy, and water immersion had only a limited effect on flea efficacy, and a negligible effect on tick efficacy.
- 4. Efficacy against lice (dogs only): The efficacy against lice in dogs (Trichodectes canis) was documented in Bayer Report ID No. 33694. Dogs carrying an active lice infestation were treated with the imidacloprid 10%/flumethrin 4.5% collar. Efficacy was monitored at day 2 after treatment and for one consecutive month to evaluate not only the acute effect on the adult lice living on the dog, but also to monitor the effective eradication of the lice population. Efficacy against lice was 95.1% and 100% at days 2 and 7 after treatment, respectively. No lice reoccurred during the time of the study. Therefore it can be concluded that the animal was completely cured from the lice population within 48 hours.
- 5. Efficacy against Sarcoptic mange: The efficacy against Sarcoptic mange (Sarcoptes scabiei) was documented in a study with dogs (33691). A 100% reduction in mite numbers was observed in Sarcoptes scabiei infested dogs following treatment with the imidacloprid 10%/flumethrin 4.5% collar. A complete resolution of clinical signs (papules and crusts) associated with Sarcoptes scabiei infestations, and a >90% improvement in hair re-growth were observed in 80% of the dogs following treatment with the collar. Since the identical pest (Sarcoptes scabiei) infests both dogs and cats, we are proposing a general claim for PNR1427 Insecticide for the treatment of Sarcoptic mange on cats and dogs.

G. COMPANION ANIMAL SAFETY

Safety of the collar was investigated in adult cats (≥ 6 months), kittens (10-weeks), adult dogs (≥ 6 months), and puppies (7-weeks). During the safety studies, companion animals were exposed to different dose treatments including a 5x over-dosage, i.e. 5 collars were affixed around the animals' necks. Collars exhibited an excellent safety profile. There were no treatment-induced adverse systemic or local effects. Minor, transient, hair loss due to mechanical irritation from the presence of multiple collars, was observed in a few animals.

Four, separate studies were conducted to evaluate the tolerance and safety of imidacloprid 10%/flumethrin 4.5% collars in adult cats, kittens, adult dogs, and puppies:

o Both the adult cat (33800/33826) and adult dog (33805) safety studies were composed of the following four treatment groups: 0x (negative control), 1x (end-product), 5x (end-product), and 5x (placebo control). New 5x (end-product) collars were re-applied at 14-day intervals. Both studies were two-months in duration. Prior to study

- initiation, the study protocols underwent Agency review: adult cats (MRID 47776601; Decision #415122), and adult dogs (MRID 47776901; Decision #415125).
- o Both the kitten (33824) and puppy (33806) safety studies were composed of the following five treatment groups: 0x (negative control), 1x (end-product), 3x (end-product), 5x (end-product), and 5x (placebo control). On days 30, 90, and 150 (± 2 days), new 1x (end-product), 3x (end-product) and 5x (end-product) collars were reapplied. Both studies were six-months in duration. Prior to study initiation, the study protocols underwent Agency review: kittens (MRID 47776801; Decision #415124) and puppies (MRID 47776701; Decision #415123).

In these four safety studies, it was requested by the Agency to conduct the analysis of the collars' two active ingredients released during the studies. This information was generated and is recorded in the respective reports.

In addition to these four studies, two additional safety studies were conducted to specifically support European Union (EU) registration. As a result, the two European studies were not precisely compliant with OPPTS 870.7200. In the EU studies, no local or systemic effects, in addition to the findings already observed during the aforementioned EPA Guideline studies, were discovered. The EU studies are not enclosed but, if the Agency desires, these reports can be provided.

General safety studies in adult cats and dogs: There were no adverse treatment-induced findings or clinical effects observed in male and female cats (33800/33826), or male and female dogs (33805), continuously treated for 61 days with either zero, one, or five end-product or with five placebo collars. Mild thinning of hair, presumed to be induced by the mechanical irritation associated with multiple collars, was primarily observed in the throat area of animals wearing 5 collars (both end-product and placebo). These local changes resolved in all animals within a 7 to 35 days post study recovery period in which the 5 collars were reduced to one collar. Overall, end-product collars worn by the adult cats and dogs at 5x the recommended label dose rate for 61 consecutive days were determined to be safe.

General safety studies in kittens and pupples: No adverse treatment related findings or clinical effects were observed in male and female kittens (33824), or male or female pupples (33806) continuously treated, for 180 days with either zero, one, three, or five end-product collars or with five placebo collars. Mild hair thinning and/or hair loss, presumed to be induced by the mechanical irritation associated with multiple collars, was primarily observed in the throat and chin regions of animals wearing 5 collars (both end-product and placebo). However, these local changes self-resolved by the end of the 180-day exposure period. Overall, end-product collars worn by 10-weeks-old kittens and 7-weeks-old pupples at 1x, 3x, and 5x of the recommended label dose for 180 consecutive days were well tolerated and determined to be safe for use.

Based on the re-application of new 5x end-product collars at 30-60 day intervals throughout the kitten and puppy studies, there should be no label limitation as to when the collar can be replaced, if it were lost before its effectiveness is depleted.

Studies on potential impact of optional reflector clips on active ingredient release: Four companion animal safety studies were conducted with adult cats (35986), adult dogs (35637), puppies (33822) and kittens (33823). The studies were conducted to demonstrate the dermal

tolerance of imidacloprid 10%/flumethrin 4.5% collars when administered with or without three reflector clips. No over dosage was applied and the study duration was limited to one month. After this month, the possible adverse reactions as well as the influence of the reflectors on active ingredient release were compared between the group with and without reflectors. An important additional objective of this study was to determine if the presence of the reflectors resulted in a significant net weight loss (>10%) of the collars as compared to the collars without the reflectors (see Attachment 6).

As the standard target animal safety studies had been run without reflectors to have a "worst case scenario" with the biggest potential for maximum active ingredient release and exposure, the Agency felt it necessary for us to investigate whether the presence of the reflectors would lead to increased a.i. release and therefore increased animal exposure (See Attachment 7). The results of the studies indicate that the presence of the reflectors did not cause any adverse clinical signs nor did the presence of the reflectors and that there was no increase in the release of the active ingredients.

Companion animal tolerance and safety – conclusions: The companion animal safety studies demonstrated that the application / reapplication of end-use product to adult cats (≥ 6 months), kittens (10-weeks), adult dogs (≥ 6 months), and puppies (7-weeks) at up to 5 times the recommended unit dose applied dermally in two-monthly intervals for six months was well-tolerated with no evidence of adverse or undesirable clinical, physical (food consumption, body weight) or hematological effects.

The excellent general tolerance and safety by both cats and dogs provides a special benefit of the imidacloprid 10%/flumethrin 4.5% collar, being an ideal solution in mixed cat and dog households. As the same product can be used on both dogs and cats living closely together, they can be protected against ectoparasites, without cross-over toxicity concerns.

The safety evaluations are underlined by the results of the hair coat kinetic (35642 and 35643) studies which revealed that the matrix system releases both active ingredients slowly and continuously from the collar towards the animal thereby avoiding peak concentrations even during the first few days after treatment.

H. OCCUPATIONAL/ RESIDENTIAL EXPOSURE

An assessment (33861) of the potential exposure resulting from the use of PNR 1427 antiparasitic collars containing imidacloprid and flumethrin as the active ingredients was calculated for both handlers (applying collar) and the post application contact with treated cats, small dogs, and large dogs. The daily application rate of the active ingredients from the collars to the pets was determined based on release rate kinetic studies (35992). Hair kinetic data supported the release rate kinetics (35642 and 35643). The soluble surface data used in the analysis are also provided (35118).

The revised HED guidelines for pet exposure and risk assessments were used with the release rate data to estimate the exposure and risks to adults applying the collars and to both adults and small children contacting pets wearing the collars. Margins of Exposure (MOEs) to adults applying the collars ranged from 40,400 to 149,000. MOEs for adult post application contact with the treated pets ranged from 2,160 to 3,620. The aggregate oral and dermal MOEs for small children ranged from 1,300 to 1,630. Therefore, there should be no safety concerns for the collar

with respect to the user either during or after application of the product, provided that the product is used according to label instructions.

I. LABEL DEVELOPMENT

1

The collar is available in *only* 2 different sizes - small (38 cm long; 12.5g) or large (70 cm long; 45g). The collar is intended to be potentially marketed in four (4) presentations: 1) large collar for large dogs (only for dogs up to 18 lbs.), 2) small collar for cats, 3) small collar for small dogs (less than 18 lbs.) or 4) small collar for cats or small dogs. Regarding presentation #4, since the companion animal safety studies with the small collar show excellent tolerance in both cats and small dogs, it may be desirable to market a single collar for optional use on either small dogs or cats. In addition to the foil pouch containing the collar, the outer package will also contain 3 optional visibility reflector clips in a separate pouch. With all this in mind, one label is enclosed for review that encompasses the label language for all these presentations, as well as, for the reflector clips. The optional label language is designated by [brackets] or (parentheses.)

<u>Ingredient statement:</u> In the pre-registration teleconference with the Agency on March 24, 2009 (see Attachment I), Dr. Mathur provided direction on how the flumethrin isomer ratio should be expressed on the label.

The precautionary label language: Because the pet collar by its very nature (solid plastic) presents unusual physical properties, not all of the acute toxicity studies normally associated with a new formulation were conducted, and waivers are being requested for those where it is impractical or impossible to conduct the respective studies. However, based on the available acute toxicity data, the over-all toxicity category for the proposed product should be Category IV (See page 8 of this application).

40 CFR § 156.64 provides guidance on the required signal words for pesticide products:

"Toxicity Category IV. A pesticide product meeting the criteria of Toxicity Category IV by all routes of exposure is not required to bear a signal word. If a signal word is used, it must be "CAUTION." Furthermore, the Label Review Manual (page 7-17) states that for products with toxicity category IV "...precautionary statements are not normally required... [but] it is recommended registrants use precautionary statements triggered by toxicity category III. Registrants may propose alternate labeling which should be reviewed by the precautionary labeling reviewers."

To that end, we have proposed CAUTION as the signal word on the subject product, and have proposed modified label language in the "HAZARDS TO HUMANS" section. We are also including First Aid statements.

Personal Protective Equipment

Neither the use pattern (residential/consumer) nor the toxicity of the product necessitate the need for any specific protective clothing.

Environmental Hazards: As described in the Label Review Manual (Page 8-1) – "1. Products which are intended for use exclusively indoors may omit the Environmental Hazards statement." Since this product is considered "Indoor – Non-Food", and the product does not have rinsate that could contaminate water (i.e., it is not a dog dip), this section is not included on the proposed label.

Storage & Disposal: Pursuant to 40 CFR § 156.140(a)(5), pet collars are exempt from the requirements of the "Container and Containment Rule." We have proposed alternative language appropriate for this type of product.

J. ECOLOGICAL EFFECTS

The specific use pattern for proposed pet collars (domestic animals), according to the Pesticide Use Index, is determined to be Group Number 99 "Indoor - Non-Food."

As described in 40 CFR §158.630 (Terrestrial and aquatic non-target organisms data requirements), there are two Conditional Requirements (CR) listed in the respective table for the "Indoor Use Pattern": 1) Freshwater fish toxicity (GL No. 850.1075) and 2) Acute toxicity freshwater invertebrates (GL No. 850.1010). However, Footnote 2 of the table that applies to both Conditional Requirements states that "The study is not required if there is no potential for environmental exposure."

Bayer discussed this with the Agency during the pre-registration meeting on 9/14/2006 (see Attachment 4) and was told that as long as we certified that the end-use product was not to be produced in the United States, then there would be "no potential for environmental exposure" and therefore these studies would not be required. Bayer HealthCare, Animal Health Division, certifies that the proposed product will <u>not</u> be produced in the United States. As evidenced by a statement on the proposed label, this product is "Made in Germany." Therefore, data in these areas are not enclosed with this application.

K. DISCUSSION OF OTHER REQUIREMENTS

<u>Residue Chemistry</u> - No residue chemistry data are provided with this application as none are necessary; this application is for a non-food use.

<u>Child-resistant packaging</u> - Certification that the packaging for *PNR1427 Insecticide* meets the child-resistant packaging standards in 40 CFR 157.32 is <u>not</u> necessary because *PNR1427 Insecticide* does not meet any of the toxicity criterion listed in 40 CFR 157.22 (a) for products requiring child resistant packaging.

L. BENEFITS/PUBLIC INTEREST

Information regarding the benefits of this new active ingredient-containing product is contained in the document entitled: "Benefits of Flumethrin Active Ingredient and the Imidacloprid/Flumethrin Collar for Cats and Dogs (PNR1427), Bayer Report ID No. 33860" which should allow the Agency to make the determination that "...the use of the pesticide will not cause any unreasonable risk to the environment; and the use of the pesticide is in the public interest." This document is being submitted with the application for registration of Flumethrin Technical, being submitted simultaneously with this registration action.

M. DATA COMPENSATION

As demonstrated in the enclosed, completed "Certification with Respect to Citation of Data" (EPA Form 8570-34), we are choosing the Selective Method of Support for both the imidacloprid and flumethrin data. An appropriate data matrix listing all of the data necessary to support the registration of PNR1427 Insecticide is enclosed with this application.

Generic Data

Bayer CropScience is the basic registrant of imidacloprid. Accordingly, enclosed is a copy of Letter of Authorization from Bayer CropScience (EPA Company No. 264) authorizing the use of the generic imidacloprid data by the Bayer Healthcare LLC, Animal Health Division (EPA Company No. 11556).

For the flumethrin active ingredient, we are also using the selective method of support. All the data to fulfill the data requirements for flumethrin, as listed in the data matrix, are being submitted by us, Bayer HealthCare LLC, in support of the registration application of *Flumethrin Technical*, simultaneously submitted with this application.

Product Specific Data

All of the formulation specific data necessary to support the registration of *PNR1427 Insecticide* are enclosed with this application. All of these data are cited in the enclosed data matrix, and are the property of Bayer HealthCare.

N. List of Attachments

- "Minutes of Pre Reg Meeting (03/24/09) Collar Product Chemistry Requirements," email (D. Spilker to B. Alexander) dated 04/13/2009, and attached minutes from Preregistration meeting of 03/24/2009, 8pp.
- 2. "Inert determination Non-food uses," email (K. Grinstead to D. Spilker) dated 9/15/2008, 3pp.
- "Minutes of Pre-reg Meeting (03/30/09) Collar Acute Toxicity requirements," email (D. Spilker to B. Alexander) dated 04/13/2009, and attached minutes from Pre-registration meeting of 03/30/2009, 7pp.
- 4. "Minutes from US EPA & Bayer Animal Health Division Pre-Registration Meeting for Flumethrin Technical and Flumethrin Combo Products, September 14, 2006," 5pp.
- 5. "Pet Collar Deer Tick Protocol Issue for PERC," email string including 8/14/2009, 10/7/2009 and 10/15/2009, 10pp.
- 6. "Domestic Animal Safety Teleconference (DRAFT minutes) 6/4/09," and EPA response (telephone record, 6/9/2009), 4pp.
- 7. "Teleconference between Bayer Animal Health and EPA Insecticide/Rodenticide Branch & Technical Review Branch, March 11, 2009; proposed Domestic Animal Safety Requirements for Flumethrin + Imidacloprid Collar, dated 5/8/2009, 4pp.

Bayer HealthCare Animal Health

BAYER

Via Federal Express

September 23, 2010

Document Processing Desk (REGFEE) Office of Pesticide Programs (7504P) U.S. Environmental Protection Agency Room S-4900, One Potomac Yard 2777 South Crystal Drive Arlington, VA 22202-4501

Attention:

Mr. Richard Gebken/PM10

Registration Division (7505P)

Subject:

Application for Registration of a New Active Ingredient

(PRIA R110): Flumethrin Technical (CAS No. 69770-45-2)

Application for Registration of a Combination (Flumethrin +

Imidacloprid) End-Use Product: PNR1427 Insecticide

Dear Mr. Gebken:


With this application, the enclosed data and labeling, Bayer HealthCare LLC, Animal Health Division (BAH) is requesting the registration of a new technical active ingredient – "Flumethrin Technical" containing flumethrin (CAS No. 69770-45-2). A second application for registration of PNR1427 Insecticide end-use product (flea and tick pet collar) is being submitted concurrently with this application for registration of the technical active ingredient. The flumethrin technical active ingredient, which is also the manufacturing-use product, is for formulation purposes ONLY into products with indoor, non-food uses. The "specific use pattern" on domestic animals, according to the Pesticide Use Index, is determined to be Group Number 99 "Indoor – Non-Food."

The proposed Flumethrin Technical is considered a "new" active ingredient in that it is "...not currently contained as an active ingredient in any EPA registered pesticide product." The ultimate use of this technical active ingredient is for formulation into pesticide products on pets (cats and dogs), which are considered indoor use patterns by the Agency. No flumethrin-containing end-use products are proposed that would be used on or come into contact with food and/or feed items. Therefore as described in the PRIA Decision Tree, the application for registration of this new active ingredient – Flumethrin Technical - falls under the action code R110: "Nonfood use; Indoor." Furthermore, it is our understanding that all indoor non-food use products included with this technical active



Bayer HealthCare LLC Animal Health P.O. Box 390

Shawnee Mission, KS 66201-0390



ingredient application are covered by the base fee in this category, if submitted simultaneously. The application for the end-use product, *PNR1427 Insecticide*, is being submitted simultaneously with the technical product application, and therefore there should be no additional PRIA fee for the *PNR1427 Insecticide* application.

Flumethrin, a new active ingredient, is intended as a Technical/Manufacturing Use Product for formulating insecticides for indoor uses (on domestic animals; cats and dogs). Flumethrin Technical is proposed for use in combinations with other EPA-registered active ingredients (such as imidacloprid). PNR1427 Insecticide is a new pesticide end-use product combining two active ingredients, imidacloprid and flumethrin, in a pet collar formulation. It is intended for the prevention and treatment of public health pests, such as ticks and fleas, on kittens, cats, puppies and dogs.

The Agency is not unfamiliar with this active ingredient and end-use product, as Bayer Healthcare has had several pre-registration meetings and/or teleconferences with the Agency to discuss these registration actions and the specific 40 CFR Part 158 requirements for these products. Detailed overviews of the two actions are attached to the respective Applications for Pesticide Registration (EPA Form No. 8570-1), and the Bayer-EPA interactions will be referenced in the respective sections of these overviews, and copies of referenced documents provided. We request that copies of the two applications with attachments be forwarded to the respective review groups, as we think this information could be quite helpful during their review processes.

Information regarding the benefits of this new active ingredient-containing product is contained in the document entitled: "Benefits of Flumethrin Active Ingredient and the Imidacloprid/Flumethrin Collar for Cats and Dogs (PNR1427), Bayer report No. 33860," which should allow the Agency to make the determination that "...the use of the pesticide will not cause any unreasonable risk to the environment; and the use of the pesticide is in the public interest."

If you have any questions, please do not hesitate to call me at 913-268-2751.

Sincerely,

Douglas A. Spilker. Ph. D.

Manager, EPA Regulatory Affairs

Jaga A. Jille

Doug.Spilker@Bayer.com

Enclosures:

1. Copy of Check – Check No. 2000542090 (\$209,475.00), cover letter, dated 9/20/10, and delivery confirmation, dated 9/21/2010


2. Application for Registration - Flumethrin Technical

- a. Administrative Volume (Volume 1 on Transmittal Document)
 - i. Cover letter (Extra Copy)
 - ii. Copy of PRIA Payment (Check No. 2000542090)
 - iii. Application for Registration Flumethrin Technical (Form 8570-1), 10pp. w/ 6 attachments
 - iv. Transmittal document
 - v. Confidential Statement of Formula, dated 11/15/2008 (2 copies)
 - vi. Certification with Respect to Citation of Data (Form 8570-34)
 - vii. Data Matrix (CONFIDENTIAL) "Flumethrin Active Ingredient Specific, dated 9/20/2010," 7pp.
 - viii. Data Matrix (PUBLIC) "Flumethrin Active Ingredient Specific, dated 9/20/2010," 7pp.
 - ix. Product label, dated 9/20/2010 (3 copies)
- b. Bayer Reports ID Nos. 23979, 23980, 23940, 14838, 18186, 23941, 14837, 16302, 17815, 17817, 33853, 14967, 76066, 14561, 32545, 32570, 30932, 30931, 18177, 201706, 19360, 15285, 19383, 18255, 18968, 35286, 32775, 13252, 30322, 30686, 30517, 32365, 14173, 14174, 30687, 15461, 31492, 74691, 31489, 30951, 15198, 14867, 14368, 22813, 30971, 15839, 22818, 22819, 15987, 35217, 35038 (3 copies each)

3. <u>Application for Registration – end-use product PNR1427</u> Insecticide

- a. Administrative Volume (Volume 1 on Transmittal Document)
 - i. Cover letter (Extra Copy)
 - Application for Registration PNR1427 Insecticide (Form 8570-1), 17pp. w/ 7 attachments
 - iii. Confidential Statements of Formula (3) Basic, Alt 1, and Alt 2, dated 8/25/2010; 2 copies each)
 - iv. Transmittal Document
 - v. Certification with Respect to Citation of Data (Form 8570-34)

- vi. Letter of Authorization from Bayer CropScience (for imidacloprid), dated 9/7/2010
- vii. Data Matrix (CONFIDENTIAL) PNR1427 Insecticide: "Flumethrin Active Ingredient Specific (pages 1-7), Imidacloprid Active Ingredient Specific (pages 8-14), and PNR1427 Insecticide Specific (pages 15-18); dated 9/20/2010," total pages – 18
- viii. Data Matrix (PUBLIC) PNR1427 Insecticide: "Flumethrin Active Ingredient Specific (pages 1-7), Imidacloprid Active Ingredient Specific (pages 8-14), and PNR1427 Insecticide Specific (pages 15-18); dated 9/20/2010," total pages -18
- ix. Product label, dated 9/20/2010 (3 copies)
- b. Bayer Reports ID Nos. 33752, 33854, 33855, 33856, 33857, 33749, 33750, 33800, 33826, 33805, 33806, 33824, 33822, 33823, 35986, 35637, 33801, 33802, 33803, 35630, 35631, 35635, 35644, 35645, 35980, 35987, 33464, 35981, 35979, 35982, 33467, 33694, 33691, 36172, 15962, 35642, 35643, 15749, 33860, 33861, 35992, 35118 (3 copies each)



TRANSMITTAL DOCUMENT

Name and Address of Submitter: Bayer HealthCare LLC

Animal Health Division

Box 390

Shawnee Mission, Kansas 66201-0390

Regulatory action in support of which this package is submitted:

Application for registration of

PNR1427 Insecticide

EPA Reg. No./File Symbol:

Company Number: 11556- XXX

Alternate Test Material Names:

N/A

Transmittal Date:

September 23, 2010

Box Count:

19 - 24

Volume Number	Citation	MRID Number
	Administrative Materials	y 2 2 3
	- Cover letter (Extra Copy)	;
	- Application for Pesticide Registration (with Attachments),,,,	> > 3 > > 3 > 3 7 9
	- Confidential Statement of Formula (2 copies)	7
1	- Transmittal Document	5 7 5 3 3 5
•	- Certification with respect to Citation of Data (8570-34)	3 3 2
	- Letter of Authorization from Bayer CropScience (imidacloprid)	3 3 3 3
	- Data Matrix (CONFIDENTIAL)	7
	- Data Matrix (PUBLIC)	3 3 357328 5
	- Product Label (3 copies)	
2	Rose, J.E., 2009, Chemistry Evaluation of M915 Insecticide,	3 2 2 3
	33752 (1 book, 3 copies).	
_	Chopade, H., 2010, Request for Waiver from the Requirement	
3	of Acute Oral Toxicity Study – PNR 1427 Insecticide, 33854 (1	
	book, 3 copies).	
	Chopade, H., 2010, Request for Waiver from the Requirement	
4	of Acute Dermal Toxicity Study – PNR 1427 Insecticide, 33855	
	(1 book, 3 copies).	<u>.</u>
-	Chopade, H., 2010, Request for Waiver from the Requirement	
5	of Acute Inhalation Toxicity Study – PNR 1427 Insecticide,	
	33856 (1 book, 3 copies).	
6	Chopade, H., 2010, Request for Waiver from the Requirement	
6	of Acute Eye Irritation Toxicity Study – PNR 1427 Insecticide,	
<u></u>	33857 (1 book, 3 copies). Durando, J., 2009, Primary Skin Irritation Study in Rabbits,	
7	33749 (1 book, 3 copies).	
	00/48 (1 book, 0 copies).	

Volume Number	Citation	MRID Number
8	Durando, J., 2009, Dermal Sensitization Study in Guinea Pigs (Buehler Method), 33750 (1 book, 3 copies).	
9	Madsen, T.J., 2010, Safety of PNR 1427 in adult cats, 33800 (1 book, 3 copies).	
10	Madsen, T.J., 2010, Amendment to Bayer Report No.33800- Safety of PNR1427 in Adult Cats, 33826 (1 book, 3 copies).	
11	Madsen, T.J., 2010, Safety of PNR 1427 in Adult Dogs, 33805 (1 book, 3 copies).	
12	Madsen, T.J. & Chopade, H., 2010, Safety of PNR1427 in Puppies, 33806 (2 books, 3 copies).	
13	Madsen, T.J., 2010, Safety of PNR 1427 in Kittens, 33824 (2 books, 3 copies).	
14	Madsen, T.J., 2010, Safety of PNR1427 With Reflectors in Puppies, 33822 (1 book, 3 copies).	
15	Madsen, T.J., 2010, Safety of PNR1427 with Reflectors in Kittens, 33823 (1 book, 3 copies).	
t6	Delport, P.C., 2010, Target animal safety with a PNR 1427 collar with and without reflectors when applied once to adult cats, 35986 (1 book, 3 copies).	\$ \$ \$ \$ \$
17	Bach, T., 2010, Target Animal Safety With A 10% Imidaçloprid + 4.5% Flumethrin Collar With or Without Reflector Clips Applied Once To Adult Dogs, 35637 (1 book, 3 copies).	2
18	Everett, W.R., Davis, W.L., & Settje, T.L., 2010, Efficacy of PNR1427 Against Tick (Dermacentor variabilis, Rhipicephaius sanguineus) and Flea Infestations on Dogs, 33801 (1 book, 3' copies).	8 h 5 4 7 h 5 h 3 5 2 h 9 p 5 3
19	Everett, W.R., Davis, W.L., & Settje, T.L., 2010, Efficacy of PNR1427 Against Tick (Amblyomma americanum) and Flea Infestations on Cats, 33802 (1 book, 3 copies).	2 8 3 4 2 5 5 3
20	Everett, W.R., Davis, W.L., & Settje, T.L., 2010, Evaluation of the Effects of Shampooing or Water Immersion on the Efficacy of PNR1427 Against Flea (Ctenocephalides felis) and Tick (Dermacentor variabilis, Rhipicephalus sanguineus) Infestations on Dogs, 33803 (1 book, 3 copies).	
21	Strube, K., Stanneck, D., Schroeder, I., & Kruedewagen, E., 2010, Efficacy of a 10% imidacloprid / 4.5% flumethrin collar against experimental tick (Ixodes ricinus) and flea (Ctenocephalides felis) infestations in cats, 35630 (1 book, 3 copies).	

Volume Number	Citation	MRID Number
22	Strube, K., Stanneck, D., Schroeder, I., & Kruedewagen, E., 2010, Efficacy of a 10% imidacloprid / 4.5% flumethrin collar against experimental tick (Ixodes ricinus and Rhipicephalus sanguineus) and flea (Ctenocephalides felis) infestations in dogs, 35631 (1 book, 3 copies).	
23	Wolken, S., & Stanneck, D., 2010, Efficacy of a 10% imidacloprid / 4.5% flumethrin collar against experimental tick (Ixodes ricinus) and flea (Ctenocephalides felis) infestations in cats, 35635 (1 book, 3 copies).	
24	Rass, J. & Stanneck, D., 2010, Evaluation of the Efficacy, Persistency and Safety of "Imidacloprid 10%/Flumethrin 4.5% Collar" in Cats Naturally Infested with Fleas and/or Ticks in a Multi-Centric Clinical Field Study in the EU, 35644 (1 book, 3 copies).	
25	Rass, J. & Stanneck, D., 2010, Evaluation of the Efficacy, Persistency and Safety of "Imidacloprid 10%/Flumethrin 4.5% Collar" in Dogs Naturally Infested with Fleas and/or Ticks in a Multi-Centric Clinical Field Study in the EU, 35645 (1 book, 3 copies).	
26	Strube, K. & Schroeder, I., 2010, Onset of Efficacy of a 10% Imidacloprid/ 4.5% Flumethrin Collar on Cats When Experimentally Infested with the Cat Flea Ctenocephalides felis (C. felis), 35980 (1 book, 3 copies).	
27	Kok, D.J., 2010, Onset of Efficacy of an Imidacloprid/Flumethrin Collar Formulation Against Fleas (Ctenocephalides felis) on Dogs, 35987 (1 book, 3 copies).	
28	Turberg, A. & Settje, T., 2010, Comparative in-vitro study of flumethrin efficacy against two Ixodes species in a glass vial contact assay, 33464 (1 book, 3 copies).	
29	Strube, K., 2010, Onset of efficacy of a 10% Imidacloprid/ 4.5% flumethrin collar on cats when experimentally infested with <i>Ixodes ricinus (I. ricinus)</i> , 35981 (1 book, 3 copies).	
30	Ketzis, J. & Schroeder, I., 2010, A controlled, randomized study to confirm the efficacy of Imidacloprid/Flumethrin containing collars against artificially induced infestations of Ixodes ricinus on beagles, 35979 (1 book, 3 copies).	
31	Strube, K., 2010, Onset of Efficacy of a 10% Imidacloprid/ 4.5% Flumethrin Collar on Dogs when Experimentally Infested with <i>Ixodes ricinus</i> and <i>Rhipicephalus sanguineus</i> , 35982 (1 book, 3 copies).	

Volume Number	Citation	MRID Number
32	Turberg, A., 2010, Comparative in-vitro study of efficacy of a 1: 1.85 flumethrin: imidacloprid mixture against larvae, nymphs and adults of I. ricinus and R. sanguineus and larvae and adults of D. reticulatus ticks in a glass vial contact assay, 33467 (1 book, 3 copies).	
33	Ketzis, J. & Stanneck, D., 2010, A Controlled, Randomized Study to Confirm the Efficacy of Imidacloprid/Flumethrin Containing Collars Against a Natural Infestation of Dog Lice (<i>Trichodectes canis</i>) on Mixed Bred and Purebred Dogs, 33694 (1 book, 3 copies).	
34	Fourie, J.J., 2010, Evaluation of the Efficacy of an Imidacloprid/Flumethrin Collar Formulation on Dogs with Naturally Acquired Infestations of <i>Sarcoptes scabiei</i> , 33691 (1 book, 3 copies).	
35	Kruedewagen, E., 2010, In-vitro Efficacy of Hair Coat Samples From Cats and Dogs Treated with Imidacloprid 10%/Flumethrin 4.5% Collars Against Ticks (<i>R. sanguineus</i>), 36172 (1 book, 3 copies).	
36	Gyr, P. & Hopkins, T., 1995, Residues of BAY t 7391 10% w/v Spot-on in the Coat of Dogs at Various Times After Treatment, 15962 (1 book, 3 copies).	
37	Delport, P.C., 2010, Serum and Hair Coat Kinetics of an Imidacloprid 10%/Flumethrin 4.5% Collar in Cats, 35642 (1 book, 3 copies).	
38	Delport, P.C., 2010, Serum and Hair Coat Kinetics of an Imidacloprid 10%/Flumethrin 4.5% Collar in Dogs, 35643 (1 book, 3 copies).	
39	Jacobs, D.E., 1995, Imidacloprid Spot-on 10% (BAY t 7391) for the Control of Fleas on Dogs - Clinical Field Study, 15749 (1 book, 3 copies).	
40	Spilker, D.A., & Davis, W.L., 2010, "Benefits of Flumethrin Active Ingredient and the Imidacloprid/Flumethrin Collar for Cats and Dogs (PNR1427)", 33860 (1 book, 3 copies).	
41	Lunchick, C., 2010, Occupational and Residential Exposure and Risk Assessment for PNR 1427 Dog and Cat Collars Formulated with Imidacloprid and Flumethrin, 33861 (1 book, 3 copies).	
42	Stanneck, D., 2010, Dosage of the imidacloprid 10%/flumethrin 4.5% collar and release of the active ingredients over time in cats and dogs – Review Compilation, 35992 (1 book, 3 copies).	

Volume Number	Citation	MRID Number
43	Kruedewagen, E., 2010, Soluble Surface Content of Flumethrin and Imidacloprid of a Collar Containing 10% Imidacloprid plus 4.5% Flumethrin After Beeing Worn by Cats for Different Time Periods, 35118 (1 book, 3 copies).	

Company Official: Douglas A. Spilker, Ph.D., Manager

EPA Regulatory Affairs

Company Name: Bayer HealthCare LLC

Animal Health Division

Company Contact: Douglas A. Spilker, Ph.D.

Douglas A. Spilker, Ph.D. Phone: (913) 268-2751 Fax: (913) 268-2135

Email: doug.spilker@bayer.com



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 1200 Pennsylvania Avenue, N.W. WASHINGTON, D.C. 20460

	•	
Paperwork Reduction Act Notice: The public reporting burden for this collection of information and 0.25 hours per response for reregistration and special review activities, including time for comments regarding burden estimate or any other aspect of this collection of information, including Division (2822T), U.S. Environmental Protection Agency, 1200 Pennsylvania Aver to thus address.	reading the instruction uding suggestions for r	s and completing the necessary forms. Send reducing the burden to: Director, Cottection
Certification with Respect to C	Cifation of Data	-
Applicant's/Registrant's Name, Address, and Telephone Number Bayer HealthCare LLC, Animal Health Div., BOX 390, Shawnee Mission, KS 6620	ı (913-268-275 f)	EPA Registration Number/File Symbol.
Active Ingredient(s) and/or representative test compound(s) Imidacloprid; Flumethrin		Date 23 Sept 2010
General Use Pettern(s) (list all those claimed for this product using 40 CFR Part 158 Indoor; Non-food Use)	Product Name 3 2 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
NOTE: If your product is a f00% repackaging of another purchased EPA-registers submit this form. You must submit the Formulator's Exemption Statement (EPA Formulator's Exemption Statement)		r all the same uses on your label, youd on need to
I am responding to a Data-Call-In Notice, and have included with this form a be used for this purpose).	list of companies se	nt offers of compensation (the Data Matrix form should
SECTION I: METHOD OF DATA SUPP	ORT (Check one m	ethod only)
I am using the cite-all method of support, and have included with this form a list of companies sent offers of compensation (the Data Matrix form should be used for this purpose).	under the	the selective method of support (or cite-all option selective method), and have included with this form a list of data requirements (the Data Matrix form must be
SECTION II: GENERAL (OFFER TO PAY	
Required if using the cite-all method or when using the cite-all option under the selection. I hereby offer and agree to pay compensation, to other persons, with regard to	,	
SECTION III: CERT	FICATION	
I certify that this application for registration, this form for reregistration, or the application for registration, the form for reregistration, or the Data-Call-In response. In indicated in Section I, this application is supported by all data in the Agency's files that substantially similar product, or one or more of the ingredients in this product; and (2) is requirements in effect on the date of approval of this application if the application souguess.	addition, if the cite- t (1) concern the pro is a type of data that that the inilial registral	all option or cite-all option under the selective method is perties or effects of this product or an identical or would be required to be submitted under the data tion of a product of identical or similar composition and
I certify that for each exclusive use study cited in support of this registration the written permission of the original data submitter to cite that study.	or reregistration, tha	it I am the original data submitter or that I have obtained
t certify that for each study cited in support of this registration or reregistratic submitter; (b) I have obtained the permission of the original data submitter to use the scompensation have expired for the study; (d) the study is in the public literature; or (e) offered (t) to pay compensation to the extent required by sections 3(c)(1)(F) and/or 3(d) amount and terms of compensation, if any, to be paid for the use of the study.	study in support of th I have notified in wri	is application; (c) all periods of eligibility for ting the compeny thet submitted the study and have
I certify that in all instances where an offer of compensation is required, cop accordance with sections 3(c)(1)(F) and/or 3(c)(2)(B) of FIFRA are available and will be evidence to the Agency upon request, I understand that the Agency may initiate action FIFRA.	e submitted to the A	gency upon request. Should I fail to produce such
I certify that the statements I have made on this form and all attachm knowingly talse or misleading statement may be punishable by fine or impriso		
Signature Defle A. filler	Date 23 Sejít 20 10	Typed or Printed Name and Title Douglas A. Spilker, Mgr. EPA Reg. Affairs

EPA Form 8570-34 (12-2003) Electronic and Paper versions available. Submit only Paper version.



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not seed the form to the address.

		DATA	MATRIX CO	DNFIDENT	IAL VERSION	· · · · · · · · · · · · · · · · · · ·	
Date: September	er 23, 2010		EPA Reg No	JFile Symb	ol: 11556-XXX	Page 1 of 18	
Bayer Health Ca Animal Health I P.O. Box 390 Shawnee Missic			PNR1427 Insecticide Flumethrin Technical (pages 1 -7) linidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) lmidacloprid (CAS 138261-41-3)	
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments	

	Flumethrin Active Ingredient Specific (Pages 1 - 7)							
Product Chemis	try, Section 158.300							
830.1550	Product identity and Composition	11556	OWN	23979 (BR 2625)				
830.1600	Description of materials used to produce the product	11556	OWN	23979 (BR 2625)				
830.1620	Description of production process	11556	OWN	23979 (BR 2625)				
830.1650	Description of formulation process				N.A EP Only			
830.1670	Discussion on formation of impurities	11556	OWN	23979 (BR 2625)				
830.1700	Preliminary analysis	11556	OWN	23979 (BR 2625)				
830.1750	Certified of limits	11556	OWN	23979 (BR 2625)				
830.1800	Enforcement method	11556	OWN	23979 (BR 2625)				
830.1900	Submittal of samples		<u> </u>		Samples available upon request			
830.6302	Color	11556	OWN	23980 (BR 2624)				
830.6303	Physical state	l 1556	OWN	23980 (BR 2624)				
830.6304	Odor	11556	OWN	23980 (BR 2624)				
830.6313	Stahility	11556	OWN	23980 (BR 2624)	,			
830.6314	Oxidizing / reducing action	11556	OWN	23980 (BR 2624)				
830.6315	Flammability	11556	OWN	23980 (BR 2624)				
830.6316	Explodability	11556	OWN	23980 (BR 2624)				
830.6317	Storage stability	11556	OWN	23980 (BR 2624)				
830.6319	Miscibility	11556	OWN	23980 (BR 2624)				
830.6320	Corrosion characteristics	11556	OWN	23980 (BR 2624)				
830,6321	Dielectric breakdown volt	11556	OWN	23980 (BR 2624)				
830.7000	рН	11556	OWN	23980 (BR 2624)				



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

·····		DATA	MATRIX CO	NEIDENT	IAL VERSION	
Date: September	23, 2010		EPA Reg No	./File Symb	ol: 11556-XXX	Page 2 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• In	lumethrin Te nidacloprid I	NR1427 Insecticide relinical (pages 1 -7) fechnical (pages 8 -14) ecticide (pages 15 – 18)	Ingredienl: Flumethrin (CAS 69770-45-2) lmidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
830.7050	UV/Visible absorption		11556	OWN	23980 (BR 2624)	
830.7100	Viscosity		11556	OWN	23980 (BR 2624)	N.A. – Not a liquid
830.7200	Melting point		11556	OWN	23980 (BR 2624)	
830,7220	Boiling point		11556	OWN	23980 (BR 2624)	
830,7300	Density, bulk-density, or specific gravity		11556	OWN	23980 (BR 2624)	
830.7370	Dissociation constant in water		11556	OWN	23980 (BR 2624)	N.A Does not dissociate
830,7520	Particle size, fiber length, and diameter distribution		11556	OWN	23980 (BR 2624)	
830.7550 830.7560 830.7570	Partition coefficient (II-octanol/water)		11556	OWN	23980 (BR 2624)	
830.7840 830.7860	Water solubility		11556	OWN	23980 (BR 2624)	
830.7950	Vapor pressure		11556	OWN	23980 (BR 2624)	
Terrestrial and a	aquatie non-target organisms data requirements, Sect	tion 158.630				
850.2100	Avian oral toxicity					N.A.
850.2200	Avian dietary toxicity					N.A.
850.2400	Wild mammal toxicity					N.A.
850.2300	Avian reproduction					N.A.
850,2500	Simulated or actual field testing					N.A.
850,1075	Freshwater fish toxicity					N.A.
850,1010	Acute toxicity freshwater invertebrates					N.A.
850,1025 850,1035 830,1045 830,1055 830,1075	Acute toxicity estuarine and marine organisms					N.A.
850.1300	Aquatic invertebrates life cycle (freshwater)					N.A.



Approved OMB No. 2070-0060

Paperwork Reduction Act Nutice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environnental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DAT	'A MATRIX – CO	NFIDENT	AL VERSION	
Date: September	23, 2010		EPA Reg No	./File Symb	ol: 11556-XXX	Page 3 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• 111	umethrin Te nidaeloprid T	NR1427 Insecticide chnical (pages 1 -7) Fechnical (pages 8 -14) acticide (pages 15 — 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guidelinc Study Name	MRID Number	Submitter	Status	Report Number	Comments
850.1350	Aquatic invertebrates life cycle (saltwater)			-		N.A.
850.1400	Fish early-life stage (freshwater)					N.A.
850.1400	Fish carly-life stage (saltwater)					N.A.
850.1500	Fish life cycle					N.A.
850.1710 850.1730 850.1850	Aquatic organisms bioavailability, biomagnifications, toxicity					N.A.
850.1950	Simulated or actual field testing for aquatic organisms					N.A.
850.1735	Whole sediment: acute freshwater invertebrates					N.A.
850.1740	Whole sediment: acute marine inverlebrates					N.A.
850.3020	Honey bee acute contact toxicity					N.A.
850.3030	Honey bee toxicity of residues on foliage					N.A.
850.3040	Field testing for pollinators					N.A.
Toxicology, Sect	ion 158,500	, <u>, , , , , , , , , , , , , , , , , , </u>				
870.1100	Acute oral toxicity - rat		11556	OWN	76064 (ID 23940)	
			11556	OWN	14838	Supplemental
			11556	OWN	18186	Supplemental
870.1200	Acute dermal toxicity		11556	OWN	76065 (ID 23941)	
			11556	OWN	14837	Supplemental
870.1300	Acute inhalation toxicity - rat		11556	OWN	16302	
			11556	OWN	17815	Pilot study
			11556	OWN	17817	Pilot study



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Envirunmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

	122 12010					
Date: September 23, 2010 Bayer Health Care, LLC Animul Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			EPA Reg No			Page 4 of 18 Ingredient: Flumethrin (CAS 69770-45-2) Iniidacloprid (CAS 138261-41-3)
			• in	umethrin Te tidacloprid "	NR1427 Inserticide chnical (pages 1 -7) Technical (pages 8 -14) acticide (pages 15 – 18)	
Suideline Reference Yumber	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
870.2400	Primary eye irritation – rabbit		11556	OWN	33853	Waiver request
			11556	OWN	14967	Stipplemental Study
870.2500	Primary dermal irritation		11556	OWN	76066 (ID 23942)	
870.2600	Dermal sensitization		11556	OWN	14561	
870.6100	Delayed neurotoxicity (acute) - hen			 		N.R Not an organophosphate
870.6200	Acute neurotoxicity - rat		11556	OWN	201861 (ID 32545)	N.R Not an organophosphate
870.3100	90-day oral - rodent					No oral exposure
870,3150	90-day feeding - non-rodent					N.R. – Nonfood use
870,3200	21-day dermal - rabbit/rat					N.R Nonfood use
870,3250	90-day dermal toxicity		11556	OWN	32570	
			11556	OWN	30932	Pilot study for 32570
			11556	OWN	30931	Pilot study for 32570 and 30932
870.3465	90-day inhalation		11556	OWN	18177	
870,6100	28-day delayed neurotoxicity - hen			<u> </u>		N.R Not an organophosphate
870,6200	90-day neurotoxicity - rat		11556	OWN	201706 (ID 32054)	
870,4100	Chronic oral toxicity - rodent		11556	OWN	19360	Listed as study type 870.4300 (combined)
			11556	OWN	15285	Pilot study for ID 19360
870,4200	Carcinogenicity - rat		11556	OWN	19360	Listed as study type 870,4300 (combined)
			11556	OWN	15285	Pilot study for ID 19360
870.4200	Carcinogenicity - mouse		11556	OWN	19383	See protocol discussion
·····			11556	OWN	18255	Pilot study for ID 19383
870.3700	Developmental toxicity - rat		11556	OWN	18968	
870.3700	Developmental toxicity - rabbit		11556	OWN	35286	



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden ta: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC

		DAT	A MATRIX CO	NFIDENT	AL VERSION	
Date: September	23, 2010		EPA Reg No	./File Symb	ol: 11556-XXX	Page 5 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shatvnee Mission, KS 66201-0390			• In	lumethrin Te nidacloprid I	NR1427 Insecticide chnical (pages 1 -7) feclutical (pages 8 -14) teticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Suideline leference lumber	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
				•		
870.3800	Reproduction and fertility effects		11556	OWN	32775	
			11556	OWN	13252	Pilut study for 32775
		***************************************	11556	OWN	30322	Pilot study for 32775
			11556	OWN	30686	Pilot study for 32775
	1		11556	OWN	30517	Supplement to 30686
870.6300	Developmental neurotoxicity		11556	OWN	201747 (ID 32365)	
870.5100	Bacterial reverse mutation assay		11556	OWN	14173	
		********	11556	OWN	14174	
			11556	OWN	30687	
870-5300	In vitro maminalian cell assay		11556	OWN	15461	
870.5375		***	11556	OWN	31492	
			11556	OWN	74691 (ID 16145)	
			11556	OWN	31489	
870.5385	In vitro cytogenetics		11556	OWN	30951	
870.5395			11556	OWN	15198	
870.5550	Unscheduled DNA Symhesis		11556	OWN	14867	
870.7485	Metabolism and pharmacokinetics		11556	OWN	14368	
			11556	OWN	22813	
			11556	OWN	30971	
	Į.		11556	OWN	15839	Cattle - Supplemental Study
			11556	OWN	22818	Sheep - Supplemental Study
			11556	OWN	22819	Slicep - Supplemental Study
	:		11556	OWN	15987	Cattle - Supplemental Study
870.7200	Companion animal safety			ļ		N.A. for EP Only
870,7600	Dermal penetration	l	ı		1	N.R See Risk Assessment



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environtmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

Datas Cantambas	22 2010		A MATRIX - CO	***		Page 6 of 18
Date: September 23, 2010 Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• fu	Flumethrin To	PNR1427 Insecticide schnical (pages 1-7) Technical (pages 8-14) ecticide (pages 15-18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-3) Comments
uideline Guideline Sludy Name MRID Number umber		MRID Submitter		Status	Report Number	
870.7800	Immunotoxicity	1	11556	OWN	1 35217	
875.2400	Post-Application Expusure (Oermal)					N.A. EP Only
None	1998 EMEA Summary/Overview on Flumethtrin		11556	own	35038	Requested by Agency in Pre-Reg Meeting of 11/11/06
None	1996 FAO/WHO JMPR Monograph for Flumethrin		11556	OWN	35059	Requested by Agency in Pre-Reg Meeting of 11/11/06
Environmental l	Fale, Section 158.1300					•
835.2120	Hydrolysis					N.A.
835.2240	Photodegradation - water					N,A.
835,2410	Photodegradation - soil					N.A.
835,2370	Photodegradation - air					N.A.
835,4100	Aerobic soil metabolism					N.A.
835,4200	Angerubic soil metabolism					N.A.
835,4300	Aerobic aquatic metabolism					N.A.
835.4400	Anaerobic aquatic metabolism					N.A.
835.1230 835.1240	Leaching / adsorption/desorption					N.A.
835.1410	Volaulity - laboratury					N.A.
835,8100	Volatility - field					N.A.
835,6100	Terrestrial field dissipation			<u> </u>		N.A.
835.6200	Aquatic (sediment)			ļ		N.A.
835,6300	Forestry					N.A.
835.6400 835.7100	Combination and tank mixes Ground water monitoring					N.A.



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estinated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA	MATRIX - CC	NFIDENT.	IAL VERSION	
Date: September	23, 2010		EPA Reg No	/File Symb	ol: 11556-XXX	Page 7 of 18
Bayer Health Care Animal Health Di- P.O. Box 390 Shawnee Mission,	vision		• in	lumethrin Te uidaclop n id "	PNR1427 Insecticide eclinical (pages 1 -7) Fechnical (pages 8 -14) eclicide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

	Nature of residue - plants	N.A.
	Nature of residue - livestock and poultry	N.A.
	Residue analytical method - plants	N.A.
	Residue analytical metiod - animal	N,A,
	Storage stability	N.A.
	Magnitude of residues - meat/milk/poultry/egg	N.A.
	Magnitude of residue - crop field trials	N.A.
	Magnitude of residue - processed food/feed	N.A.
	Method validation/ multiresidue method	N.A.
None	Benefits Reports	N.A.
None	Dietary Analysis	N.A.
810.3300	Treatments to control pesis of humans and pets	N.A. for EP Only



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA	MATRIX - CC	NFIDENT	IAL VERSION	
Date: Septemb	per 23, 2010		EPA Reg No	/File Symb	ol: 11556-XXX	Page 8 of 18
Bayer Health C Animal Health P.O. Box 390 Shawnee Missi			• 1n	lumethrin To nidacloprid I	NR1427 Insecticide clinical (pages 1 -7) Fechnical (pages 8 -14) acticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-31
Guideline Reference Number	Guideline Study Name	MRID Number	Submilter	Status	Report Number	Comments

		Imidacloprid Ac	tive Ingre	dient Sp	pecific (Pages 8 – 14)	
roduct Chem	istry, Section 158,240					
		42055302	264	PER	BR 1759 (TGAI)	
61-1	Chemical identity	43306001	264	PER	BR 1879 (TGAI)	
		42055302	264	PER	BR 1759 (TGAI)	
		43306001	264	PER	BR 1879 (TGAI)	
61-2	Statement of Composition	42270801	264	PER	BR 1785 (TGAI)	
61-3	Formation of impurities	42055302	264	PER	BR 1759 (TGAI)	
		42055303	264	PER	BR 1760 (TGAI)	
		43306002	264	PER	BR 1880 (TGAI)	
62-1	Preliminary analysis	42270802	264	PER	BR 1786 (TGAI)	
		42055303	264	PER	BR 1760 (TGAI)	—
62-2	Cenification of limits	43306002	264	PER	BR 1880 (TGAI)	
		42055303	264	PER	BR 1760 (TGAI)	
	***************************************	43213001	264	PER	BR 1874 (TGAI)	
62-3	Analytical method	43306002	264	PER	BR 1880 (TGAI)	
63-1	Chemical and Physical Properties	42055304	264	PER	BR 1761 (TGAI)	
63-2	Appearance	42055304	264	PER	BR 1761 (TGAI)	
63-3	Physical state	42055304	264	PER	BR 1761 (TGAI)	
63-4	Odor	42055304	264	PER	BR 1761 (TGAI)	
63-5	Melting point	42055304	264	PER	BR 1761 (TGAI)	
63-6	Boiling point	42055304	264	PER	BR 1761(TGAI)	
63-7	Density	42055304	264	PER	BR 1761 (TGAI)	



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA 1	MATRIX CC	NFIDENT	IAL VERSION	
Date: Septembe	г 23, 2010		EPA Reg No	./File Symb	ol: 11556-XXX	Page 9 of 18
Anintal Health E P.O. Box 390	Bayer Health Care, LLC Anintal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			lumethrin Te nidactoprid 1	PNR1427 Insecticide echnical (pages 1 -7) Feclinical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) Intidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name MRID Number		Submitter	Status	Report Number	Comments
63-8	Solubdity	42055304	264	PER	BR 1761 (TGAI)	
63-9	Vapor pressure	42055304	264	PER	BR 1761 (TGAI)	
63-10	Dissociation constant		 	<u> </u>	***************************************	N.A Does not dissociate
63-11	Octanol / water partition	42055304	264	PER	BR 1761 (TGAI)	
63-12	рН	42055304	264	PER	BR 1761 (TGAI)	
63-13	Stability	42055304	264	PER	BR 1761 (TGAI)	***
63-14	Oxidizing / reducing action		····			N.A No oxidative or reductive characteristics
63-15	Flanunability	42055304	264	PER	BR 1761 (TGAI)	
63-16	Explodability	42055304	264	PER	BR 1761 (TGAI)	
63-17	Storage stability	42055304	264	PER	BR 1761 (TGAI)	
63-18	Viscosity			1.		N.A Solid
63-19	Miscibility					N.A Solid
63-20	Corrosion characteristics	42055304	264	PER	BR 1761 (TGAI)	
63-21	Dielectric breakdown volt					N.A Solid
64-1	Submittal of samples				Samples available upon request	
	quatic Organisms, Section 158.490					
71-I	Acute avian oral - quail/duck					N.A.
71-2(a)	Avian dietary - quail					N.A.
71-2(b)	Avian dietary - duck					N.A.
71-3	Wild maininal toxicity			1		N.A.
71-4(a)	Avian reproduction - quail					N.A.
71-4(b)	Avian reproduction - duck					N.A.
71-5	Simulated or actual field study					N.A.
72-1(a)	Fish toxicity - bluegill					N.A.



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting borden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA	MATRIX - CO	INFIDENT.	IAL VERSION	
Date: September	23, 2010		EPA Reg No	./File Symb	ool: 11556-XXX	Page 10 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• In	lumethrin Te nidaeloprid	PNR1427 Insecticide echnical (pages 1-7) Technical (pages 8-14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) finidacloprid (CAS 138261-41-3)
Guideline Reference Nomber	Guideline Study Name	MRID Number	Submitter	Stalus	Report Number	Comments
72-1(b)	Fish toxicity bluegill - tep		<u> </u>			N.A.
72-2(a)	Invertebrate toxicity - Daplinia	<u> </u>				N.A.
72-2(b)	Invertebrate toxicity - Amphipods	<u> </u>	<u> </u>			N.A.
72-2(e)	Acute aquatic invertebrate toxicity - Chironomids		1	1		N.A.
72-3(a)	Estuarine / manne toxicity - fish			*		N.A.
72-3(b)	Estuarine / marine toxicity - mollusk					N.A.
72-3(c)	Estuatine/marine toxicity - shrimp					N.A.
72-4(a)	Early life stage - fish					N.A.
72-4(b)	Life cycle invertebrate					N.A.
72-7	Sîmolated or actual field study					N.A.
None	Foliar half-life and distribution for potatoes					N.A.
None	Runoff and Erosion predictions for apple/potato/cotton					N.A.
None	Risk assessment for apple/potato/eotton					N.A.
Toxicology, Sect	fion 1S8.340					
81-1	Acute oral toxicity rat	42(155331	264	PER	Report No. 100040 (TGAI)	
81-2	Acute dermal toxicity, rat/rabbit	42055332	264	PER	Report No. 100041 (TGAI)	
		42055333	264	PER	Report No. 99806 (TGAI)	
81-3	Acute inhalation toxicity, tat	42286101	264	PER	Report No. 99806-1 (TGAI)	
81-4	Primary eye irritation - rabbit	42055334	264	PER	Report No. 99679 (TGAI)	
8I-5	Primary dermal irritation - rabbit	42055335	264	PER	Report No. 99804 (TGAI)	
81-6	Dermal sensitization - guinea pig	42055336	264	PER	Report No. 99800 (TGAI)	



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

20460. Do not se	and the form to the address.					
		DATA I			IAL VERSION	
Date: September	23, 2010		EPA Reg No	/File Symb	ool: 11556-XXX	Page 11 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• In	lumethrin To	PNR1427 Insecticide echnical (pages 1 -7) Technical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) lmidacloprid (CAS 138261-41-3)
Guidelinc Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
		43170301	264	PER	Report No. 106348	
		43285801	264	PER	Report No. 106348-1	
81-8(SS)	Acute neurotoxicity	42770301	264	PER	Report No. 103979	
82-1(a)	90-day feeding - rodent	42256327	264	PER	Report No. 100036	
82-1(b)	90-day feeding - non-rodent	42256328	264	PER	Report No. 100176	
		42256329	264	PER	Report No. 100688	
82-2	21-day dermal - rabbit/rat	48024009	264	PER	Report No. M-357205	
82-5(b)	90 day neurotoxicity - mammal	43286401	264	PER	Report No. 106356	
		42256331	264	PER	Report No. 100652	
		42256332	264	PER	Report No. 101931	
		42256333	264	PER	Report No. 102658	
83-1(a)	Chronic feeding toxicity - rodent	42256334	264	PER	Report No. 99672	
83-1(b)	Chronic feeding toxicity - non-rodent	42273002	264	PER	Report No. 100015	
		42256331	264	PER	Report No. 100652	
		42256332	264	PER	Report No. 101931	
		42256333	264	PER	Report No. 102658	
83-2(a)	Oncogenicity - rat	42256334	264	PER	Report No. 99672	
		42256335	264	PER	Report No. 100693	
		42256336	264	PER	Report No. 101929	
83-2(b)	Oncogenicity - mouse	42256337	264	PER	Report No. 99808	
83-3(a)	Developmental toxicity - rat	42256338	264	PER	Report No. 98571	
83-3(b)	Developmental toxicity - rabbit	42256339	264	PER	Report No. 98572	
83-4	Two generation reproduction - rat	42256340	264	PER	Report No. 100647	



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the hurden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address,

		DRIA			IAL VERSION	
Date: Septembe			EPA Reg No		TANADATA TANADATA	Page 12 of 18
Bayer Health Care, LLC Animal Health Division I'.O, Box 390 Shawnee Mission, KS 66201-0390			• h	lumethria Tu nidacloprid '	PNR1427 Insecticide eclinical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 – 18)	Ingredient: Flumethrin (CAS 69770-45-2) lmidacloprid (CAS 138261-41-3)
Juideline Reference Jumber	eference		Submitter	Status	Report Number	Comments
		10056241	7 064	T NED	101076	
		42256341	264	PER	Report No. 101276	
04.2%	Cours australian (annua tant)	42256342	264	PER	Report No. 98584	
84-2(a)	Gene mutation (anies test)	42256343	264	PER	Report No. 98570	
		42256344	264	PER	Report No. 100021	
		42256345	264	PER	Report No. 99262	······································
)	42256346	264	PER	Report No. 99257	
	†	42256347	264	PER	Report No. 102652	<u> </u>
		42256348	264	PER	Report No. 102654	
84-2(b)	Structural chromosomal aberration	42256349	264	PER	Report No. 102655	
		42256350	264	PER	Report No. 99676	
		42256351	264	PER	Report No. 101275	
		42256352	264	PER	Report No. 98573	
84-4	Other genotoxic effects	42256353	264	PER	Report No. 102653	
		42256354	264	PER	Report No. 101999	
		42256355	264	PER	Report No. 87264	
	***************************************	42256356	264	PER	Report No. 87265	
85-1	General metabolism	42256357	264	PER	Report No. 102617	
870.7200	D					N.A. for EP Only
(86-1)	Domestic Animal Safety		-	 	<u> </u>	NA GARDONIA
95-9	Efficaey		<u> </u>	<u> </u>		N.A. for EP Only
	n, Section 158.540			· · · · · · · · · · · · · · · · · · ·		
122-2	Aquatic plant growth			 		N.A.
123-2	Aquatie plant growth			<u> </u>		N.A.
141-1	Honey bee acute contact	i	1	}	1	N.A.



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA	MATRIX - CO	NFIDENT.	IAL VERSION	
Date: September 23	5, 2010		EPA Reg No	/File Symb	ol: 11556-XXX	Page 13 of 18
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			• l ₇	lumethrin Te nidaelopก่ป	PNR1427 Insecticide echnical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 - 18)	Ingredient: Fluncthrin (CAS 69770-45-2) huidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments
141-2	Honcy bee residue on foliage		<u> </u>	<u>T</u>		N.A.
Reentry Protection						
	y Control of the Cont	42256386	264	PER	Report No. 94273	
230-236	Mixer/loader/applicator exposure	43790701	11556	OWN	Report No. 106743	
Environmental Fat	te, Section IS8.290	····•4·······	····!	1		
161-1	Hydrolysis					N.A.
161-2	Photodegradation - water					N.A.
161-3	Photodegradation - soil					N.A.
162-1	Aerobic soil metabolism				······································	N.A.
162-2	Anerobic soil metabolism					N.A.
162-3	Anaerobie aquatie metabolism					N.A.
163-1	Leaching / adsorption/desorption	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				N.A.
164-1	Terrestrial field dissipation	<u> </u>		T		N.A.
165-1	Confined rotational crop					N.A.
165-2	Field rotational crop					N.A.
166-l	Ground water - small prospective					N.A.
None	Environmental fate sommary					N.A.
Residue, Section Is	58.240					
171-4(a)	Nature of residue - plants					N.A.
171-4(b)	Nature of residue - livestock and poultry					N.A.
171-4(c)	Residue analytical method - plants					N.A.
171-4(d)	Residue nnalytical method - animal			ļ		N.A.
171-4(e)	Storage stability			<u> </u>		N,A.
171-4(j)	Magnitude of residues - meat/milk/poultry/egg		- -			N.A.
171-4(k)	Magnitude of residue - crop field trials					N.A.
171-4(I)				L		N.A



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Oivision (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DAT	A MATRIX CO	NFIDENT	IAL VERSION	
Date: September	23, 2010		EPA Reg No			Page 14 of 18
Bayer Health Car Animal Health D P.O. Box 390 Shawnee Missior			• In	lumethrin To nidacloprid	PNR1427 Insecticide echnical (pages 1 -7) Fechnical (pages 8 -14) ecticide (pages 15 - 18)	Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRIÐ Number	Submitter	Status	Rcport Number	Comments
	Magnitude of residue - processed food/feed			1		
171-4(m)	Method validation/ multiresidue method					N.A.
None	Benefits Reports					N.A.
	Dietary Analysis					N.A.



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting hurden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

		DATA	MATRIX - CO	NFIDENT	IAL VERSION	
Date: Septemb	per 23, 2010		EPA Reg No	./File Symb	ol: 11556-XXX	Page 15 of 18
Bayer Health C Animal Health P.O. Box 390 Shawnee Missi			• In	umethrin Te idacloprid î	PNR1427 Insecticide chnical (pages 1-7) Fechnical (pages 8-14) octicide (pages 15-18)	Ingredicut: Flumethriu (CAS 69770-45-2) Inidacloprid (CAS 138261-41-3)
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments

	PNR 1427 In	secticide End-Use	e Produc	t Specific (Pages 1	(5 – 18)
Product Chemis	try, Section 158.240		Patter.		
830.1550	Product identity and Composition	11556	OWN	33752	
830.1600	Description of materials used to produce the product	11556	OWN	33752	
830.1620	Description of production process	11556	OWN	33752	
830.1650	Description of formulation process	11556	OWN	33752	
830.1670	Discussion on formation of impurities	11556	OWN	33752	
830.1700	Preliminary analysis				N.A. TGAI Only
830.1750	Certified of limits	11556	OWN	33752	- 100m
830.1800	Enforcement method	11556	OWN	33752	***************************************
830,1900	Submittal of samples		1		Samples available upon request
830,6302	Color	11556	OWN	33752	
830,6303	Physical state	11556	OWN	33752	
830.6304	Odor	11556	OWN	33752	
830,6313	Stability		···		N.A. – TGAI Only
830.6314	Oxidizing / reducing action				N.A EP not contain an oxidizing or reducing agent
830.6315	Flammability				N.R This product is not considered a combustible liquid, because the closed up flashprint for all the ingredients is > 199°F.
830.6316	Explodability				N.R This product does not contain any explosive ingredients.
830.6317	Storage stability				Pending; Available 3/31/2011
830,6319	Miscibility				N.R This product is not an emulsifiable type



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden lo: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

······		DATA	MATRIX - CO	NFIDENT	AL VERSION			
Date: September	23, 2010		EPA Reg No	PA Reg No,/File Symbol: 11556-XXX Page 16 of 18				
Bayer Health Care, LLC Animal Health Division P.O. Box 390 Shawnee Mission, KS 66201-0390			Product: PNR1427 Iusecticide Fluntethrin Technical (pages 1 -7) Imidacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)		
Guideline Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments		
830.6320	Corrosion characteristics	<u> </u>	-	T	<u> </u>	Pending; Available 3/31/2011		
830.6321	Dielectric breakdown volt		-			N.A Not intended use around electrical equipment		
830.7000	pH					N.A. – product not soluble in water and therefore pi- not required.		
830.7050	UV/Visible absorption			 		N.A. – TGAI Only		
830.7100	Viscosity					N.A. – This product is a solid and viscosity is not applicable.		
830,7200	Melting point					N.A TGAI Only		
830,7220	Boiling point		:			N.A. – TGAI Only		
830,7300	Density, bulk-density, or specific gravity							
830,7370	Dissociation constant in water					N.A. – TGAI Ooly		
830,7 <i>5</i> 20	Particle size, fiber length, and diameter distribution	<u> </u>				N.A. – Nonfiberous product		
830.7550 830.7560 830.7570	Partition coefficient (n-octanol/water)					N.A. – TGAl Only		
830.7840 830.7860	Water solubility					N.A. – TGAI Only		
830.7950	Vapor pressure					N.A. – TGAI Only		
l'oxicology, Secti	ion 158.500	***************************************						
870.1100	Acute oral toxicity - rat		11556	OWN	33854	Waiver request		
870.1200	Acute dermal toxicity		11556	OWN	33855	Waiver request		
870,1300	Acute inhalation toxicity - rat		11556	OWN	33856	Waiver request		
870.2400	Primary eye irritation - rabbit		11556	OWN	33857	Waiver request		
870,2500	Primary dermal irritation		11556	OWN	33749			
870,2600	Dermal sensitization		11556	OWN	33750			
870.6100	Delayed neurotoxicity (acute) - hen	 		 		N.R Not an organophosphate		



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per response for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

	and the form to the address.	DAT	A MATRIX - CO	NFIDENT	IAL VERSION		
Date: September	23, 2010		EPA Reg No	./File Symt	ol; 11556-XXX	Page 17 of 18	
Bayer Health Car Animal Health D P.O. Box 390 Shawnee Mission			Product:			Ingredient: Flumethrin (CAS 69770-45-2) Imidaeloprid (CAS 138261-41-3)	
Guidelinc Reference Number	Guideline Study Name	MRID Number	Submitter	Status	Report Number	Comments	
870.6200	Acute neurotoxicity - rat	·		T		N.R Not an organophosphate	
870.3100	90-day oral - rodent					N.R.	
870.3200	21-day dermal - rabbit/rat	· 				N.R Non-food use	
870.3250	90-day dermal					N.R Collar not affect uptake	
870.7200	Companion animal safety		11556	OWN	33800	Adult cat safety study	
			11556	OWN	33826	Amendment to adult cat study 33800	
			11556	OWN	33805	Adult dog safety study	
			11556	OWN	33806	Puppy safety study	
			11556	OWN	33824	Kitten safety study	
			11556	OWN	33822	Reflector study (puppy)	
			11556	OWN	33823	Reflector study (kitten)	
			11556	OWN	35986	Reflector study (adult cat)	
	<u></u>		11556	OWN	35637	Reflector Study (adult dog)	
	nance, Section 158.400						
810.3300	Treatments to control pests of humans and pets						
			11556	OWN	33801	Fleas and ticks (dogs)	
			11556	OWN	33802	Fleas and ticks (cats)	
			11556	OWN	33803	Efficacy with bathing and water immersion against ticks and fleas	
			11556	OWN	35630	Fleas and ticks [Ixodes ricinis] (cats)	
			11556	OWN	35631	Adult and larvacidal flea control; repellency and tick control (dogs)	
			11556	OWN	35635	Adult and larvacidal fleas, ticks study (cats)	
			11556	OWN	35644	Field studies - fleas and ticks (cats)	
			11556	OWN	35645	Field studies- fleas and ticks (dogs)	



Approved OMB No. 2070-0060

Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 0.25 hours per response for registration activities and .025 hours per tesponse for information, including suggestions for reducing the burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S.W., Washington, DC 20460. Do not send the form to the address.

Date: September	23 2010		A MATRIX CO			Page 18 of 18		
Bayer Health Can Animal Health Di P.O. Box 390	e, LLC	- ARRANGEL	Product: PNR1427 Insecticide Flumethrin Technical (pages 1 -7) Innitacloprid Technical (pages 8 -14) PNR1427 Insecticide (pages 15 - 18)			Ingredient: Flumethrin (CAS 69770-45-2) Imidacloprid (CAS 138261-41-3)		
Guideline Reference Number	Guideline Study Nome	MRID Number	Sobmitter	Status	Report Number	Comments		
······································	Treatments to control posts of pets (cont'd)		11556	OWN	35980	Speed of kill for fleas (cats)		
			11556	OWN	35987	Speed of kill for fleas (dogs)		
			11556	OWN	33464	Ixodes Bridging study		
			11556	OWN	35981	Ticks [Ixodes ricinis] (cats)		
			11556	OWN	35979	Ticks [Ixodes ricinis] (dogs)		
			11556	OWN	35982	Repellency and control of ticks (dogs)		
			11556	OWN	33467	Juvenile Ticks		
	•		11556	OWN	33694	Lice (Trichodectes canis)		
			11556	OWN	33691	Sarcoptic mange		
			11556	OWN	36172	Hair clipping study - Repellency and efficacy		
			11556	OWN	15962	Haîr clipping study		
·			11556	OWN	35642	Scrum and haircoat kinetics in cats		
			11556	OWN	35643	Serum and haircoat kinetics in dogs		
··			11556	OWN	15749	Advantage Efficacy against C. canis		
Aiscellancous								
None	Benefits Document (In the Public Interest)		11556	OWN	33860	Submitted w/ Flumethrin Technical Application		
None	ORE Risk Assessment		11556	OWN	33861			
None	Release Rate Compilation		11556	OWN	35992			
None	Soluble Surface Content of Collar	<u></u>	11556	OWN	35118			

Bayer CropScience



September 7, 2010

Document Processing Desk Office of Pesticide Programs (7505P) U.S. Environmental Protection Agency Room S-4900, One Potomac Yard 2777 South Crystal Drive Arlington, Virginia 22202-4501

Attention: Ms. Venus Eagle (PM 01, RD)

Re: Letter of Authorization: Imidacloprid
Bayer HealthCare LLC, Animal Health Division (BHC) –
Applications for Registration of PNR1427 Insecticide

Dear Ms. Eagle,

Bayer CropScience 2 T.W. Alexander Drive P. O. Box 12014 Research Triangle Park, NC 27709 Tel: 919 549-2000

Bayer CropScience LP (BCS) hereby authorizes the Agency to refer to and rely on any research and/or test data on our active ingredient imidacloprid (the active ingredient in ADMIRE® and PROVADO®) in support of the applications for registration of PNR1427 Insecticide submitted by Bayer HealthCare LLC, Animal Health Division (BHC), P.O. Box 390, Shawnee Mission, KS, 66201-0390.

Furthermore, BCS and BHC are wholly owned subsidiaries of Bayer Corporation. Both companies seek product registrations for products containing the active ingredient imidacloprid. Any confidential business information released by the Agency in data evaluation records or other documents for company number 264 can be disclosed without restriction to the BHC, company number 11556. In addition, the Agency is authorized to refer to any research and/or test data submitted under company number 264 in support of applications for registration from Bayer HealthCare LLC, Animal Health Division (BHC), company number 11556.

Please contact me at <u>jamin.huang@bayercropscience.com</u> or at 919-549-2634 if you have any questions regarding this submission.

Sincerely,

Jamin Huang, Ph.D.

Senior Regulatory Manager

CC: Doug Spilker, Ph.D., Bayer HealthCare LLC, Animal Health Division

Doug Spilker/SHAWN /AGCHEM/US/B AYER 08/14/2009

07:53 AM

To suarez.mark@epa.gov

cc alexander.bewanda@epa.gov, davis.kable@epa.gov, Wendell

Davis/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES

bcc Bruce

Martin/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES; Anja Hoelscher/TGAHL/AH/DE/BAYER@BAYERNOTES;

Jagdeep

Buch/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES;

Fiona

McLellan/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOT

ES

Subject Pet Collar - Deer Tick Protocol - Issue for PERC

Dear Mark.

Thank you for your comments in the reviews of the 4 efficacy protocols for our pursuit of the registration of a dog/cat collar. However, we still need clarification regarding the protocol for the efficacy trial against the deer tick (Ixodes scapularis.) The purpose of this email is to request the Agency (via PERC) to reconsider the study requirements as outlined in your review, due to the lack of availability of Ixodes scapularis ticks, which is a serious problem. It will be discussed in more detail later. We feel our proposal will adequately generate the efficacy data needed to meet the performance requirement on this tick.

This is in reference to:

Product Performance/Efficacy Protocol Review

Study Title: "Efficacy of Imidacloprid + Flumethrin Collar Against Nymph and Adult

Ixodes scapularis." MRID 47718501

Mark Suarez, Entomologist

Date: 15 May 2009 Decision#: 408237 DP Barcode: 364030

Action: R272

To summarize:

- A. Bayer AH participated in Pre-reg Meeting with the Agency, March 19, 2009, to discuss efficacy requirements.
- Our understandings from the meeting are contained in the meeting minutes attached.
- We are conducting the appropriate studies to get a general tick claim.
- We understood that it would be possible to conduct an in vitro study to secure a "kills deer ticks (Ixodes scapularis)" claim, but that we should submit a protocol for review.
- The review of the protocol indicated a much more robust study than we anticipated, nor was proposed in our Pre-registration meeting.
- B. Initial proposal (in the submitted protocol) for the *Ixodes scapularis* (Deer Tick) study for the Imidacloprid/Flumethrin collar:
- The study is based on a protocol method from PLRS (Corapeake, NC) for in vitro
 efficacy evaluation of deer ticks.
- The study would be conducted at BerTek (Greenbrier, AR).
- Two dogs were to be utilized in the study: One treated (receiving a collar) and one untreated.
- For each deer tick efficacy evaluation, hair is collected from multiple sites on the body

- of the dogs.
- After the hair collected, it is split into six Petri dishes (six replicates per dog; the
 experimental unit for the study is the Petri dish).
- Deer ticks are added to the dishes (10 ticks to each dish), and efficacy evaluated in 48 hours.
- The first evaluation for efficacy was scheduled on Day 16 (tick count day), and then monthly for 8 months.
- C. Based on the comments received from EPA (review and follow-up email, dated 5/29/09), we offer the following for Agency consideration:

1. Protocol Proposal

- The following steps would be added to the study:
 - a) an *in vitro* efficacy evaluation of hair from the dogs would be conducted pre-treatment (i.e. pre-qualification).
 - b) the first tick efficacy evaluation would be moved to Day 7 (tick count day).
- Consideration of the lack of tick availability:
 - a) This is the limiting factor in conducting *Ixodes scapularis* (Deer Tick) studies, and would prohibit us from conducting such a robust study as you requested any time in the near future.
 - b) There is only one major supplier of Ixodes ticks in the U.S. Oklahoma State University, and the ticks from OSU are not available until mid- to late 2011 (due to demand for the ticks and the difficulty in rearing them).
 - d) We have been able to secure a smaller number of ticks from the CDC to conduct the proposed *in vitro* efficacy study.

2. Alternative Bridging Proposal

We will have available appropriate efficacy tests with the collar for the control of a similar European tick species, *Ixodes ricinus*. As an alternative to the proposed protocol, would the Agency entertain the use of these data to support a deer tick claim, if we were able to provide an *in vitro* bridging study to show that efficacy was equivalent between *Ixodes ricinus* and *Ixodes scapularis*?

As you suggested, we are requesting that this issue be taken to the PERC for discussion and decision. We ask that you discuss both the: a) modified protocol and b) use of surrogate data with a bridging study, and provide us guidance. A prompt response would be appreciated.

Best regards,

Doug Spilker

Douglas Spilker, Ph.D. Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH Office: +1 913-268-2751

Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address: P.O. Box 390 Shawnee Mission, KS 66201-0390 Country: USA

Bayer Animal Health "Powered by People, Driven by Science"



PreReg Efficacy Minutes 0309 Collar,pdf



Suarez.Mark@epamail.epa.g οv

To Doug Spilker <doug.spilker.b@bayer.com>

10/07/2009 03:49 PM

CC bcc

Subject Re: Fw: Pet Collar - Deer Tick Protocol - Issue for PERC

History:

This message has been forwarded.

Doug,

The PERC discussed your tick issue today. In brief, we arrived at the following:

You must test Ix. scapularis to make claims against vectors of Lyme disease, as this is the primary vector.

If you test brown dog ticks, lone star ticks, and Ix. ricinus (with supporting bridging data for scapularis), you can make a general tick claim.

If you test on brown dog and lone star ticks, you may make claims against only those ticks.

I hope that this helps. Let me know what you want to do. I think that we still need to iron out the protocol to ensure that you have an adequate study design. But, I'll leave it to your discretion. You may feel that my previous review provided adequate direction.

Regards, Mark

Mark E. Suarez, Entomologist Insecticide Branch Registration Division (7505P) Office of Pesticide Programs Environmental Protection Agency 1200 Pennsylvania Avenue, NW Washington, DC 20460

(703)305-0120 suarez.mark@epa.gov

į	> From: >	
>- !	Doug Spilker <doug.spilker.b@bayer.com></doug.spilker.b@bayer.com>	
i	To:	

|Mark Suarez/DC/USEPA/US@EPA -----| Cc: | |BeWanda Alexander/DC/USEPA/US@EPA, Richard Gebken/DC/USEPA/US@EPA 1----> 1 Date: 1----> |110/06/2009 03:51 PM >------_____ | Subject: | >------|Fw: Pet Collar - Deer Tick Protocol - Issue for PERC

Dear Mark,

As you requested in our meeting today, please find below more information regarding the bridging study that we propose to use to support our Ixodes claim (see item 2c - "Alternative Bridging Proposal" in email attached) .

The methods of the Ixodes in vitro testing:

1) The in vitro test is a coated glass surface test

ì

- 2) The testing will be conducted with flumethrin only (that is the active ingredient that kills ticks)
- 3) A dose response test will be conducted with both Ixodes species (Ixodes scapularis and Ixodes ricinis) to determine LD50/LD95

- 4) Two strains of Ixodes scapularis will be used and one strain of Ixodes ricinis
- 5) Each trial will have three replicates and the trial will be repeated (two trials)
- 6) A positive outcome will be if the LD50/LD95 for Ixodes scapularis is equal to or more sensitive to flumethrin compared to Ixodes ricinis
- 7) We will have in vivo studies demonstrating the efficacy of the collar against Ixodes ricinis, and this will support the efficacy against Ixodes scapularis

Please let me know if you need additional information. We look forward to a response from the PERC meeting that you have tomorrow.

Best regards,

Doug Spilker, Ph. D. Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH Office: +1 913-268-2751

Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address:

P.O. Box 390 Shawnee Mission, KS 66201-0390 Country: USA

Bayer Animal Health "Powered by People, Driven by Science"

---- Forwarded by Doug Spilker/SHAWN/AGCHEM/US/BAYER on 10/06/2009 02:38 PM ----

To: suarez.mark@epa.gov

alexander.bewanda@epa.gov, davis.kable@epa.gov, Wendell Davis/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES

Pet Collar - Deer Tick Protocol - Issue for PERC Subject:

Dear Mark,

Thank you for your comments in the reviews of the 4 efficacy protocols for our pursuit of the registration of a dog/cat collar. However, we still need clarification regarding the protocol for the efficacy trial against the deer tick (Ixodes scapularis.) The purpose of this email is to request the Agency (via PERC) to reconsider the study requirements as outlined in your review, due to the lack of availability of Ixodes scapularis ticks, which is a serious problem. It will be discussed in more detail later. We feel our proposal will adequately generate the efficacy data needed to meet the performance requirement on this tick.

This is in reference to:

Product Performance/Efficacy Protocol Review Study Title: "Efficacy of Imidacloprid + Flumethrin Collar Against Nymph and Adult Ixodes scapularis." MRID 47718501

Mark Suarez, Entomologist

Date: 15 May 2009 Decision#: 408237 DP Barcode: 364030

Action: R272

To summarize:

Bayer AH participated in Pre-reg Meeting with the Agency, March 19, 2009, to discuss efficacy requirements. Our understandings from the meeting are contained in the meeting minutes attached. We are conducting the appropriate studies to get a general tick We understood that it would be possible to conduct an in vitro study to secure a "kills deer ticks (Ixodes scapularis)" claim, but that we should submit a protocol for review. The review of the protocol indicated a much more robust study than we anticipated, nor was proposed in our Pre-registration meeting.

- Initial proposal (in the submitted protocol) for the Ixodes scapularis (Deer Tick) study for the Imidacloprid/Flumethrin collar: The study is based on a protocol method from PLRS (Corapeake, NC) for in vitro efficacy evaluation of deer ticks. The study would be conducted at BerTek (Greenbrier, AR). Two dogs were to be utilized in the study: One treated (receiving a collar) and one untreated. For each deer tick efficacy evaluation, hair is collected from multiple sites on the body of the dogs.
 After the hair collected, it is split into six Petri dishes (six replicates per dog; the experimental unit for the study is the Petri dish). Deer ticks are added to the dishes (10 ticks to each dish), and efficacy evaluated in 48 hours. The first evaluation for efficacy was scheduled on Day 16 (tick count day), and then monthly for 8 months.
- Based on the comments received from EPA (review and follow-up email, dated 5/29/09), we offer the following for Agency consideration:
- Protocol Proposal l.

The following steps would be added to the study: an in vitro efficacy evaluation of hair from the dogs

- would be conducted pre-treatment (i.e. pre-qualification). the first tick efficacy evaluation would be moved to
- Day 7 (tick count day).

Consideration of the lack of tick availability:

- This is the limiting factor in conducting Ixodes scapularis (Deer Tick) studies, and would prohibit us from conducting such a robust study as you requested any time in the near future.
- There is only one major supplier of Ixodes ticks in the U.S. - Oklahoma State University, and the ticks from OSU are not available until mid- to late 2011 (due to demand for the ticks and the difficulty in rearing them).
- We have been able to secure a smaller number of ticks from the CDC to conduct the proposed in vitro efficacy study.
- Alternative Bridging Proposal

We will have available appropriate efficacy tests with the collar for the control of a similar European tick species, Ixodes ricinus. As an alternative to the proposed protocol, would the Agency entertain the use of these data to support a deer tick claim, if we were able to provide an in vitro bridging study to show that efficacy was equivalent between Ixodes ricinus and Ixodes scapularis?

As you suggested, we are requesting that this issue be taken to the PERC for discussion and decision. We ask that you discuss both the: a) modified protocol and b) use of surrogate data with a bridging study, and provide us guidance. A prompt response would be appreciated.

Best regards,

Doug Spilker

Douglas Spilker, Ph.D. Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH Office: +1 913-268-2751

Office: +1 913-268-2751 Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address:

P.O. Box 390

Shawnee Mission, KS 66201-0390

Country: USA

Bayer Animal Health "Powered by People, Driven by Science"

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

For alternate languages please go to http://bayerdisclaimer.bayerweb.com [attachment "PreReg Efficacy Minutes 0309 Collar.pdf" deleted by Mark Suarez/DC/USEPA/US]



Suarez.Mark@epamail.epa.go

10/15/2009 11:37 AM

To Doug Spilker <doug.spilker.b@bayer.com>

cc Davis.Kable@epamail.epa.gov, Gebken.Richard@epamail.epa.gov

bcc

Subject Re: PERC Ixodes Discussion

History:

This message has been forwarded.

Doug,

After discussion with the PERC, we are not inclined to consider Ix. ricinus as a substitute for Ix. scapularis. A better option would be to use wild caught Ix. scapularis from an area known to have a low incidence of Lyme disease.

Regards, Mark

Mark E. Suarez, Entomologist
Insecticide Branch
Registration Division (7505P)
Office of Pesticide Programs
Environmental Protection Agency
1200 Pennsylvania Avenue, NW
Washington, DC 20460

(703)305-0120 suarez.mark@epa.gov

From:

Doug Spilker <doug.spilker.b@bayer.com>

To:

Mark Suarez/DC/USEPA/US@EPA

Cc:

Kable Davis/DC/USEPA/US@EPA, Richard Gebken/DC/USEPA/US@EPA

Date:

10/07/2009 06:59 AM

Subject:

PERC Ixodes Discussion

Mark,

Just a thought. I am in the Residential Exposure SAP in the first floor conference room until 3:00pm today (Wed.) If the PERC needs me for more information, don't hesitate to come get me.

Doug

Doug Spilker
Manager - EPA Reg. Affairs
BAYER HEALTHCARE LLC
ANIMAL HEALTH

Office: +1 913-268-2751 Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address: P.O. Box 390 Shawnee Mission, KS 66201-0390 Country: USA

Bayer Animal Health "Powered by People, Driven by Science"

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

For alternate languages please go to http://bayerdisclaimer.bayerweb.com

Attachment 6

Doug Spilker/SHAWN/AGCH EM/US/BAYER 06/04/2009 03:45 PM To alexander.bewanda@epa.gov

CC Dan Ciszewski/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOT ES, Harish Chopade/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOT ES, Jagdeep Buch/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES

bcc Bruce Martin@BAYER-US-NOTES; Andrea
Hentges/TGHEN/AH/DE/BAYER@BAYERNOTES; Dorothee
Stanneck/VTBAT/AH/DE/BAYER@BAYERNOTES; Anja
Hoelscher/TGAHL/AH/DE/BAYER@BAYERNOTES;
Douglas
Hutchens/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOT

Subject Domestic Animal Safety Teleconference (DRAFT minutes) -

Dear Ms. Alexander,

Thank you for your time this morning for the subject teleconference. It was agreed in the teleconference that Bayer did not need to submit formal reflector protocols for EPA review. The generation of an accurate set of minutes, reviewed and concurred by the EPA, would be sufficient. Therefore, please find attached the respective meeting minutes for the Agency's concurrence.

6/4/09

However, please note, there was one item that was not discussed, which we have listed in the "Variables of Interest" - Chemical analysis of the collars. It was our assumption, although not specifically stated, that chemical analysis of the collars would not be required. We would like confirmation of this, as well.

Best regards,

Doug

Doug Spilker, Ph.D. Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH Office: +1 9 t3-268-275 t Mobile: +1 816-506-3 t02

Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address: P.O. Box 390 Shawnee Mission, KS 66201-0390 Country: USA

Bayer Animal Health "Powered by People, Driven by Science"



EPA Mtg 2009 June 4 Flu + Imid Collar DAS.doc

Bayer HealthCare Animal Health Division



Bayer HealthCare LLC Animal Health Division

Date:

June 4, 2009

File Reference:

EPA Mtg 2009 June 4 Flu + Imid Collar DAS.doc

Subject:

Teleconference between Bayer Animal Health and EPA - Insecticide/Rodenticide Branch &

Technical Review Branch, June 4, 2009; Proposed Domestic Animal Safety Requirements

for Flumethrin + Imidacloprid Collar

From:

Douglas A. Spilker

Phone:

913-268-2751

To:

Ms. BeWanda

EPA, Registration Branch (Team 13)

Alexander

Attendees:

EPA (Agency) – BeWanda Alexander, Byron Backus (TRB)

Bayer Animal Health (BAH) - Dan Ciszewski, Harish Chopade, Jagdeep Buch, and

Doug Spilker

A. PURPOSE OF THE MEETING: The teleconference was requested by BAH with the topics for discussion to include:

- 1. Concurrence of Minutes from Our Teleconference of March 11, 2009 We are in the process of developing the four protocols for Agency review. We would like some assurance that we have not misunderstood the Agency's recommendations on these topics/studies.
- 2. Effect of Reflectors on Collar AI Release Study Due to a delay in the availability of the final reflectors, we have been notified that they will not be available before the anticipated start of the discussed Domestic Animal Safety studies. As mentioned above, we are in the process of developing the four protocols, and now realize that it will not be possible to include the respective treatments, as recommended by Dr. Backus in our teleconference of March 11th. Therefore, BAH requests guidance from EPA on how to accomplish the goal in a separate study.
- **B.** BACKGROUND: End-product reflectors will not be available for use until early 2010. As a result, we will be unable to evaluate the effect of the reflectors on the release of the active ingredients (AIs) from the collar in conjunction with the 4 guideline (dog, cat, puppy, and kitten) safety studies. Therefore, the effect of reflectors on AI release will need to be evaluated in adjunct studies that are separate from the 4 guideline (dog, cat, puppy, and kitten) safety studies. The following represents the discussions and agreements that took place during the teleconference.

C. PROPOSAL: Adjunct studies to evaluate the effect of reflectors on AI release

• Subgroups: Bayer proposed that reflector studies be conducted in adult dogs and adult cats. This proposal was based on the assumption that adults, being more active than pediatrics, would generate more vigorous interaction between the reflectors and collars. EPA was willing to accept this proposal provided that our assumption was verified by chemical analysis of the collar results from the 4 guideline studies. To keep things simple, Bayer agreed to conduct separate reflector studies in healthy dogs, cats, puppies, and kittens. EPA indicated that strict age requirements, for puppies (7 weeks ± 1 day) and kittens (10 weeks ± 1 day), would not apply to the reflector studies.

Treatment Groups and Animals per Group:

Group 1 (n=2): single collar only

Group 2 (n=2): single collar plus 3 reflectors

Study Duration: 30 days

Variables of Interest:

Pre-study physical examinations

Pre-study and post-study collar weights (x.xx gms)

Daily clinical (systemic) observations

Daily local observations

Pre-study and post-study animal body weights

Hematology and clinical chemistry would not be required.

Chemical analysis of the collars will not be required. [PLEASE NOTE: This was not discussed in the teleconference.]

- Proposed initiation date of the reflector studies: QI, 2010
- Results: Compare the pre- and post-study collar weights between the groups. Similar differences
 in the pre- and post-study collar weights, in both groups, would suggest that interaction of
 reflectors with collars does not increase exposure to AI.
- EPA agreed that Bayer did not need to submit formal reflector protocols for EPA review. The
 generation of an accurate set of minutes, reviewed and concurred to by the EPA, would be
 sufficient.

D. Action items/EPA Guidance Regarding Proposal for Adjunct Reflector-Collar Study

- 1) EPA finds the conduct of a separate (adjunct) study acceptable.
- 2) BAH should prepare minutes for the Agency's confirmation of the understandings from this teleconference, and send via Ms. Alexander for distribution to Dr. Backus.
- 3) BAH will submit the four guideline study protocols for review via individual PRIA actions: a) kitten, b) adult cat, c) puppy, and d) adult dog. The PRIA review timeline is 90 days. A separate electronic submission of the WORD versions of the protocols could be helpful to the Agency during their review preparation.
- 4) BAH requested, if possible, that the Agency gives priority to the review of the pediatric study protocols ahead of the adult studies.

Page 2 of 2 189

Note to Reg. Book:

Date:

June 9, 2009 (~12:30 CDT)

From:

D. A. Spilker

What:

Telephone record

Subject:

EPA Response to our DRAFT minutes of the Domestic Animal

Safety teleconference (flumethrin + imidacloprid collar) of

March 11, 2009

BeWanda Alexander (RB) and Byron Backus (TRB) of EPA called to give us feedback on the subject meeting minutes submitted to them on May 8, 2009. They had promised to do so, in our telecom of June 4th. I suggested that Harish Chopade join the telephone call (and he did), so they could discuss any questions.

Dr. Backus said everything was okay on the minutes, and that they were a good representation of the discussion. He did, however, ask that the statistical analysis (as described in the BAH-developed attachment to the draft minutes) be altered in the proposed protocols to combine the respective two control groups to allow for more robust comparisons with the treatment groups. Harish Chopade recorded additional details.

When asked about the chemical analysis of the collars in the reflector study (see email of June 4th), he said that chemical analysis would not be needed in the reflector adjunct study unless there was a significant weight loss [i.e. in reflector treatment]. Dr. Backus said: "Just off the top of my head, I would say ≥10% weight loss would be significant."

Das 061009

Attachment 7

Bayer Health Care Animal Health Division



Bayer HealthCare LLC Animal Health Division

Date:

May 8, 2009

File Reference:

EPA Mig 2009 Mar I I Flu + Imid Collar DAS.doc

Subject:

Teleconference between Bayer Animal Health and EPA - Insecticide/Rodenticide Branch &

Technical Review Branch, March 11, 2009; Proposed Domestic Animal Safety

Requirements for Flumethrin + Imidacloprid Collar

From:

Douglas A. Spilker,

Phone:

913-268-2751

Ph.D.

To:

Ms. BeWanda

EPA, Registration Branch (Team 13)

Alexander

Attendees:

EPA (Agency) – BeWanda Alexander, Richard Gebken (PM), Byron Backus (TRB)

Bayer Animal Health (BAH) - Dan Ciszewski, Harish Chopade, Lisa Lowseth, Bruce

Martin, Mary Hunt, and Doug Spilker

A. Purpose of Meeting

The teleconference and discussion basically followed the handout order (see attached document, 4 pp.). The purpose of this meeting was to discuss with the Agency the study/data requirements to support the submission of an application for registration of a flumethrin + imidacloprid combination dog/cat flea and tick collar. Domestic Animal Safety data requirements for a spot-on formulation were previously discussed in a Pre-registration meeting with the Agency on October 11, 2006. However, due to the change in proposed formulation from a spot-on to a collar, this additional discussion was warranted due to the fact that some of the studies might not be possible due to the nature of the active ingredient and/or formulation. Please find below Bayer Animal Health's understandings from the teleconference, and the request for the Agency's concurrence on these points.

B. Study Design

Bayer indicated that the proposed studies were designed to satisfy the requirements contained in OPPTS 870.7200. However, as Bayer plans to use these safety studies to satisfy the regulatory requirements of

several different governmental agencies (EPA/USA and EMEA/EU), the Agency representatives will notice that the proposed designs sometime exceed EPA standards. The testing requirements of the EMEA, described in VICH GL 43 (Target Animal Safety for Veterinary Products), occasionally supplant the EPA guidelines and vice-versa.

)

Bayer provided outlines that described the design of collar safety studies in 2 distinct age/size groups of companion animals: Pediatrics (pupples & kittens / less than or equal to 8 kg body wt) and Adults (dogs & cats / greater than 8 kg body wt) [see pp 3 - 6]. During the teleconference, the outlines were addressed and discussed on a line-by-line basis. In general, the Agency accepted many of the design proposals described in Bayer's 2 study outlines. However, all recommendations, and/or revisions to the original outlines, expressed by the Agency during the teleconference, are presented below:

Pediatrics (puppies & kittens)

- Treatment Groups and Animal Numbers/Group: EPA recommended use of the limit test (deletion of the 3x group) only if we were confident that no adverse effects would develop in the 5x puppies/kittens. However, the limit design will not be used in the pediatric studies as a 3x pediatric group is an EMEA requirement.
- Chemical Analysis: Prior to use in studies, each batch of collars will have a certificate of analysis for the percentage (w/w) of imidacloprid and flumethrin contents. The proposed study designs for EPA teleconference had called for chemical analysis of the collars for residual imidacloprid and flumethrin contents after their use only in the adult dogs and cats; chemical analysis of the collars in the pediatric studies was not proposed. EPA, however, indicated that collars must be analyzed for the residual contents of the two active ingredients in both the pediatric and adult studies so that accurate exposure rates can be determined in both age groups and species. Bayer agreed to do that.
- Chemical Analysis Procedure: With regards to chemical analysis of the collars in each study, the EPA recommended weighing individual collars at the beginning and then after their use at each collar application interval. For each collar application interval in a study, collars from one male and one female showing the maximum chemical exposure [calculated as collar wt loss (g) ÷ body weight (kg)] should be analyzed for imidacloprid and flumethrin contents. As agreed to by the Agency, a batch analysis of the collar from each selected animal will be performed with the Bayer analytical method (HPLC with UV detection).

<u>Clinical Signs:</u> If localized hair loss develops in some puppies and kittens, presumably due to the
physical irritation associated with multiple collars (5) applied in a single layer, EPA advised us to
maintain these animals following official study termination (day 180), apply one collar, and
document whether or not resolution of the local irritation/hair loss occurs.

Adults (dogs & cats)

• Necropsy of study animals is required by the EPA only in the event of severe (life-threatening) reactions or death. Although not anticipated, the EMEA has indicated that the necropsy of all surviving 0x and 5x cats may become necessary if multiple non-life threatening adverse reactions develop in several adult cats. Additionally, if gross and /or microscopic lesions are identified in adults at necropsy, post-mortem examination of the kittens may also be required by EMEA. If general necropsies of the adult cats and kittens are required by EMEA, EPA requests that EMEA's decision be documented via protocol amendment.

C. Consideration of testing with Reflector Device (components = clip and reflector)

- Bayer indicated that collars may be packaged with 3 reflectors. The collar and reflectors will be
 in separate bags, but both bags will be contained within a single product box. Owners will have
 the option of affixing these reflectors to their pet's flea and tick collar.
- Bayer proposed to conduct the companion animal safety studies without reflectors in order to create conditions of maximum exposure.
- EPA proposed incorporation of an additional 1x group (n=4) to each study. For 30 days, two animals would wear a single collar without reflectors, while two different animals would each wear a single collar affixed with 3 reflectors. The collars would be weighed before application and again at the conclusion of the 30-day period. Similar pre- and post-test weights would suggest that interaction of the reflectors with the collar does not increase exposure rates.

D. Other information

During the teleconference, reference was made to the previous general pre-registration meeting on this project (March 4, 2009; D. Spilker with B. Alexander, R. Gebken and B. Backus). In the aforementioned meeting, the list of required toxicology studies [based on HED concurrence; March

14, 2007] shown did not include a chronic dog study, since this study is not required for a residential indoor use pattern. At that meeting, Dr. Backus inquired regarding the availability of a sub-chronic or chronic dog study with technical flumethrin. He inferred that these studies might be useful, if the duration of the domestic animal safety study was not adequate. In the subject teleconference, Bayer informed the Agency of the availability of two 90-day feeding studies in dogs. However, since BAH plans to conduct the domestic animal safety studies for the full duration of the label claim (6 months), this exposure duration should be adequate for the Agency to assess long-term exposure to flumethrin. However, BAH plans to submit these supplemental studies with our application for registration.

E. Action items/EPA Guidance

- 1) BAH should prepare minutes for the Agency's confirmation of the understandings from this teleconference, and send via Ms. Alexander for distribution within the Agency.
- 2) BAH will submit four protocols for review via individual PRIA actions: 1) kitten, 2) adult cat, 3) puppy, and 4) adult dog.

Attachment: "Companion Animal Safety Testing" [Document used for discussion purposes in teleconference of March 24, 2009; (4pp.)]

Das 050809

Flumethrin Technical Isomer Ratio

Flumethrin Technical is 96.2% flumethrin by weight (nominal percent of flumethrin trans-Z1 + trans-Z2 isomers). The trans-Z1 isomer is present from 54-66% and the trans-Z2 isomer is present from 34-46%. Following are some examples of how the isomer ratio could be expressed on the product label. We request the EPA's guidance on how the agency would like to see the isomer ratio expressed on the product label.

- 1) flumethrin 4.5%*
 *isomer ratio: 60:40, trans-Z1:trans-Z2
- 2) flumethrin 4.5%* *isomer ratio: 54-66% trans-Z1, 34-46% trans-Z2
- 3) flumethrin 4.5%*
 *isomer ratio: 60% trans-Z1, 40% trans-Z2
- 4)¹ flumethrin 4.5%* *isomer ratio: 2.4-3.0% trans-Z1, 1.5-2.1% trans-Z2
- 5)² flumethrin 4.5%* *isomer ratio: 2.7% trans-Z1, 1.8% trans-Z2
- 6)³ flumethrin 4.5%* *isomer ratio: 2.7:1.8, trans-Z1:trans-Z2

Absolute ratio of trans-Z1:trans-Z2

Absolute percent ranges of each isomer in the product based on the nominal percent flumethrin in the product.

Absolute percent of each isomer in the product based on the nominal percent flumethrin in the product,

Ecto Development Corporation Date Typed: February 25, 2009

Supersedes: None

Ecto Protocol number: M915P03 Ecto Study Number: M915S03

Page 7 of 8

PROTOCOL

Exhibit A

PHYSICAL AND CHEMICAL PROPERTIES TEST REQUIREMENTS

Section and Title	Test Substance <u>End Use Product</u> (Test Method SOP#/REF#)
63-2 (830-6302) Color:	YES (SOP126)
63-3 (830-6303) Physical State:	YES (SOP126)
63-4 (830-6304) Odor:	YES (SOP126)
63-5 (830-7200) Melting Point:	N/A* (1)
63-6 (830-7220) Boiling Point:	N/A*(1)
63-7 (830-7300) Density, bulk density, or specific gravity:	YES (SOP129)
63-8 (830-7840) Solubility: (830-7860)	N/A*(1)
63-9 (830-7950) Vapor Pressure:	N/A*(1)
63-10 (830-7370) Dissociation Constant:	N/A*(1)
63-11 (830-7550) Octanol/water partition coefficient	N/A*(1)
63-12 (830-7000) pH:	N/A*(2)
63-13 (830-6313) Stability:	N/A*(1)
63-14 (830-6314) Oxidation or reducing:	Will not act as an oxidizing or reducing agent
63-15 (830-6315) Flammability - flashpoin (combustible liquids only	
63-16 (830-6316) Explodability:	N/A*(4)
63-17 (830-6317) Storage Stability:	N/A*(5)
63-18 (830-7100) Viscosity: (Liquids Only)	N/A*(9)
63-19 (830-6319) Miscibility: (emulsifiable liquids and is to be diluted with petroleum solvent)	N/A*(6)

^{*} N/A = Not Applicable

Ecto Development Corporation Date Typed: February 25, 2009

)

Supersedes: None

Ecto Protocol number: M915P03 Ecto Study Number: M915S03

Page 8 of 8

PROTOCOL

PHYSICAL AND CHEMICAL PROPERTIES TEST REQUIREMENTS (continued)

Test Substance

Section and Title End Use Product (Test Method SOP#/REF#)\

63-20 (830-6320) Corrosion characteristics:

N/A*(8)

(when packaged in metal, plastic or paper containers)

63-21 (830-6321) Dielectric breakdown voltage: (yes if for use around electrical equipment)

N/A*(7)

61-3 (830-1670)Formation of unintentional ingredients during manufacturing

Not likely to form unintentional ingredients

during manufacturing

- Per 40 CFR 158.190 This test is only required on Technical grade of active ingredient and not for end use product.
- 2) Per 40 CFR 158.190, This product is not soluble in water and pH of the test substance is not required.
- 3) Per 40 CFR 158.190; 63-15(a) This product is not considered a combustible liquid, because the closed cup flashpoint for all the ingredients is greater than 199E F.
- 4) Per 40 CFR 158.190; 63-16(a) This product does not contain any explosive ingredients.
- 5) Per 40 CFR 158.190; 63-17 This is a study to support stability of the product in the market container. Stability is not part this study but will done under a separate study.
- 6) Per 40 CFR 158.190; 63-19(a) This product is not an emulsifiable concentrate type product.
- 7) Per 40 CFR 158.190; 63-21(a) This product is not intended for use around electrical equipment.
- 8) Per 40 CFR 158.190; 63-20 This is a study to support corrosion of the product in the market container and not part of his study but done under a separate study.
- 9) Per 40 CFR 158 190, 63-18. The product is a solid and viscosity is not applicable

^{*} N/A = Not Applicable

Attachment 2

Inert ingredient information may be entitled to confidential treatment



Grinstead.Keri@epamaii.epa. gov

09/15/2008 06:28 PM

To Doug Spilker < doug.spilker.b@bayer.com>

oc bcc

Subject Re: Inert determination - Non-Food uses

History:

This message has been replied to and forwarded.

Hi Doug,



Here are some general instructions for submitting a new nonfood inert ingredient request and supporting data/discussion to the Inert Ingredient Assessment Branch (IIAB). There is currently no fee associated with a new nonfood inert ingredient request and the review time for a complete/adequate submission is approximately 6-12 months, dependent upon how many requests are ahead of you in the queue. (Note: Submissions of new conventional product registrations or amendments are not accepted until the inert is approved)

Your submission package should include a request letter and any/all supporting data/discussion. The request letter should be used as the cover letter for the submission and needs to include (1) Subject line that reads "Request for Approval of a New Nonfood Use Inert Ingredient: [insert your chemical name and CAS Reg. No.]", (2) Summary details of your request (description, proposed use, etc.), and (3) A list of studies you are submitting with your package in support of your request.

The information typically used by the Agency to make a decision for these types of requests includes: physical/chemical properties, toxicity data (from animal studies), environmental fate and effects data, ecotoxicity data, as well as your discussion of anticipated exposure from your proposed use of this chemical and your discussion of how, based on the overall toxicity profile of the chemical, your proposed use of the chemical would be considered safe for human health and the environment.

We may also consider other publicly available information from review programs such as High Production Volume Challenge Program, IUCLID

datasets, OECD SIDS, etc., as well as other publicly available, peer-reviewed literature. Information on surrogate chemicals and structure activity relationships may also be considered.

All study data need to be included in your submission package. Please be aware that there are standard data format requirements for all study data submitted to the Agency under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and Certain Provisions of the Federal Food, Drug, and Cosmetic Act (FFDCA). These requirements are outlined in (PR) Notice 86-5. For your reference, a link to this Notice is provided below. Submitted data packages that do not conform to these requirements may be returned to the submitter for necessary revision.

http://www.epa.gov/PR_Notices/pr86-5.html

Upon receipt, IIAB screens all submission packages for completeness. Only those packages deemed complete are placed in queue for IIAB review. Submissions are placed in the review queue in the order they are deemed complete. You will be notified of any deficiencies.

All submissions to IIAB need to be received and processed by our Document Processing Desk. Please use the addressing instructions below. **Please note** the address is different depending on the type of delivery service you plan to use.

Address for U.S. Post Office deliveries ONLY:

Inert Ingredient Assessment Branch/Registration Division Office of Pesticide Programs
Document Processing Desk (Mail Code 7504P)
U.S. Environmental Protection Agency
1200 Pennsylvania Avenue, NW
Washington DC, 20460

Address for FedEx, UPS, DHL, Courier Deliveries ONLY:

Inert Ingredient Assessment Branch/Registration Division Office of Pesticide Programs
Document Processing Desk, 4th Floor Room S-4900
U.S. Environmental Protection Agency
2777 South Crystal Drive
Arlington, VA 22202

Please let me know if you have any questions or need further clarification.

Thanks,

Keri

Doug Spilker <doug.spilker.b@bayer.com>

09/15/2008 12:32 PM Keri Grinstead/DC/USEPA/US@EPA

CC

Subject

Inert ingredient information may be entitled to confidential treatment

)

Inert determination - Non-Food
uses

Hi Keri,

It was good to talk with you this morning. Thanks for the guidance on how to proceed with our questions. Please find below two inert ingredients we would like to use in a NON-FOOD USE product. Would you please check to see if these can be used, and if not - would you please provide us with guidance on what we would need to provide to EPA to get these approved for NON-FOOD USE by EPA?

Again, if I can do anything to facilitate getting the information you need to evaluate please do not hesitate to call.

Thanks, Doug

Doug Spilker, Ph.D. Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH

Office: +1 913-268-2751 Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address: P.O. Box 390

Shawnee Mission, KS 66201-0390

Country: USA

Bayer Animal Health "Powered by People, Driven by Science"

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

Attachment 3

Doug Spilker/SHAWN/AGCHEM/US /BAYER

04/13/2009 10:49 AM

To alexander.bewanda@epa.gov

cc Lisa

Lowseth/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTE S, Bruce

Martin/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES

bcc Mary

Hunt/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES; Jagdeep

Buch/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES;

Douglas

Hutchens/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOT

EŞ

Subject Minutes of Pre Reg Meeting (03/30/09) - Collar - Acute

Toxicity Requirements

Dear Ms. Alexander,

One of the action items from the Pre-registration meeting (subject - Acute Toxicity Requirements) of March 30, 2009 between Bayer Animal Health and the Agency was for us to prepare and submit meeting minutes containing our understandings from the meeting. Therefore, please find attached the respective minutes from the subject meeting, and the attachment we used during the discussion.

We ask for the Agency's review and concurrence that our understandings from the pre-registration meeting are correct. If there are any misunderstandings or inaccuracies, we ask that you let us know as soon as possible.

Best regards,

Doug

Doug Spilker Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH

Office: +1 913-268-2751 Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address: P.O. Box 390

Shawnee Mission, KS 66201-0390

Country: USA

Bayer Animal Health "Powered by People, Driven by Science"





Questions for EPA - acute toxicity March 30 2009.doc EPA Mtg 2009 Mar 30 Flu + Imid Collar Acute Tox.doc

Bayer Health Care Animal Health Division



Bayer HealthCare LLC Animal Health Division

Date:

April 13, 2009

File Reference:

EPA Mtg 2009 Mar 30 Flu + Imid Collar Acute Tox.doc

Subject:

Teleconference between Bayer Animal Health and EPA - Insecticide/Rodenticide Branch &

Technical Review Branch, March 30, 2009; Proposed Acute Toxicity Requirements for

Flumethrin + Imidacloprid Collar

From:

Douglas A. Spilker,

Phone:

913-268-2751

Ph.D.

To:

Ms. BeWanda

EPA, Registration Branch (Team 13)

Alexander

Attendees:

EPA (Agency) - BeWanda Alexander, Richard Gebken (PM), Byron Backus (TRB)

Bayer Animal Health (BAH) - Lisa Lowseth, Rex Henry, Bruce Martin, Mary Hunt,

Jagdeep Buch and Doug Spilker

A. Purpose of Meeting

The teleconference and discussion basically followed the handout order (see attached document, 3 pp.). The purpose of this meeting was to discuss with the Agency the study/data requirements to support the submission of an application for registration of a flumethrin + imidacloprid combination dog/cat flea and tick collar. Acute toxicity data requirements/protocols for a spot on formulation were previously discussed in a Pre-registration meeting with the Agency on October 11, 2006. However, due to the change in proposed formulation from a spot-on to a collar, this additional discussion was warranted due to the fact that some of the studies might not be possible due to the nature of the active ingredient and/or formulation. Please find below Bayer Animal Health's understandings from the meeting, and the request for the Agency's concurrence on these points.

B. Data to Support Imidacloprid TGAI

BAH will receive authorization from Bayer CropScience to cite the toxicity data on imidacloprid TGAI previously submitted and accepted by the Agency.

C. Data to Support Flumethrin TGAI

There are limitations in the conduct of acute toxicity studies due to physical characteristics of the TGAI [glass-like solid at 20°C; difficulty in accurately measuring small quantities for dosing unless material is heated and diluted.]

1. Acute Ocular irritation in rabbits

BAH asked whether EPA would entertain a waiver request for the requirement of a primary eye irritation study with flumethrin TGAI. Due to the physical characteristics of the TGAI, it is not possible to accurately remove a 0.1 ml or 100 mg sample per OPPTS 870.2400 for placement in the conjunctival sac. Flumethrin must be heated to 60-70°C to form a liquid which can then be mixed with an appropriate vehicle such as corn oil for more accurate dosing.

BAH conducted an acute ocular irritation study in rabbits with flumethrin at a concentration of 10% in olive oil (1994, according to OECD 405, EPA 798.4500 and 81.5). In this study, the AI was not an ocular irritant.

Agency Response: No firm commitment was made from the Agency regarding the granting of a waiver for this requirement. Dr. Backus recommended we try a cryogenic grinding method for the TGAI, and observe whether the TGAI stays finely ground, or whether it reverts to the original amorphous phase. If the testing shows that it reverts to the amorphous glass-like phase then the study does not seem feasible. BAH should try this, and then discuss it again with Dr. Backus. Under these circumstances, a waiver might be possible.

We only need to submit the previously conducted study using 10% flumethrin in olive oil if we find it useful as background information.

2. Acute dermal Irritation in Rabbits

BAH would like concurrence from the Agency regarding a modification of the acute dermal irritation study with flumethrin TGAI.

BAH recently (2008) conducted an acute dermal irritation study in rabbits with flumethrin diluted 50% in corn oil. Flumethrin was warmed in a water bath to 66°C, diluted 50% with corn oil, cooled to RT and 1.0 ml of this mixture used for the dermal dose. The 0.5 ml of TGAI was still administered per OPPTS 870.2500. Results: slight erythema only at 1 hr post-dressing removal; assigned to Toxicity Category IV.

Agency response: This study is reasonable, and conforms to variations allowed by the guidelines for conduct of such studies.

D. End-Use Product - Collar

BAH planned to request a waiver of 5 of the 6 studies required for the end-use product similar to what was done for the cattle ear tags, due to physical characteristics of the collar (solid plastic material). BAH will conduct an acute dermal irritation study with the final collar product. The studies for which a waiver was planned included:

- Acute oral toxicity
- · Acute ocular irritation
- Acute dermal toxicity
- Dermal sensitization
- Acute inhalation

Page 2 of 3 206

Agency response: This plan is reasonable except for the omission of the dermal sensitization requirement. A dermal sensitization study should be conducted using ground collar material (may be frozen and then ground). Furthermore, the Agency asked that we include information on the release rate of the active ingredient from the collar in our justification for the waiver of the acute oral toxicity data requirement.

E. Consideration of testing with Reflector Device (components = clip and reflector)

The reflector [device] is made of two components: 1) Clip material – Makrolon® (polycarbonate) and 2) Reflector material - polymethyl-methacrylate. Neither component contains any pesticide.

BAH proposes that no toxicity testing is needed for the reflector.

Agency response: This plan is acceptable since the reflector is a device, will not be a part of the collar in the package (i.e. in separate bag), and contains no active ingredients. Furthermore, the aforementioned studies should be conducted without the reflector, this being considered the worse-case scenario in that the reflectors *might* reduce AI release.

F. Action items/EPA Guidance

BAH should prepare minutes for the Agency's confirmation of the understandings from this teleconference, and send via Ms. Alexander for distribution within the Agency.

For submission with the Application for Registration, each waiver request should be prepared as a stand alone document, with its own report number and formatted according to PRN 86-5. This is so that each requirement is addressed separately and has its own MRID number (for tracking purposes.)

Attachment:

"Questions for EPA - acute toxicity March 30 2009.doc"

Das 041309

Page 3 of 3

Information for Discussion Bayer HealthCare, LLC Animal Health (BAH) and EPA Teleconference March 30, 2009 at 11:00 AM (eastern)

RE: Acute toxicity testing of flumethrin technical grade (AI) and end-use product – flea/tick collar for use on puppies/dogs and kittens/cats

Background:

PowerPoint presentation made by BAH to EPA on October 11, 2006 - BAH requested that the Agency waive the acute ocular irritation study in rabbits and the acute dermal irritation study in rabbits due to the physical limitations posed by flumethrin (glass-like solid at 20°C).

Original discussion was for a spot-on for flea/tick control product with flumethrin, which has been discontinued.

The new product under development is a plastic collar with flumethrin and imidacloprid as AIs.

Flumethrin will be a new AI registration. Imidacloprid is currently registered.

Items for Discussion March 30, 2009

1. Flumethrin TGAI

1.1. Physical Characteristics

Limitations due to physical characteristics of the TGAI:

- Glass-like solid at 20°C
- Difficulty in accurately measuring small quantities for dosing in acute ocular and dermal irritation studies unless material is heated and diluted

1.2. Acute Ocular irritation in rabbits

BAH would like concurrence from the Agency that a waiver will be granted for the requirement for a primary eye irritation study with flumethrin TGAI. Due to the physical characteristics of the TGAI, it is not possible to accurately remove a 0.1 ml or 100 mg sample per OPPTS 870.2400 for placement in the conjunctival sac. Flumethrin must be heated to 60-70°C to form a liquid which can then be mixed with an appropriate vehicle such as corn oil for more accurate dosing.

BAH conducted an acute ocular irritation study in rabbits with flumethrin at a concentration of 10% in olive oil (1994, according to OECD 405, EPA 798.4500 and 81.5). In this study, the AI was not an ocular irritant.

Is this acceptable to the Agency?

1.3. Acute dermal Irritation in Rabbits

BAH would like concurrence from the Agency regarding a modification of the acute dermal irritation study with flumethrin TGAI.

BAH recently (2008) conducted an acute dermal irritation study in rabbits with flumethrin diluted 50% in corn oil. Flumethrin was warmed in a water bath to 66°C, diluted 50% with corn oil, cooled to RT and 1.0 ml of this mixture used for the dermal dose. The 0.5 ml of TGAI was still administered per OPPTS 870.2500. Results: slight erythema only at 1 hr post-dressing removal; assigned to Toxicity Category IV.

Is this acceptable to the Agency?

2.0 End-Use Product - Collar

- 2.1 BAH requests a Waiver of 5 of the 6 studies required for the end-use product similar to what was done for the cattle ear tags due to physical characteristics of the collar (solid plastic material)
 - Acute oral toxicity
 - Acute ocular irritation
 - Acute dermal toxicity
 - Sensitization
 - Acute inhalation

BAH will conduct an acute dermal irritation study with the final collar product.

Is this acceptable to the Agency?

2.2. Consideration of testing for Reflector Device (components = clip and reflector)

Clip Material: Makrolon® (polycarbonate)

Very stable material, widely used Used in medical devices such as corrective eyeglasses and needle-less syringes, water bottles, protective head gear for sports, vehicle headlights Reflector Material: polymethyl methacrylate

Very stable material, widely used Used in medical devices such as intraocular lenses and orthopedic implants, toys, glazing on aircraft, lenses, light pipes

The Reflector Device does not contain any pesticide active ingredients.

BAH proposes that no additional toxicity testing is needed for the reflector.

Does the Agency concur?

Page 3 of 3 210

Attachment 4

Minutes from US EPA Bayer—Animal Health Division Pre-R tration Meeting for Flumethrin Technical and Flumethrin Combo Products September 14, 2006

Meeting Attendees

BayerEPATerry McNamaraGeorge LaRoccaRD/IBUlrich HeukampBewanda AlexanderRD/IBWendell DavisKevin SweeneyRD/TRBMary HuntShyam MathurRD/TRB

Doug Spilker Anja Hoelscher Bob Arther

Meeting Purpose

Describe new products; agree on data requirements; streamline registration process; defer discussion on toxicology/human safety and domestic animal safety data requirements.

Agenda/Powerpoint Presentation

Generally, the powerpoint presentation was followed and speakers described their respective portions of the presentation. Copies of the presentation and the draft label were distributed (both attached).



Description of Products

Terry McNamara began the presentation, describing the products. Powerpoint slides 1-5.

World Wide Status of Flumethrin

At slide six, Ulrich Heukamp began explaining the established, world wide use of flumethrin in a variety of products (slide 7).

- Bob Arther clarified why Bayer had not pursued a flumethrin registration previously.
 Coumaphos has been used successfully in U.S. livestock applications, and Bayer U.S.
 could not justify the time and expense to develop and register flumethrin for livestock
 uses. However diseases carried by ticks have lately become a greater concern, the
 companion animal market is large, and flumethrin combined with imidacloprid represents
 an attractive flea and tick product for companion animals.
- George LaRocca pointed out that if the product works systemically, it would be
 considered an FDA regulated drug. Bob Arther explained that flumethrin is not systemic,
 but behaves like other pyrethroids, such as permethrin. In Europe the regulatory
 authorities do not distinguish between pesticides and drugs; all animal products are
 considered veterinary medicines.
- Ulrich Heukamp continued the program with his discussion on isomers. At this time,
 Shyam Mathur said he prefers the product labels to identify the amounts of the two Z



Exponent

Jim Messina

- isomers. This can be at action of the two Z isomers -Z1 and Z2 as a listing of a percent for each.
- The Agency asked about the nominal percent active ingredient for the TGAI/MUP product. Bayer U.S. is currently working on this and agreed that the final claim will be based upon these analyses.
- On slide 15, any impurity listed on the Confidential Statement of Formula should be listed by chemical name and CAS number (if available) and all impurities greater than 0.1% must be listed. All impurities can be listed, but those greater than 0.1% must be listed. Any impurity of toxicological significance must be listed regardless of the level.
- The estimated submission timeframe was discussed. Bayer U.S. estimates a submission to EPA during the first quarter 2008 (calendar year).

Description of Spot-on Products and Flumethrin Spot-on

Wendell Davis began his portion of the presentation, demonstrating how to open a tube and administer the product (the tube contained water, slide 16).

Data Requirements

Terry McNamara began the discussion on data requirements. George LaRocca agreed that cat/dog use is considered an indoor residential use pattern (slide 23).


- For Product Chemistry, since the TGAI will be registered as an MUP, storage stability/corrosion characteristics and stability must be done with the MUP.
- George LaRocca agreed that no Environmental Fate hydrolysis study would be required (slide 29). This is based on the understanding that no manufacturing of the TGAI/MUP will occur in the U.S.
- George LaRocca emphasized the Agency's concern with technical product is with shipment within the U.S. For example, such data would be helpful if there is a spill of technical material within the U.S. Both George LaRocca and Kevin Sweeney agreed that there is no environmental exposure concern for the technical since it will not be manufactured or imported to the U.S. for formulation. Therefore the Ecological Effects studies should not be required. However, George LaRocca will review this with EFED and respond to Bayer.

Product Performance/Efficacy

Wendell Davis began the product performance portion of the presentation, describing the product and dose sizes (slide 38).

• There was much discussion regarding the label claim for waterproof (vs. water resistant). It was obvious this has been a significant discussion item within EPA. George stated he would never allow a waterproof claim. It seems there is variation among currently registered product labels. Bayer U.S. confirmed that Frontline Plus has the waterproof claim approved on its label. It was agreed that data will need to be submitted to support the claim. Kevin Sweeney acknowledged that if other products have the claim, EPA must treat all products in the same manner.

- George LaRocca asked about exposure of pets to water/bathing. Following exposure, what keeps the product on the dog? Terry McNamara responded that it was a result of the chemical properties of pyrethoids and the natural oils of the animal.
- The Agency said that the 12-hour efficacy claim may be an issue. Bayer U.S. explained that this claim is supported by data. Additionally, the Agency approved it for Advantage. EPA stated that it is probably not an issue if they have already approved the language for another product, although they will need to review the product specific data.
- Kevin Sweeney asked if 1.2 ml provides sufficient efficacy for big cats (>10 pounds). Bayer U.S. confirmed that it does and the same is true for large dogs.
- Kevin Sweeney asked about the *Ixodes scapularis* studies (slide 42). At this time, Bayer is planning *in vitro* hair laboratory studies. Kevin Sweeney will review the type of studies (*in vitro or in vivo*) which have been used in recent years to register products, and inform Bayer if the testing regime is acceptable.
- Kevin Sweeney is interested in reviewing dose titration studies for flumethrin and synergist. How was the amount of flumethrin used in end product determined? The study(ies) can be non-GLP. As the combination product contains flumethrin and MGK 264, a pyrethroid synergist, these studies should be with both flumethrin and the synergist. He prefers "spot on" study(ies) in the target animals, and not applications in other species. This will be submitted by Bayer as a supplemental study(ies) included with the submission package.



Environmental Fate - no studies per George LaRocca.

Ecological Effects – possibly no studies; George LaRocca will review with EFED and inform Bayer.

Product Chemistry – ratio of Z isomers on product labels, and MUP (=TGAl) storage stability/corrosion characteristics and stability studies.

Efficacy – *Ixodes* study – need to determine *in vitro* or *in vivo*. Kevin Sweeney will review and inform Bayer. Prefer no European species of ticks.

Draft Label

Bewanda Alexander asked that we include the word "may" in regards to ticks carrying or transmitting disease. Also, it was requested that we include the statement "Do Not Rub In" on the product label.

Kevin Sweeney said that generally the Agency doesn't allow time of kill claims on labels, however if a claim is already approved on another label, then there should be no problem. For example, "Kills 98-100% of the adult fleas on dogs within 12 hours and continues to prevent infestations for at least four weeks."

Next meetings between US EPA and Bayer Animal Health were proposed for Wednesday, Oct. 11th. Possibly morning and afternoon meetings; one for Toxicology/Human Safety and another for Domestic Animal Safety to determine data requirements for registration.



List of Items for Agency Concurrence

Use Pattern

Under current 40 CFR Part 158 Appendix A, dog and cat uses are Indoor.

Under draft 40 CFR Part 158 proposal dog and cat uses would be Indoor Residential.

- No data requirements (based on only dog and cat end-use products) for
 - Spray drift (40 CFR Part 158.440)
 - Plant protection (40 CFR Part 158.540)
 - Non-target insect (40 CFR Part 158.590)
 - Residue chemistry (40 CFR Part 158.240)

Product Chemistry

- Data requirements for MUP and EP clearly defined in 40 CFR Part 158
- As the flumethrin TGAI will be registered as a MUP, storage stability/corrosion characteristics and stability must be done with the TGAI.
- The amounts of the two Z isomers must be specified on the label as a ratio or listing of each.

Environmental Fate

Under current 40 CFR Part 158, no data should be required.

Under draft 40 CFR Part 158, only 835,2120 Hydrolysis data are conditionally required under certain conditions, but these conditions are not similar to dog/cat use. Moreover, flumethrin does hydrolyze in similar manner as pyrethroids; a new hydrolysis study would provide little new information.

Therefore no environmental fate data should be required.

- Ecological Effects

Based on the use pattern (registration of a MUP for Indoor Residential Use), Bayer proposed

850.2100 Avian oral toxicity (bobwhite)

850.1075 Freshwater fish (both rainbow trout and bluegill)

850.1010 Freshwater invertebrate (Daphnia)

However the MUP will be made in India and shipped to Germany for formulation into the End Use Product (Spot On). The Spot On product is what will be imported into the U.S. Based on this, the MUP will not enter the U.S.; consequently, there will be no environmental exposure with the MUP, and these studies may not be necessary. George LaRocca will obtain an Agency decision on this.



- Efficacy
 - Flea (adult and larvae) efficacy will be supported by imidacloprid studies on file with EPA
 - Flea ovicidal (egg) efficacy will be supported by pyriproxyfen studies on file with EPA
 - Tick efficacy to support a general tick claim will be demonstrated by new GLP studies:
 - o Dermacentor variabillis (American Dog Tick) conducted in dogs
 - o Rhipicephalus sanguineus (Brown Dog Tick) conducted in dogs
 - Laboratory (in vitro) studies for immature life stages
 - o Amblyomma americanum (Lone Star Tick) conducted in cats
 - o Ixodes scapularis (Deer Tick)
 - Laboratory (in vitro) studies for all life stages
 - Bathing/Water studies to support waterproof claim for dogs
 - Bath group weekly infestations and counts with one bath approximately 2 weeks post-treatment.
 - Water group weekly infestations and counts, with weekly water immersions performed between counts and infestations.

Kevin Sweeney will review and respond.



Attachment 5

Doug Spilker/SHAWN/AGCHEM/US /BAYER 04/13/2009 t0:00 AM To alexander.bewanda@epa.gov

cc Jochem

Rueter/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES, Rev

Henry/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES

bcc Bruce

Martin/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES;

Mary

Hunt/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES;

Jagdeep

Buch/SHAWN/AGCHEM/US/BAYER@BAYER-US-NOTES

Subject Minutes of Pre Reg Meeting (03/24/09) - Collar - Product

Chemistry Requirements

Dear Ms. Alexander,

One of the action items from the Pre-registration meeting (subject - Product Chemistry Requirements) of March 24, 2009 between Bayer Animal Health and the Agency was for us to prepare and submit meeting minutes containing our understandings from the meeting. Therefore, please find attached the respective minutes from the subject meeting, and the attachment we used during the discussion.

We ask for the Agency's review and concurrence that our understandings from the pre-registration meeting are correct. If there are any misunderstandings or inaccuracies, we ask that you let us know as soon as possible.

Best regards,

Doug

Doug Spilker Manager - EPA Reg. Affairs BAYER HEALTHCARE LLC ANIMAL HEALTH

Office: +1 913-268-2751 Mobile: +1 816-506-3102 Fax: +1 913-268-2135

Email: doug.spilker.b@bayer.com

Address: P.O. Box 390 Shawnee Mission, KS 66201-0390 Country: USA

Bayer Animal Health "Powered by People, Driven by Science"





EPA Mtg 2009 Mar 24 Flu + Imid Collar Prod Chem.doc Flumethrin Isomer Raio & Product Chemistry.pdf

Bayer Health Care Animal Health Division



Bayer HealthCare LLC Animal Health Division

INTERNAL MEMORANDUM

Date:

April 13, 2009

File Reference:

EPA Mtg 2009 Mar 24 Flu + Imid Collar Prod Chem.doc

Subject:

Teleconference between Bayer Animal Health and EPA - Insecticide/Rodenticide Branch &

Technical Review Branch, March 24, 2009; Proposed Product Chemistry Requirements for

Flumethrin + Imidacloprid Collar

From:

Douglas A. Spilker,

Phone:

913-268-2751

Ph.D.

To:

Ms. BeWanda

EPA, Registration Branch (Team 13)

Alexander

Attendees:

EPA (Agency) – BeWanda Alexander, Richard Gebken (PM), Shyam Mathur (TRB)

Bayer Animal Health (BAH) - Rex Henry, Jochem Rueter, Bruce Martin, Mary Hunt,

Jagdeep Buch and Doug Spilker

A. Purpose of Meeting

The teleconference and discussion basically followed the handout order (see attached document, 3 pp.). The purpose of this meeting was to discuss with the Agency the study/data requirements to support the submission of an application for registration of a flumethrin + imidacloprid combination dog/cat flea and tick collar. Product chemistry data requirements for a spot-on formulation were previously discussed in a Pre-registration meeting with the Agency on September 14, 2006. However, due to the change in proposed formulation from a spot-on to a collar, this additional discussion was warranted due to the fact that some of the studies might not be applicable due to the nature of the formulation. Furthermore, BAH requests additional clarification from the Agency regarding the expression of the isomer ratio of flumethrin on the label. Please find below Bayer Animal Health's understandings from the teleconference, and the request for the Agency's concurrence on these points.

B. Flumethrin Isomer Ratio Expression on Formulated Product Label (see page 1 of handout)

BAH presented several options for the label expression of the isomer ratio of the flumethrin component of the formulation. The Agency instructed that the label claim should appear as a maximum/minimum expression:

Trans Z-1/Trans Z-2 ratio: max 66% trans Z-1 and min 34% trans Z-2

C. Technical Material - Flumethrin Expression on Confidential Statement of Formula (CSF)

Only the nominal value of the flumethrin technical needs to be reported on the CSF for the flumethrin technical (TGAI); no isomers need to be itemized.

D. Formulated Product - Flumethrin Expression on Confidential Statement of Formula (CSF)

Only the nominal value of the flumethrin technical needs to be reported on the CSF for the flumethrin technical (TGAI); no isomers need to be itemized.

E. Physical and Chemical Properties Test Requirements for Formulated Product

In the list below is our understanding of the discussions from the teleconference for each of the study categories for the formulated product (collar):

Section and Title	Requirement
63-2 (830-6302) Color:	YES
63-3 (830-6303) Physical State:	YES
63-4 (830-6304) Odor:	YES
63-5 (830-7200) Melting Point:	N/A*(1)
63-6 (830-7220) Boiling Point:	N/A* (1)
63-7 (830-7300) Density, bulk density, or specific gravity:	YES
63-8 (830-7840) Solubility: (830-7860)	N/A* (1)
63-9 (830-7950) Vapor Pressure:	N/A* (1)
63-10 (830-7370) Dissociation Constant:	N/A*(1)
63-t1 (830-7550) Octanol/water partition coefficient	N/A* (1)
63-12 (830-7000) pH:	YES; Request Waiver (2)
63-13 (830-6313) Stability:	N/A*(1)
63-14 (830-6314) Oxidation or reducing:	YES; Request Waiver -Will not act as an oxidizing or reducing agent
63-15 (830-6315) Flammability - flashpoint (combustible liquids only)	N/A*(3)

63-16 (830-6316) Explodability: YES; Request Waiver (4)

63-17 (830-6317) Storage Stability: Required (5) – Condition of registration; will provide after

first production

63-18 (830-7100) Viscosity: N/A*(6)

(Liquids Only)

63-19 (830-6319) Miscibility: N/A*(7)

(emulsifiable liquids and is to be diluted with petroleum solvent)

63-20 (830-6320) Corrosion characteristics: Required (8) - Condition of registration; will provide after

first production

(when packaged in metal, plastic or paper containers)

63-21 (830-6321) Dielectric breakdown voltage: N/A*(9)

(yes if for use around electrical equipment)

61-3 (830-1670) Formation of unintentional YES; Discussion Required ingredients during manufacturing

* N/A = Not Applicable

- 1) Per 40 CFR 158.190 This test is only required on Technical grade of active ingredient and not for end use product.
- Per 40 CFR 158.190, This product is not soluble in water and pH of the test substance is not required.
- 3) Per 40 CFR 158.190; 63-15(a) This product is not considered a combustible liquid, because the closed cup flashpoint for all the ingredients is greater than 199° F.
- 4) Per 40 CFR 158.190; 63-16(a) This product does not contain any explosive ingredients.
- 5) Per 40 CFR 158.190; 63-17 This is a study to support stability of the product in the market container. Stability is not part this study but will done under a separate study.
- 6) Per 40 CFR 158 190, 63-18. The product is a solid and viscosity is not applicable
- 7) Per 40 CFR 158.190; 63-19(a) This product is not an emulsifiable concentrate type product.
- 8) Per 40 CFR 158.190; 63-20 This is a study to support corrosion of the product in the market container and not part of his study but done under a separate study.
- 9) Per 40 CFR 158.190; 63-21(a) This product is not intended for use around electrical equipment.

Page 3 of 4 221

F. Consideration of testing with Reflector Device (components = clip and reflector)

The reflector [device] is made of two components: 1) Clip material - Makrolon® (polycarbonate) and 2) Reflector Material: polymethyl methacrylate. Neither component contains any pesticide active ingredients.

BAH proposes that no product chemistry information be required for the reflector.

Agency response: This is acceptable to the Agency since the reflector is a device, will not be a part of the collar in the package (i.e. in separate bag), and contains no active ingredients.

G. Action items/EPA Guidance

- 1) BAH should prepare minutes for the Agency's confirmation of the understandings from this teleconference, and send via Ms. Alexander for distribution within the Agency.
- 2) In addition to the paper copies, the storage stability information may also be submitted in electronic format (PDF or TIF files), but this is not a requirement.
- 3) The Agency reminded BAH that the enforcement method (Guideline No. 830.1800) should include both active ingredients (flumethrin and imidacloprid).

Attachment: Flumethrin Isomer Ratio & Product Chemistry.pdf

Das 041309

Page 4 of 4 222

FOR OFFIGIAL USE ONLY

FILE	SYMBO	DL.	 	 :	
	197 (21 44)		A	 	
REG	STRAT	ON NO	75.	1.4	

CONFIDENTIAL STATEMENT OF FORMULA ENCLOSED

DATE	SUBMITTED BY (//)					
SUBMITTED	APPLICANT	BASIC SUPPLIER				
SEP 2 7 2010						
·						

Do Not Write Comments, Formula, or Parts of Formula on This Envelope

NOTE

It shall be unlawful—for any person to use for his own advantage or to reveal, other than to the Secretary, or officials or employees of the United States Department of Agriculture or other Federal agencies, or to the courts in response to a subpoena, or to physicians, and in emergencies to pharmacists and other qualified persons, for use in the preparation of antidotes, in accordance with such directions as the Secretary may prescribe, any information relative to formulas of products acquired by authority of Section 4 of the "Federal Insecticide, Fungicide, and Rodenticida Act."

